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ABSTRACT 
Pseudomonas aeruginosa is ubiquitous in the natural environment and is an important pathogen known to infect Cystic Fibrosis (CF) patients. Colonisation of the CF lungs with this bacterium has been associated with increased rates of morbidity and mortality in these patients. The presence of clonal P. aeruginosa strains circulating within specialised CF clinics worldwide has generated a great deal of concern owing to their association with adverse clinical prognosis and apparent transmissibility. The transmission route of these clonal strains has not yet been defined; current theories include acquisition from an environmental source or through patient-to-patient spread. The current methods used to study P. aeruginosa strains that include Multilocus Sequence Typing (MLST) and Pulsed Field Gel Electrophoresis (PFGE) are expensive, time consuming, and cannot easily be applied as a routine typing method in standard laboratories. The purpose of this study was to develop a robust Single Nucleotide Polymorphism (SNP) genotyping system interrogated with High Resolution Melt Analysis (HRMA) that would allow differentiation between environmental, clinical and clonal P. aeruginosa strains and facilitate P. aeruginosa population studies. In this study, nine highly discriminatory SNPs in P. 
aeruginosa MLST genes were identified using the program ‘Minimum SNPs’, which derives SNP sets with optimised resolving power based on the Simpson’s index of diversity. The nine SNP profile provided a cumulative D-value of 0.98. SNP interrogation with SybrGreen®/HRMA in practice proved challenging and resulted in only four SNP types that displayed distinguishable melt groups. Sequence validation and bioinformatics analysis revealed that P. aeruginosa housekeeping genes are highly diverse and that the presence of other polymorphisms within the PCR amplicon influences melt group formation and therefore the ability to differentiate melt curves based on D-value SNP alone.  In silico SNP profile and eBURST analysis of P. aeruginosa strains listed on the MLST database demonstrated a similarity between the environmental and several CF clonal strains and also highlighted occurrence of environmental P. aeruginosa strains in CF infections. The significance of these findings is that ‘Minimum SNPs’ is capable of deriving SNP sets with high resolving power from P. aeruginosa housekeeping genes and that alternative methods for SNP interrogation or other molecular methods should be explored to further clarify the relationship between environmental and CF clonal P. aeruginosa strains.   
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CHAPTER 1 
1.0 Introduction 
Pseudomonas aeruginosa is an opportunistic pathogen that is widely distributed in nature. It is often isolated from various water and soil sources as well as foodstuffs. Its high metabolic versatility, impressive array of intrinsic virulence factors and highly adaptable nature allow it to colonise various environments and cause serious health complications in humans, especially those with compromised defence/immune systems.  This is particularly the case for individuals with Cystic Fibrosis (CF).  CF is the most common lethal genetic disease in Caucasian populations (Sanchez et al., 2003). In Australia alone, 1 in 2986 people are diagnosed with CF (Bell et al., 2011). This condition is caused by defects to the CF transmembrane conductance regulator gene, which as a side effect is responsible for abnormal chloride mucosal secretions within the CF lungs that are typically highly viscous and difficult to clear (Goldberg, 2010). The CF lung environment favours microbial colonisation. At present, P. aeruginosa is considered the most prevalent and important microbe infecting CF patients (Bell et al., 2011). Once P. aeruginosa has successfully established colonisation, it is difficult to eradicate (Aaron, 2006) and a rise in patient morbidity and mortality is observed (McCallum et al., 2001).  The development of molecular genotyping methods has facilitated the detection of P. aeruginosa clonal strains present within numerous CF clinics worldwide. These clonal strains, (strains derived from the same ancestral lineage) shared amongst CF patients, have generated a great deal of concern owing to their association with adverse clinical outcomes following infection and apparent transmissibility. Of the Australian clonal strains, infection with the Australian epidemic strain-I (AES-I) has been linked with increased rates of morbidity (Armstrong et al., 2002; Nixon et al., 2001), the AES-II has been associated with declining lung function (O'Carroll et al., 2004) and infection with AES-III requires complicated treatment regimes (Bradbury, Champion, & Reid, 2008). This association between infection with clonal strains and poor clinical prognosis has also been reported for other international clonal strains, such as the Liverpool epidemic strain (Aaron et al., 2010; Al-Aloul et al., 2004; Chambers et al., 2005) and Manchester epidemic strain (Jones et al., 2010).  The transmission route for the clonal strains of P. aeruginosa as yet, is not defined. Current theories include acquisition from an environmental source or transmission via patient-to-patient spread. Patient-to-patient spread is currently considered the most likely mode of 
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acquisition as several studies have failed to identify an environmental reservoir (Campana et al., 2004; Cheng et al., 1996; Jones & Webb, 2003; McCallum et al., 2001) and segregation of patients based on clonal strain status has prevented the incidences of new clonal strain infection (Griffiths et al., 2005; Griffiths, Wurzel, Robinson, Carzino, & Massie, 2012; Jones et al., 2005a). Moreover, CF patients have been shown to be a possible source of clonal strain dissemination as several studies have identified a clonal strain on patients’ hands (Panagea, Winstanley, Walshaw, Ledson, & Hart, 2005) and in biological cough aerosols produced by CF patients (Wainwright et al., 2009). Despite this, conclusive evidence for patient-to-patient spread has not been demonstrated and the environment as a potential reservoir for clonal strains has not been extensively studied and therefore cannot be ruled out.  The current methods used for detection and epidemiological studies of the clonal strains, such as Pulsed field gel electrophoresis, Multilocus sequence typing and Repetitive element –PCR are time consuming, costly and have limited ability to be applied universally across laboratories. Therefore, there is an urgent need for the development of a cost effective, highly discriminatory and reproducible genotyping method that is capable of differentiating between environmental, clinical and clonal strains.  SNP-based genotyping methods have been applied recently to characterise strains from many bacterial species (Foster et al., 2008; Huijsmans et al., 2011; Wiehlmann et al., 2007). Our research group has successfully applied the ‘Minimum SNPs’ technology to derive SNP sets with optimal resolving power interrogated and combined with high-resolution melt analysis (HRMA) to genotype various bacterial pathogens (Hussain, 2011; Rathnayake, Hargreaves, & Huygens, 2011; Robertson et al., 2004; Sheludchenko, Huygens, & Hargreaves, 2010). HRMA is an attractive platform for genotyping studies as it is quick, cost-effective and can be performed on a single generic instrument. Moreover, the data generated through this system can be easily compared between laboratories.  This study seeks to apply the Minimum SNPs technology together with HRMA to assess the genetic relatedness of P. aeruginosa strains isolated from various sources. The successful development of this method will facilitate global studies of P. 
aeruginosa populations and allow rapid and accurate characterisation of clonal P. aeruginosa isolates that will enable implementation of effective infection control protocols, particularly with respect to the management of CF patients.          
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CHAPTER 2 
2.0 Literature review 
2.1 Pseudomonas genus All members of the Pseudomonas genus are Gram-negative rods that are characterised by a positive oxidase reaction with some members capable of producing pigments (Meyer, 2000). Pseudomonads are metabolically and physiologically versatile (Palleroni, 1992) allowing survival in a diverse range of biotic and abiotic habitats and are especially important organisms in plant and human disease and as biotechnological agents (Silby, Winstanley, Godfrey, Levy, & Jackson, 2011). Figure 1 demonstrates the functional and ecological versatility of members of the Pseudomonas genus.     
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The diverse range of functional and ecological capabilities of Pseudomonas Spp (Silby et al. 2011)   
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2.2 An overview of Pseudomonas aeruginosa 
2.2.1 P. aeruginosa physiology 
P. aeruginosa is a highly adaptable organism capable of using over 80 different organic compounds as energy and carbon sources (Palleroni, 1984).  This high metabolic versatility enables growth in harsh conditions with limited nutrient availability as shown by its isolation from distilled water (Favero, Carson, Bond, & Petersen, 1971; Moore & Flaws, 2011b), disinfectant solutions and petroleum fuel (Tripathy et al., 2007).  Although classed as an obligate aerobe, in the absence of oxygen P. aeruginosa can use nitrate, nitrite or nitrous oxide as final electron acceptors (Carlson & Ingraham, 1983; Davies, Lloyd, & Boddy, 1989). When nitrate or nitrites are not available, arginine can be used for anaerobic growth via fermentation (Vander Wauven, Piérard, Kley-Raymann, & Haas, 1984). This ability allows P. aeruginosa to adapt to the oxygen-restricted anaerobic environment found in biofilm layers and mucus within the CF lung (Hassett, 1996; Worlitzsch et al., 2002; Yoon et al., 2002). Physiological characteristics of P. aeruginosa include swimming, twitching and swarming motility by means of a single polar flagella (Leone, Chirillo, Raso, Zucca, & Savoia, 2008;Yahr, 2006), multiple cell surface pili (Driscoll, Brody, & Kollef, 2007), growth at 42°C (Palleroni, 1984) and pigment production.   Some strains of P. aeruginosa overproduce the extracellular polysaccharide alginate, which gives rise to a mucoid phenotype (Driscoll et al., 2007). The production of alginate supports biofilm formation (Driscoll et al., 2007). 
2.2.2 The presence of P. aeruginosa in environmental sources The primary habitat of P. aeruginosa is the natural environment, although it is considered to be more abundant in aquatic environments than soil (Selezska et al., 2012). It has been isolated from natural and treated water sources including marine environments (Khan et al., 2007; Kimata, Nishino, Suzuki, & Kogure, 2004), river water (Aoi, Nakata, & Kida, 2000; Pellett, Bigley, & Grimes, 1983; Pirnay et al., 2005), pond sediment  (Tripathy et al., 2007), bottled natural mineral water (Hunter, 1993), swimming pools (Barben, Hafen, Schmid, & Swiss Paediatric Respiratory Research, 2005), hot tubs (Huhulescu et al., 2011), tapwater (Cholley, Thouverez, Floret, Bertrand, & Talon, 2008; Reuter, Sigge, Wiedeck, & Trautmann, 2002) and waste water (Filali et al., 2000). Contamination of natural water sources with waste (i.e. from agriculture, residential or industry) may influence the concentration of P. aeruginosa in water sources.  A study performed on a river in Brussels (Belgium), established that P. aeruginosa was more frequently isolated from polluted than non-polluted areas of the river (Pirnay et al., 2005).  
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P. aeruginosa has been isolated with low efficiency in unmodified soil samples (Holden, Todd, Ferguson, Olsen, & McGuffie, 1996; Ringen & Drake, 1952) or not at all (Aoi et al., 2000; Lavenir, Jocktane, Laurent, Nazaret, & Cournoyer, 2007). It has been suggested that P. aeruginosa is a poor competitor in unmodified soil environments but prospers when appropriate conditions are made available such as increased soil moisture (Minion, 2010), nutrient supply or reduced microbiota (Vives-Flórez & Garnica, 2006). Vives-Flórez and Garnica (2006) found that P. 
aeruginosa was more likely to be isolated from oil contaminated soil samples than from undisturbed soil environments. These findings are supported by other studies that have also isolated P. aeruginosa in high numbers in hydro-carbon contaminated sites (Akbar, AL-Otaibi, Drobiova, Obwekue, & Al-Saleh, 2008; Kaszab et al., 2010).   Over the last thirty years a number of published works have identified contamination of vegetable produce with P. aeruginosa (Correa, Tibana, & Gontijo, 1991; Curran, Morgan, Honeybourne, & Dowson, 2005; Green, Schroth, Cho, Kominos, & Vitanza-jack, 1974; Kominos, Copeland, Grosiak, & Postic, 1972; Shooter, Cooke, Faiers, Breaden, & O'Farrell, 1971; Viswanathan & Kaur, 2001; Worlitzsch, Lautrou, Ulrich, & Döring, 2006; Wright, Kominos, & Yee, 1976). A recent study in Germany examined the prevalence of P. aeruginosa in foodstuffs and detected the bacterium in 7.4 % of green salad samples, 10 % of tomato samples and in 13.8 % of cucumber samples (Worlitzsch, Lautrou, Ulrich, Doring, 2006). The source of contamination is presumably through water and soil sources.  Green et al. (1974) detected P. aeruginosa in 24 % of the agricultural soil samples but in low numbers of vegetable samples but indicated that optimal conditions in temperature and moisture increased P. aeruginosa numbers. 
2.2.3 P. aeruginosa genome The genome of P. aeruginosa is relatively large compared to other bacteria that have been sequenced. Its size varies considerably between strains, ranging from 5.5 to 7 Mbp (Lee et al., 2006).  The core genome is composed of highly conserved regions including housekeeping genes that have a low nucleotide divergence of 0.5-0.7 % (Klockgether, Cramer, Wiehlmann, Davenport, & Tümmler, 2011). The accessory genome, representing more than 20 % of the total genome size, is responsible for the variance in genome size and diversity between strains (Klockgether, Wiehlmann, & Tummler, 2006). The P. aeruginosa accessory genome consists of extrachromosomal components such as plasmids, islands and blocks of DNA that are integrated into the chromosome at various sites (Klockgether et al., 2011). These components may be acquired from other species of bacteria through mechanisms such as horizontal gene transfer.  The ‘mosaic’ and plastic genome structure of P. aeruginosa provides this bacterium with the ability to modify, cause infection and adapt to a wide range of habitats (Norgaard-Gron, 2010).  
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2.2.4 P. aeruginosa pathogenicity 
P. aeruginosa is equipped with an arsenal of virulence factors that allow it to successfully infect and colonise human, animal and plant hosts. These virulence factors summarised in Table 1, allow the organism to attach to host cells, invade host tissue and suppress the immune response (Moore & Flaws, 2011a).   
Table 1:  P. aeruginosa virulence factors and their function. Adapted from (Moore & Flaws, 2011a) 
Virulence Factor Function 
Fimbriae 
Attachment to host cells and activation of proinflammatory gene expression 
Polar Flagella Motility, attachment to host cells and activation of Interleukin-8 
Type III secretion system Injects toxins (ExoS, ExoT, ExoU, ExoY) into host cells 
ExoS Stimulates tumor necrosis factor alpha production 
ExoT Activates GTPase 
ExoU Cytotoxin 
ExoY Adenylate cyclase activity 
Quorum-sensing 
molecules 
Coorinated expression of genes among other pseudomonal cells and promotes the formation of biofilms 
Pyochelin and pyoverdin Bind iron 
Elastase, proteases, 
hemolysins, and 
leukocidin 
Aid in tissue invasion and lyse host cells 
Pyocyanin 
Inhibits lymphocyte proliferation and cilia function and produces reactive oxygen intermediates 
Exotoxin A 
Inhibits protein synthesis in host cells and helps organism disseminate 
Lipopolysaccharide 
Alginate 
Free radical scavenger; inhibits phagocytosis, neutrophil chemotaxis and activation of complement. Biofilm formation  
2.2.5 P. aeruginosa infection in humans Despite its array of virulence factors and abundance in the natural environment, P. aeruginosa is not a frequent coloniser of healthy individuals. Nevertheless, it is occasionally isolated in low concentrations in the human gastrointestinal tract (Moore & Flaws, 2011a). P. aeruginosa is considered an opportunistic pathogen that usually only causes infection in healthy individuals when access is granted via inhalation, ingestion, instrumentation or damage to skin/ mucous membranes (Leboffe & Pierce, 2005). 
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Environmental strains of P. aeruginosa are often implicated in various outbreaks in community and nosocomial acquired infections. Typical community acquired P. aeruginosa infections are often caused by contaminated recreational waters or solutions with environmental strains of P. 
aeruginosa. P. aeruginosa is capable of surviving at high temperatures in mildly chlorinated or disinfectant solutions and as a result is often isolated from swimming pools, hot tubs, cleaning and contact lens solutions. An example of a common community acquired P. aeruginosa infection is contact-lens induced keratitis, a condition caused by contaminated contact lens solutions (de Melo, Aggio, Höfling-Lima, d'Azevedo, & Pignatari, 2007; Moore & Flaws, 2011b). Cases of serious health complications caused by P. aeruginosa following hot tub/whirlpool usage are reported frequently.  Specifically, exposure to P. aeruginosa strains isolated from hot tubs was directly responsible for severe necrotizing pneumonia (Christopher, Gordon, & Andes, 2003), pneumonia (Germinario et al., 2012; Huhulescu et al., 2011), pseudomonas hot foot syndrome and folliculitis (Yu, Cheng, Wang, Dunne, & Bayliss, 2007) in previously healthy individuals.  The occurrence of P. aeruginosa infections may be attributed to the confined space in hot tubs, heated water and aeration of the water by jets.  Under-chlorinated swimming pools have also been implicated in outbreaks of similar community-acquired P. aeruginosa infections. Natural recreational waters and swimming pools contaminated with P. aeruginosa have been implicated in otitis externa infections (also known as swimmer’s ear) (Reid & Porter, 1981; Van Asperen et al., 1995). Inflatable swimming pool toys have also been shown to be a source of P. aeruginosa infection.  Tate, Mawer and Newton (2003) described an outbreak of folliculitis occurring in 35 individuals in the UK that was caused by contaminated swimming pool inflatable toys.   Characteristic nosocomial P. aeruginosa infections include: “bacteremia, urinary tract infection (e.g from catheritisation), pneumonia (including ventilator associated pneumonia), meningitis, malignant otitis externa and wound infections” (Moore & Flaws, 2011a). There have been many reports of water sources in the hospital setting (i.e tap water, sinks, faucets or bath water) being contaminated with P. aeruginosa strains that were later confirmed by molecular testing, to be directly responsible for various infection outbreaks (Bert, Maubec, Bruneau, Berry, & Lambert-Zechovsky, 1998; Blanc, 2004; Ferroni et al., 1998; Richard et al., 1994; Trautmann, Michalsky, Wiedeck, Radosavljevic, & Ruhnke, 2001). In the majority of these incidences, infection was caused when medical instrumentation (e.g catheter), staff hands, open wounds (e.g burn wounds) and medical solutions (e.g nutrition solutions) were exposed to contaminated water sources.  
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P. aeruginosa is an opportunistic pathogen that is widely distributed in the environment. Together with its intrinsic virulence factors and highly adaptable nature, it is capable of causing serious health complications in humans, especially to those with compromised defense systems. This is especially the case for Cystic Fibrosis (CF) patients.  
2.3 Cystic Fibrosis Cystic fibrosis is the most common lethal genetic disease in Caucasian populations (Sanchez, et al., 2003). In Australia 1 in 2986 people are diagnosed with CF (Bell et al., 2011). However, the prevalence of this condition varies between countries and ethnic groups. CF is caused by defects to the cftr gene located on chromosome 7. This gene ‘encodes the CF transmembrane conductance regulator CFTR protein, which is expressed in many epithelial cells and blood cells’ (O'Sullivan & Freedman, 2009). Since the discovery of the cftr gene in 1989 (Riordan et al., 1989), over 1600 mutations of the CFTR gene have been described. As shown in Table 2, the cftr mutations are divided into 5 classes based on the type of mutation and its associated impact on CFTR production and function (Welsh & Smith, 1993). The most common mutation (diagnosed in up to 60% of CF patients) is the class 2 mutation Delta F508 (codon deletion of phenylalanine at position 508) (Goldberg, 2010).  
Table 2: The five functional classes of cftr mutations.  Adapted from (http://www.cysticfibrosismedicine.com) 
Class of 
mutation CFTR production and function 
Class 1 
Defective protein production with premature termination of CFTR protein production. Class 1 mutations produce few or no functioning CFTR chloride channels 
Class 2 Defective trafficking of CFTR so that it does not reach the apical surface membrane where it is intended to function 
Class 3 
Defective regulation (opening and closing) of the CFTR chloride channel which allows movement of chloride in and out of the cell even though the CFTR protein is able to reach the apical cell surface 
Class 4 CFTR reaches the apical surface but conduction (passage of chloride ions through the channel) is defective 
Class 5 Associated with reduced synthesis of functional CFTR  One major function of the CFTR protein is to regulate proper chloride channel function.  Mutations to the cftr gene results in abnormal chloride secretions from epithelial cells. These abnormal secretions accumulate to form a dehydrated and highly viscous mucous layer, which cannot easily  be cleared from the body (Goldberg, 2010). This steady mucous layer provides a niche environment for microbial colonization (Hart & Winstanley, 2002).  Bacterial colonisation 
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and infection of the CF lung results in episodes of inflammation, lung damage and respiratory function decline which ultimately leads to death (Goldberg, 2010). Defected chloride channel function also causes viscous secretions in organs other than the lungs. Many CF patients suffer from pancreatic insufficiency which results in malabsorption of nutrients affecting the nutritional health of patients and thus stunting growth (Goldberg, 2010). It is common for CF patients to suffer from fertility problems. In women in particular, the viscous cervical mucus restricts pregnancy by reducing sperm motility and penetration (Van Daele, 2006).    The current method for CF diagnosis is the ‘sweat test’, which measures the chloride concentration in sweat. Patients with CF typically have a chloride concentration greater than 60 mmol/L compared to healthy individuals at 10-40 mmol/L (O'Sullivan & Freedman, 2009). Subsequent molecular testing is used to confirm the diagnosis.  
2.3.1 Microbiology of the CF lung A number of microbes are capable of colonising the unique environment in the CF lung. The most common organisms known to colonise the CF lung include: P. aeruginosa, Staphylococcus 
aureus, Haemophilus influenzae, Burkholderia cepacia complex (BCC), and Stenotrophomonas 
maltophilia (Campana et al., 2004; De los Rios Perez et al., 2010; Valenza et al., 2008).  Less frequently isolated organisms are: the bacteria non-tuberculous mycobacteria (NTM) (Olivier, 2004), Achromobacter xylosoxidans, Ralstonia spp., Pandoria spp., Moraxella spp. (Foweraker, 2009); fungi: Aspergillus fumigatus, A. terreus, Scedosporium apiosperuym; and yeast: Candida 
albicans (Pihet et al., 2009; Sauteur et al., 2008) . Bacterial infections of the CF lung usually follow an age-specific pattern. In infancy, S. aureus and H. influenzae are the most predominant pathogens of the CF lung (Valenza et al., 2008). In later years, P. aeruginosa and BCC colonise the CF lung, outnumbering the childhood pathogens (Hart & Winstanley, 2002). Although infections with P. aeruginosa are more prevalent in older CF patients, P. aeruginosa has been identified in children less than three years of age (Burns et al., 2001). Table 3 indicates the prevalence of bacterial infections in CF patients with respect to age group. At present, P. aeruginosa is considered the most prevalent and important organism infecting CF patients.   
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Table 3: Findings from microbiological culture of sputum or bronchoscopy samples from Australian patients 
with cystic fibrosis. Adapted from Bell et al. (2011).  
 1Children 1Adolescents 1Adults 1All age groups (0-11 years) (12-17 years) (≥18 years) Total number of patients 808 423 1011 2242 Methicillin-sensitive 
Staphylococcus aureus 413 (51.1%) 211 (49.9%) 341 (33.7%) 965 (43.0%) 
Haemophilus influenzae 203 (25.1%) 38 (9.0%) 52 (5.1%) 293 (13.1%) 
Pseudomonas aeruginosa 214 (26.5%) 225 (53.2%) 859 (85.0%) 1298 (57.9%) 
Burkholderia cepacia complex 13 (1.6%) 15 (3.5%) 75 (7.4%) 103 (4.6%) Methicillin-resistant  
S. aureus 14 (1.7%) 13 (3.1%) 68 (6.7%) 95 (4.2%) 1Number and percentage of patients with at least one culture positive for the organism. 
2.3.2 P. aeruginosa and CF Infection of CF patients with P. aeruginosa is often associated with higher rates of hospitalisation, decline in lung function and mortality.  Early P. aeruginosa infections are usually intermittent and involve different strains that are presumably acquired from the environment. These strains are typically non-mucoid, motile, sensitive to antibiotics and express an array of virulence factors to promote acute infection (Goldberg, 2010). During prolonged infection, P. 
aeruginosa undergoes adaptive transformations allowing it to survive and persistently colonise the CF lung (Miller & Mahenthiralingam, 2003). As part of the in-vivo transformation process, P. 
aeruginosa assumes a mucoid phenotype leading to development of a complex biofilm structure, which protects against phagocytosis and antibiotic penetration (Anthony et al., 2002). In addition, P. aeruginosa may also down-regulate flagella, pilli and exoenzyme expression (Goldberg, 2010) as these factors are actively targeted by the human immune system (Mahenthiralingam, Campbell, Foster, Lam, & Speert, 1996; Vu-Thien et al., 2007). Once P. 
aeruginosa has successfully established colonisation, it is very difficult to eradicate and an increase in patient morbidity is observed (Aaron, 2006).  
2.4 P. aeruginosa population structure The population structure of P. aeruginosa has been studied by a number of researchers seeking to understand the relationship between environmental and clinical/CF strains of P. aeruginosa.  The population structure of P. aeruginosa is under considerable debate, having been described as ‘clonal’ (Vernez, Hauser, Bernasconi, & Blanc, 2005), ‘non-clonal’ (Curran, Jonas, Grundmann, Pitt, & Dowson, 2004), ‘net like’ (Kiewitz & Tümmler, 2000) and ‘non-clonal epidemic’ (Maatallah et al., 2011; Pirnay et al., 2009). The contrasting population structure classifications possibly result from the bacterial strains and molecular typing methods used by the authors. Vernez et al. (2005) employed MLST of housekeeping genes to describe a clonal population structure.  The majority of isolates used in this study were derived from clinical sources, 
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creating a sample bias. Around the same time, another study using an MLST scheme was published (Curran et al., 2004). This paper interrogated a different set of housekeeping genes and used both environmental and clinical strains to describe a non-clonal population structure. More recently, a non-clonal epidemic population structure was suggested by Maatallah et al. (2011) by performing MLST of mostly clinical and some environmental strains derived from Mediterranean countries. However, the population structure described may not be representative of the global population of P. aeruginosa as the strains used in this study were isolated from a restricted geographical location.  Some studies have suggested that the population structure of P. aeruginosa cannot be reliably assessed using a single genetic marker (Denamur, Picard, Decoux, Denis, & Elion, 1993; Picard, Denamur, Barakat, Elion, & Goullet, 1994).  To rectify this, Pirnay et al. (2009) applied a ‘polyphasic approach’ to determine the population structure of P. aeruginosa using 328 clinical and environmental strains sourced globally.   Multiple targets were analysed, these include: O-serotype, Fluorescent Amplified Length Polymorphism patterns, nucleotide sequences of oprI, oprL and oprD genes,  pyoverdine receptor gene profile (fpvA type and fpvB type prevalence) and the occurrence of exoenzyme genes (exoS and exoU) and group 1 pilin gylcosyltransferase gene, tfpO.  Concatenation of the data set revealed a ‘nonclonal epidemic’ population structure whereby frequent recombination events gave rise to highly successful epidemic clones. The diverse collection of CF isolates used in this study clustered into a ‘core-lineage’ that is predominant in both environmental and clinical habitats. Whilst these strains were genotypically not-identical, they shared a set of characteristics (Pirnay et al., 2009).    A number of studies have confirmed a close relationship between clinical and environmental isolates. Specifically, Pirnay et al. (2005) identified known clinical clonal complexes in water samples from the Woluwe River in Brussels, Belgium and found that the river strains clustered closely with representative clinical isolates originating from diverse geographical locations.  Similarly, Curran et al. (2004) identified environmental strains belonging to clonal complexes that were responsible for invasive disease. Khan et al. (2008) identified a close relationship between freshwater, soil and clinical strains but found that the deep ocean strains formed a distinct cluster. Foght et al. (1996) demonstrated that P. aeruginosa strains derived from gasoline contaminated aquifers could not be distinguished from the representative clinical strains (including CF strains). However, this study is limited in that it examined a single gene target, the 16S-23S rDNA internal transcribed spacer region, only.  The incorporation of additional sequence data from other genes may demonstrate increased variation between strains. Although previous studies have found some relationships between clinical and 
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environmental strains, little is known about what influences or determines P. aeruginosa population structure. It has been proposed that P. aeruginosa’s diverse population structure is mostly influenced by the natural environment (Selezska et al., 2012) whereby genetic mechanisms such as horizontal gene transfer alter the genetic material to facilitate survival in diverse natural and clinical environments (Mathee et al., 2008).  
2.5 CF clonal strains The presence of clonal strains (strains that are derived from the same ancestral line) known to be ‘shared’ amongst CF patients is a well-studied issue. A number of CF clonal strains are also referred to as ‘epidemic’ strains when patient-to-patient transmission events are strongly suspected. A summary of the clonal strains present within CF communities worldwide is provided in the following pages.   
2.5.1 United Kingdom clonal strains 
1.5.1.1 The Liverpool epidemic strain Cheng et al. (1996), who applied molecular testing, were the first to provide evidence of an epidemic strain of P. aeruginosa circulating within the CF community.  This strain,  that was resistant to ceftazidime and other β-lactam antibiotics, confirmed with PFGE and flagellin typing was found to be infecting 55 out of 65 children treated at the paediatric Liverpool CF clinic (Cheng et al., 1996). A number of years later, this clonal strain now termed the Liverpool epidemic strain (LES), was isolated from adult CF patients, present in 63 out of 80 adult patients tested (Panagea et al., 2003). The spread of the LES to other geographical locations was discovered through a survey performed on 849 isolates from CF centers in England and Wales (Scott & Pitt, 2004). The Liverpool epidemic strain was the most prevalent clonal strain represented in 11 % of isolates and was present in 48 % of centres studied (Scott & Pitt, 2004).  Studies in the UK have identified LES at CF centres in WestMidlands (Chambers et al., 2005); Sheffield (Edenborough et al., 2004); Manchester (Jones et al., 2005b) and Belfast (Kakinuma et al., 2010).  The spread of the LES outside of the UK has also been reported. The LES has been isolated from patients attending CF clinics in Ontario, Canada and was found to be present in 15 % of patients tested (Aaron et al., 2010). The LES has also been identified in Australian CF patients (Kidd, Grimwood, Ramsay, Rainey, & Bell, 2011). A number of studies have highlighted the deteriorating clinical status of CF patients infected with the LES. Al-Aloul et al. (2004) compared the clinical course of matched patients over a five year period and found that infection with LES was associated with greater loss of lung function and malnutrition of patients compared with those who harboured unique strains (Al-Aloul et al., 2004). Further studies have supported these findings and concluded that infection with LES in 
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their respective centres was associated with a higher mean number of days spent in hospital (Chambers et al., 2005), a greater rate of death or lung transplantation compared with those with a unique strain (Aaron et al., 2010) and plural empyema (Mohan et al., 2010). There have also been reports of increased antibiotic resistance by LES compared with unique strains (Chambers et al., 2005). In another study, Ashish et al. (2012) found that over a five year period the LES developed a greater resistance to antibiotics and exhibited an enhanced rate of acquisition of antibiotic resistance over time. The difficulty in treating this strain and the use of aggressive antibiotics has been associated with acute renal failure in some CF patients (Al-Aloul, Miller, Stockton, Ledson, & Walshaw, 2005). It has been proposed that the LES may exhibit enhanced virulence, as LES transmission has been reported from chronically infected CF patients to CF-negative parents (McCallum et al., 2002), to a pet cat (Mohan et al., 2008) and to another CF-negative child (Wallace et al., 2005). Forthergill et al. (2007) observed an overproduction (OP) phenotype in some LES isolates. The OP phenotype is characterised by deregulation of the Quorum Sensing system leading to increased production of virulence related exoproducts such as pyocyanin. Excess production of pyocyanin has also been linked with pulmonary exacerbations (Mowat et al., 2010). Recent studies have confirmed that the LES virulence varies intra-clonally (Carter et al., 2010; Salunkhe et al., 2005). Table 4 provides a summary of these findings.  
Table 4: Studies of Liverpool epidemic strains in infection models.  Adapted from Forthergill et al. (2012) 
Isolate OP1 Mouse2 C.elegans2 Biofilm3 Comments LESB58  + Low High High CF isolate, 1988 LES431 +  High High Low Isolated from non-CF parent of a CF patient in 200; missing LES prophage 2 LES400 -  Low Low High CF isolate, 1998; lasR mutant 
LESB65  + Medium High High CF isolate, 2003; missing prophage 5; established long persistance in lungs and nasopharynx in murine model 1OP, overproduction phenotype 2 Columns headed mouse and Caenorhabditis elegans refer to levels of virulence in the respective infection models 3 Column headed Biofilm refers to levels of biofilm formation  
2.5.1.2 Manchester epidemic strain The presence of a clonal strain common to patients attending the CF unit in Manchester was first discovered in 2001 (Jones et al., 2001).  The Manchester Epidemic Strain (MES) was present in 14% of patients attending this clinic (Jones et al., 2001) with the prevalence of infection rising in later years (Jones et al., 2005a). Since its discovery, MES has also been 
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identified in CF centres located elsewhere (Chambers et al., 2005). Jones et al.  (2003) examined inflammatory markers in patients infected with MES compared with patients that harboured unique strains and concluded that infection with MES was not linked with a heightened inflammatory response (Jones et al., 2003b).  This study conflicts with more recent findings that patients infected with MES experienced more frequent respiratory exacerbations and a greater need for intravenous antibiotics and inpatient care. However, no differences in lung function or nutritional status were observed (Jones et al., 2010).  As with the LES infections, super-infection of unique strains with the MES has also been observed, occurring in 13 patients examined over an eight year study period (Jones et al., 2010). 
2.5.1.3 Midlands epidemic strain A study conducted in the mid 2000’s of patients attending the West Midlands Adult CF centre identified Midlands epidemic strain (MID) that infected 30% of patients (Chambers et al., 2005). The MID strain has also been isolated from other CF facilities apart from West Midlands and is  considered the second most common genotype in a survey of CF centres in England and Wales as 29 % of isolated strains were the MID epidemic strains (Scott & Pitt, 2004).  Despite its abundance, infection with MID strains was not significantly associated with poorer clinical outcome or treatment requirements compared with those harbouring unique strains (Chambers et al., 2005). However, this was a cross-sectional study and impacts of infection with MID strains over a longer time period were not explored. Antibiotic resistance patterns of both MID and unique strains were comparable except that MID strains were notably more resistant to colomycin (Chambers et al., 2005). 
2.5.1.4 Leeds Denton et al. (2002) reported a small outbreak of a colistin-resistant strain infecting patients attending the Regional Paediatric Cystic Fibrosis Unit in Leeds, UK. Molecular testing confirmed the transmission of a genetically identical strain between patients (Denton et al., 2002). 
2.5.1.5 Sheffield The Sheffield CF facility reported the presence of the LES and a Sheffield transmissible strain circulating in patients attending their clinic. In a survey performed, 18 % of patients harboured the Sheffield strain (Edenborough et al., 2004). The study concluded that infection with the Sheffield strain was linked with increased treatment requirements and poorer lung function and lower nutritional status (Edenborough et al., 2004). 
 2.5.1.6 Stoke/Trent Scott and Pitt (2004) identified the presence of a small cluster of genetically identical strains in regional UK, these were designated the Stoke and Trent strains. At present, no studies have assessed the clinical impact of infection with the Stoke or Trent genotypes.  
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2.5.2 Other European and Scandinavian CF clonal strains 
2.5.2.1 Netherlands Molecular testing using AFLP analysis was carried out on P. aeruginosa strains isolated from children attending a cystic fibrosis summer camp in the Netherlands. This study revealed the presence of genotypically identical strains shared among patients (Brimicombe et al., 2008). More recently, an MLST approach was used to identify two distinct clonal strains circulating among patients attending CF clinics in the Netherlands (van Mansfeld et al., 2009). Sequence Type (ST) 406 was found to be present in 15 % of the patients tested whereas ST497 was present in 5 % of the patients. ST406 was more likely to be isolated from patients aged between 15 and 24 whereas ST497 was isolated from mostly older patients (van Mansfeld et al., 2009). A follow up study that assessed the clinical impacts found no association between infection with ST406 and an unfavourable clinical outcome (de Vrankrijker et al., 2011).   
2.5.2.2 Copenhagen A recent study that employed SNP ArrayTube biochips technology, indentified two distinct clones isolated from patients attending the Copenhagen CF clinic (Jelsbak et al., 2007). Analysis performed on stored samples, suggests that these strains could have been present in the Copenhagen CF unit for nearly 20 years (Jelsbak et al., 2007). Despite its persistence in this population, the clonal strains exhibited reduced virulence in a Caenorhabditis elegans killing assay compared with a unique strain harboured by another CF patient (Jelsbak et al., 2007). 
2.5.2.3 Clone C Clone C is widely distributed in both environmental and clinical habitats. It has been isolated from river water, drinking water and swimming pool water in Germany (Römling, Wingender, Müller, & Tümmler, 1994) and river water in Belgium (Pirnay et al., 2005).  CF patients in France (Dinesh, Grundmann, Pitt, & Römling, 2003), Canada (Speert et al., 2002), Germany (Kresse, Dinesh, Larbig, & Römling, 2003; Römling, Kader, Sriramulu, Simm, & Kronvall, 2005; Romling, Schmidt, & Tummler, 1997), England (Scott & Pitt, 2004) and Australia (Kidd et al., 2011) have also been reported to harbour Clone C isolates. Clone C’s pathogenicity extends beyond the CF population as this type has been isolated from ear infections (Römling et al., 1994), urinary tract infections and peritoneal dialysis fluid (Dinesh et al., 2003). Romling et al.  (2005) did not detect enhanced biofilm formation or antibiotic resistance in Clone C strains. Further studies will be required to elucidate the reason for this strain’s ability to adapt to diverse habitats, at present this remains unknown.  
2.5.2.4 Norway In Norway a genetically identical strain was shared by 45 % of the 60 patients tested who attended a CF center (Fluge et al., 2001). Several minor strains shared between two to four 
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patients were also detected (Fluge et al., 2001). Infection with the predominant strain was significantly associated with attendance at summer camps or training courses (Fluge et al., 2001).  There was no link between admissions to hospital and infection with the predominant strain (Fluge et al., 2001).  
2.5.3 Canadian clonal strains MLST typing of isolates harboured by patients attending CF clinics in Ontario identified the presence of LES strains (strain A) and another distinct clonal strain, ST439 (strain B) (Aaron et al., 2010). Strain B was present in 7 % of the adult CF patients tested and unlike strain A, strain B was not associated with a greater risk of death or lung transplants compared with those harbouring unique strains (Aaron et al., 2010). A study that examined transmission of P. 
aeruginosa strains between patients attending CF clinics in Vancouver found that there was an ‘extremely low risk’ of patients acquiring infection from clonal strains (Speert et al., 2002).  
2.5.4 Australian clonal strains There have been a number of reports that have documented presence of clonal strains circulating in Australian CF clinics. Evidence for a P. aeruginosa clonal strain infecting CF patients was first identified in Melbourne (Armstrong et al., 2002; Nixon et al., 2001). This strain, initially identified as pulsotype 1 by PFGE and now known as Melbourne epidemic strain or Australian epidemic strain I (AES-I), was isolated from 23 % of paediatric CF clinic patients (Armstrong et al., 2002) and was linked to the death of five children (Armstrong et al., 2002; Nixon et al., 2001). Longitudinal studies performed on this population found that patients infected with AES-I were more likely to be hospitalised for severe respiratory exacerbations and to die from lung disease (Armstrong et al., 2002). A follow up study performed on CF AES-I infections found that this epidemic strain was generally more resistant to antibiotics compared with non-epidemic strains and that cohort segregation procedures were successful in reducing the proportion of patients infected with this strain (Griffiths, Armstrong, Carzino, & Robinson, 2004).   Molecular testing of sputum samples produced by patients attending the CF facility at the Royal Prince Alfred Hospital (RPAH) in Sydney detected a clonal strain harboured by more than one third of the patients examined (Anthony et al., 2002). A more recent study that examined presence of AES-I in the adult CF population at the RPAH, found that 38 % of patients tested were infected with AES-I (Tingpej et al., 2010). This study also reported presence of other minor clonal strains; Sydney 1 (S-1) present in 5 % of the population and S-2 present in 3 % of patients tested (Tingpej et al., 2010).   
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O’Carroll et al.  (2004) identified a clonal strain in Brisbane CF clinics which was harboured by 59 % of adult and paediatric CF patients tested and was distinct from the one found in the Melbourne and Sydney centres. This strain, now referred to as AES-II, was associated with significantly lower lung function and more inpatient days compared with patients harbouring unique strains (O'Carroll et al., 2004). However, this study was cross-sectional in design and a more longitudinal approach is needed to elucidate the impact of this clonal strain on the CF population.  A third distinct Australian CF clonal strain was identified in Tasmania by Bradbury, Champion and Reid (2008). This strain, now designated as AES-III, was harboured by 26 % of adults tested and also present in clinics in all regions of Tasmania (Bradbury et al., 2008).  This study was limited however, because infection with AES-III in younger (<15 yrs) CF patients was not examined. The authors also identified a minor clonal strain present in 11 % of adult patients tested. Clinical impact on patients harbouring AES-III were examined in a two year study, and the authors concluded that infection with AES-III was associated with greater treatment requirements compared with patients harbouring unique strains (Bradbury et al., 2008).  There have been a number of reports that have demonstrated the spread of clonal strains to each major city along the east coast of Australia. The AES-I strain, common in Melbourne and Sydney, has also been isolated from adult and paediatric patients CF centres in Brisbane (O'Carroll et al., 2004) and in Tasmanian CF centres (Bradbury et al., 2008). Similarly, AES-II common in Brisbane, has been isolated in 5 % of adult CF patients attending a Sydney clinic (Tingpej et al., 2010).  Co-infection with multiple Australian clonal strains has also been observed (Bradbury  et al., 2008; Tingpej et al., 2010).   Tingpej et al.  (2010) examined patients that had either AES-I, AES-II, S-1 or S-2 and recognized a trend between infection with an epidemic clone and higher median number of days of hospitalization.  A study that examined virulence of AES-I and AES-II concluded that both strains were significantly more likely to produce proteases than non-clonal strains, but the link between protease activity and transmissibility or increased virulence was not established (Tingpej et al., 2007).  Gene expression studies that examined AES-I and AES-II concluded that AES-I displays enhanced biofilm formation (Manos et al., 2008) while AES-II exhibits an upregulated type III secretion system gene cassette (Manos et al., 2009).  
2.5.5 Negative studies A number of studies could not identify the presence of transmissible strains circulating within their respective CF centres. These include in New Zealand (Schmid et al., 2008), Ireland (Clarke et al., 2008), Prague (Vosahlikova et al., 2007), Brazil (Silbert, Barth, & Sader, 2001) and New 
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Delhi (India) (Agarwal, Kapil, Kabra, Das, & Dwivedi, 2005).  The presence or absence of a clonal strain circulating within a CF clinic may be due to the different segregation and infection control policies implemented by individual CF clinics.  The proposed mechanisms by which clonal strains are spread to CF patients are discussed in detail in the following sections.   
2.6 Modes of transmission Transmission routes of clonal P. aeruginosa strains are still largely undefined and remain a significant knowledge gap. It has been proposed that clonal strains may be acquired from an environmental source or transmitted by patient-to-patient spread (direct or indirect).   Apart from Clone C, no other international clonal strain known to infect CF patients has been detected in the natural environment. Kidd et al. (2012) performed MLST on samples from natural environments and did not detect any of the three major Australian CF clonal strains. Similar results were obtained by Minion (2010) who did not detect any of the Australian or UK clonal strains in their collection of isolates derived from vegetables, water or soil. Despite negative findings, acquiring of the clonal strains from the natural environment cannot be ruled out. The natural environment covers a large spatial area and even a single isolated geographical region has been shown to host a diverse collection of P. aeruginosa strains (Pirnay et al., 2005). Therefore, just because clonal strains have not been detected in the natural environment, it does not necessarily mean that they do not exist there. This is supported by the finding that AES-I has been isolated from the bloodstream of a patient in the Czech Republic, indicating that the strain could have been acquired independently (ie from routes other than person-to-person spread) (Nemec, Krizova, Maixnerova, & Musilek, 2010).   A number of CF centres have performed environmental surveys within their clinic to detect potential environmental reservoirs of clonal strains (Armstrong et al., 2002; Bosshammer et al., 1995; Campana, et al., 2004; Cheng et al., 1996; Jones & Webb, 2003; McCallum et al., 2001; Tubbs et al., 2001; Zembrzuskasadkowska, Sneum, Ojeniyi, Heiden, & Hoiby, 1995). While P. 
aeruginosa has been isolated from inanimate objects (Bosshammer et al., 1995; Jones & Webb, 2003) and moist conditions (McCallum et al., 2001; Zembrzuskasadkowska et al., 1995) such as from showers, sinks, drains or toilets, none of these sources were consistent environmental reservoirs for clonal strains. Bosshammer et al. (1995) showed that a paediatric CF clinic in Hannover (Germany) was highly contaminated with several genotypically identical strains of P. 
aeruginosa, that were present in multiple sources throughout the clinic including in a non-CF patient room. Table 5 outlines the genotypically identical strains found and the locations were they were isolated. Despite their presence in the clinic environment, transmission of the strains 
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to CF patients was rare. This indicates that environment to patient transmission is not always an effective route and that other factors such as strain virulence may be important for transmission. This study is in conflict however, with findings presented by Schelstraete et al. (2008) who found that the genotypes of numerous newly infected CF patients were identical to those isolated from the home environment. However, environmental household sampling took place one month after the first P. aeruginosa positive culture found in CF patients and therefore it is possible that the patients acquired P. aeruginosa elsewhere and then infected the home environment.  
Table 5: Location of common P. aeruginosa clones. Adapted from Bosshammer et al. (1995) 
Clone 
First study 
(1989/1990): Moist 
habitats 
Second study 
(1993/1994): Moist 
habitats 
Second study: Other 
locations 
M Patients' room (CF ward; 1,2,6,7) Patients' room (CF ward) 1-10 and Patients' room (non-CF ward) 1 
Physiotherapy room 1: cream and Physiotherapy room 3: soap solutions 
AA Examination room (outpatient clinic) Physiotherapy room 1   
TT Patients' room (CF ward) 4 Patients' room (CF ward) 2   
UU Examination room (CF ward) Examination room (CF ward) and Physiotherapy room 2 Physiotherapy room 1, 3: water in bottle  Although no continuous environmental reservoirs of clonal P. aeruginosa strains have been identified, temporary reservoirs have been observed. Panagea et al. (2005) detected the LES in a single sink drain used by a CF patient, CF patient hands, bed linen, clothes and respiratory equipment. The reservoirs were however, short-lived and it is not known whether they could provide a transmission route.  Patient-to-patient transmission is considered to be the most likely mode of acquiring clonal P. 
aeruginosa infections. This is largely because studies have failed to identify a common environmental reservoir and segregation of patients by clonal strain status has prevented incidences of new clonal strain infection and/or reduced the proportion of patients infected with clonal strains (Griffiths et al., 2005; Griffiths et al., 2012; Jones et al., 2005a; Morris et al., 2009). Moreover, Wallace et al. (2005) demonstrated the transmission of the LES from a chronically infected CF patient to a non-CF patient during a one-hour car trip, indicating that close contact between patients can be important for transmission of the clonal strains.  However, this study was published in abstract format and no further details were provided about contact 
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between subjects before and after the car trip or if the non-CF patient had made contact with other LES positive patients.   
2.6.1 Airborne transmission A number of studies have supported the theory that P. aeruginosa clonal strains can be transmitted to other CF patients via aerosols. An aerosol is defined as ‘a suspension of solid or liquid particles within a gas’ (Clifton & Peckham, 2010). Clifton et al. (2008) in their study of artificially generated aerosols, demonstrated that P. aeruginosa could survive within aerosol droplet nuclei. The authors did not detect any differences in airborne survival rate between clonal and non-clonal strains, but did indicate that a mucoid phenotype exhibited better survival in an aerosolised state. Further studies performed by Clifton et al. (2008), established that viable bacteria from artificially generated aerosols could still be detected 45 minutes after aerosol generation had ceased.  The ability of CF patients to produce biological aerosols has been examined by a number of researchers. Wainwright et al. (2009) isolated P. aeruginosa from the cough aerosols from 89 % of CF patients tested and demonstrated that CF patients were able to produce cough generated aerosols containing P. aeruginosa of various particle sizes.  Air samplings performed at numerous CF centres have also detected P. aeruginosa after physiotherapy sessions, (Ferroni et al., 2008) during airway clearance procedures, (Jones et al., 2003a; Meyer, Andersson-Marforio, & Petersson, 2006); in patient bedrooms (Ferroni et al., 2008; Panagea et al., 2005) and in ward corridors (Panagea et al., 2005). In particular, the LES was detected up to three hours after infected patients had left the room (Panagea et al., 2005).  Concentration of P. aeruginosa within cough-generated aerosols varies between patients (see Figure 2) and is likely to depend on host factors (Wainwright et al., 2009). Studies that have examined direct exposure of aerosols containing P. aeruginosa to CF patients would be unethical (Clifton & Peckham, 2010), and therefore conclusive evidence for airborne transmission and infectious dose cannot be established.            
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Figure 2: Distribution of total corrected voluntary cough aerosols.  Symbols denote: subject with Burkholderia cenocepacia (B); colony forming unit (CFU); positive ambient air samples isolated (+) (Wainwright et al., 2009).   
 The laboratory methods used for detection and epidemiological studies of clonal strains are as follows.  
2.7 Phenotyping methods Early epidemiological studies used phenotyping methods to characterise microbial isolates. P. 
aeruginosa phenotyping methods include biotyping, pyocin typing, serotyping, phage typing and antibiobiotic sensitivity profiles. These methods are limited in their ability to differentiate between P. aeruginosa strains due to their low discriminatory power (Ojeniyi, 1994), poor reproducibility (Ojeniyi et al., 1990) and variable results within strains (Armstrong et al., 2002; Fonseca et al., 2008; McCallum et al., 2001; Struelens, Schwam, Deplano, & Baran, 1993). Moreover, P. aeruginosa can undergo phenotypic change during colonisation of CF lungs, reducing the capacity of these methods to characterise strains (Hancock et al., 1983; Pitt, MacDougall, Penketh, & Cooke, 1986). Due to phenotyping limitations, genomic fingerprinting techniques or genotyping methods have been developed as an alternative approach for characterising P. aeruginosa strains.  
2.8 Genotyping methods 
2.8.1 Pulsed field gel electrophoresis PFGE is a form of restriction analysis where microbial DNA is digested with a restriction enzyme that recognises specific cut sites within the genome. In conventional agarose gel electrophoresis large DNA restriction fragments greater than 50 kbp in size do not migrate efficiently (Singh, Goering, Simjee, Foley, & Zervos, 2006). PFGE uses a specialised gel apparatus to switch the electric field direction periodically allowing separation of large sized restriction fragments (>1000 kbp) (Singh et al., 2006). The genetic relatedness of isolates are then determined by 
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visual comparison and interpretation of band patterns produced, using the criteria described by (Tenover et al., 1995) or through computer software programs capable of analysing gels.   The first PFGE method was developed for yeast by Schwartz and Cantor in 1984 (Schwartz & Cantor, 1984). Since then PFGE has been performed on at least 40 different species of pathogens (Singh et al., 2006) including P. aeruginosa, and has been long considered to be the ‘gold standard’ genotyping method (Spencker et al., 2000) due to its high discriminatory power and good reproducibility (Grundmann, Schneider, Hartung, Daschner, & Pitt, 1995). Despite this, PFGE has been widely criticised as a molecular typing method for P. aerguinosa and alternative methods have been sought.  PFGE is time consuming and labour-intensive often-taking 4-5 days to complete (Syrmis et al., 2004). Specialised gel electrophoresis equipment is required and qualified technicians are needed to perform and analyse the results (Doléans-Jordheim et al., 2009).  Degradation of DNA can result in reduced ability to be typed (Grundmann et al., 1995; Römling & Tümmler, 2000) and mucoid P. aeruginosa variants can skew estimations of cell density, an essential step in the process, that can lead to unresolved restriction fragment patterns (Kersulyte, Struelens, Deplano, & Berg, 1995).   PFGE has also been criticised for its lack of inter-laboratory reproducibility, as it requires thorough standardisation to achieve consistent results (Harrington et al., 2007) and has limited capacity to be digitalized using a global data management system.  Forthergill et al. (2010) suggested that PFGE is only suitable for analysing isolates involved in local breakouts in hospitals or communities that last for short periods (one to three months) and should not be used to type bacteria responsible for prolonged chronic infection such as those common in CF patients. Their reasoning is that point mutations, insertions and deletions of DNA increase genomic variation and therefore impact the banding patterns produced by PFGE that give misleading or inaccurate results (Fothergill et al., 2010). Kidd et al. (2011) stated that in repeated sputum collections of CF patients, 47 % of isolates with the same ST experienced changes in one to five PFGE bands that affected strain classification.  This evidence adds further support to the observation that PFGE is not suitable for longitudinal studies.  
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Figure 3: Example of a PFGE gel image illustrating the differentiation of strains based on band patterns 
produced (Dinesh et al., 2003) 
2.8.2 Random amplified polymorphic DNA (RAPD) RAPD is a PCR based method that uses a nine to ten base pair arbitrary primer to randomly bind to DNA at low annealing temperatures (Tyler, Wang, Tyler, & Johnson, 1997). Analysis is performed after agarose gel electrophoresis of amplified PCR products to give a genetic profile that is representative of the genome sequence. RAPD is considered one of the simplest typing methods as no specific knowledge of the target organism is required and analysis can be carried out with reduced quality DNA and at low DNA concentrations (~5 ng) (Kersulyte et al., 1995; Mahenthiralingam et al., 1996). This method has been used in many epidemiological investigations of CF patients (Campbell, Mahenthiralingam, & Speert, 2000; Hoogkamp-Korstanje, Meis, Kissing, van der Laag, & Melchers, 1995; Kersulyte et al., 1995; Mahenthiralingam et al., 1996; Schelstraete et al., 2010). Campbell, Mahenthiralingham and Speert (2000) suggested that the RAPD genotyping method for P. aeruginosa is highly reproducible, simple and suitable for analysis of a large number of isolates.  Despite this, its application for use as an inter-laboratory method has been criticized. RAPD analysis is susceptible to many PCR conditions including Mg2+ concentration, primer to template ratio, DNA extraction methods, variations in the Taq polymerase used and thermocycler (Tyler et al., 1997). Giske et al. (2006) identified differences in genetic profiles of the same isolate performed in different laboratories.  As a result, it has been suggested that RAPD analysis is only suitable for primary screening of samples (Campbell et al., 2000; Tyler et al., 1997) and should only be used for intra-laboratory comparisons (Giske et al., 2006). 
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2.8.3 Repetitive element PCR Non-coding repetitive sequences are wide spread across the genomes of many bacterial species (Doléans-Jordheim et al., 2009; Healy et al., 2005; Singh et al., 2006). Primers amplify the regions between these repetitive sequences to produce PCR products that vary in size creating a strain-specific profile that is visualised by agarose gel electrophoresis (Doléans-Jordheim et al., 2009; Singh et al., 2006).  Assays targeting both enterobacterial repetitive intergenic consensus (ERIC) and BOX repetitive elements have been used to type P. aeruginosa successfully with high reproducibility and efficient typing (Syrmis et al., 2004).  Rep-PCR assays are performed under highly stringent conditions and are therefore not as susceptible to PCR-related that impact RAPD approaches (Syrmis et al., 2004). In comparison with PFGE, Rep-PCR is more cost effective, simpler and quicker to perform (Doléans-Jordheim et al., 2009; Syrmis et al., 2004) but some studies reported a lower discriminatory power (Kidd et al., 2011; Syrmis et al., 2004). These findings contradict those of Silbert et al. (2004) who claimed that PFGE and ERIC-PCR shared the same level of discrimination. Recently, a semi-automated Rep-PCR assay for P. 
aeruginosa has been developed (Doléans-Jordheim et al., 2009). The ‘DiversiLab’ system eliminates the need for interpreting band patterns on agarose gels and employs a software program that analyses and digitizes microfluidic data creating a strain specific profile that can be compared with archived data uploaded onto the website (Healy et al., 2005).   
2.8.4 Multiple-Locus Variable-Number Tandem-Repeat (VNTR) analysis (MLVA) MLVA has been applied in survey studies of P. aeruginosa infection in CF patients (van Mansfeld et al., 2010; Vu-Thien et al., 2007). This PCR based method interrogates the fragment sizes of polymorphic VNTR sequences present in the loci of many bacterial genomes (Onteniente, Brisse, Tassios, & Vergnaud, 2003). The number of repeats present at the specific VNTR translates to a strain-specific barcode (Vu-Thien et al., 2007). A  few major advantages of MLVA typing are that typing data (ie barcodes) can be formatted to web-based reference databases, allowing inter-laboratory comparison of results (Vu-Thien et al., 2007) and typing with MLVA is cost effective as it does not require sequencing or expensive equipment and reagents (van Mansfeld, Bonten, & Willem, 2009). Onteniente et al. (2003) described their MLVA typing scheme as highly discriminatory. Studies however, that have compared the discriminatory power of MLVA to PFGE have produced conflicting outcomes. van Mansfeld et al. (2009) found that the two methods have comparable discriminatory powers while Khalifa et al. (2010) concluded that MLVA shows less discriminatory power than PFGE. The differences observed in discriminatory power may be due to varied gene targets or different isolates used in the respective studies.  
2.8.5 Multilocus Sequence Typing (MLST) The P. aeruginosa MLST typing scheme utilises DNA sequences from internal 400-500bp gene fragments from seven different conserved housekeeping genes. The sequence of each gene 
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fragment is compared with allele sequence data available for that particular locus and is assigned an arbitrary allele number (Aanensen & Spratt, 2005; Singh et al., 2006). If the allele sequence data differs by at least one polymorphism, it is considered a distinct allele (Singh et al., 2006). The combination of allele numbers for each locus describes an allelic profile. Each unique allelic profile is designated with a sequence type number that represents the strain (Aanensen & Spratt, 2005; Curran et al., 2004; Singh et al., 2006). The major advantage of MLST is that it facilitates inter-laboratory comparisons of typing data on a global scale as there is a centralised database available on the internet (Maiden et al., 1998). The MLST database for P. aeruginosa is hosted by Oxford University at the domain http://pubmlst.org. MLST schemes target the core genome of bacterial species and therefore provide information on the evolutionary changes and population structure of the organism (Kidd et al., 2011; Waine, Honeybourne, Smith, Whitehouse, & Dowson, 2009). Giske et al. (2006) described MLST as less discriminatory than PFGE and RAPD. This is largely due to the fact that MLST targets genes in the core genome while PFGE and RAPD target both the core and accessory genomes of bacterial species. In addition, MLST is expensive, time consuming, requires specialised equipment and specially trained technicians and as a result is not suitable for adoption in routine laboratories (Singh et al., 2006).  Despite this, Kidd et al. (2011) have suggested that MLST is highly useful in long-term studies and for detecting novel strains due to its portability and stability over time.  
 
Figure 4: The characteristic method and principles of multilocus sequence typing (Singh et al., 2006) 
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Figure 5: P. aeruginosa MLST housekeeping genes and the number of known alleles in each gene. * adapted 
from MLST database (http://pubmlst.org/paeruginosa), accessed 15/10/12 
2.8.6 Single Nucleotide Polymorphisms (SNPs) SNP-based typing approaches have recently been applied to characterise strains of many bacterial species (Foster et al., 2008; Huijsmans et al., 2011; Rathnayake et al., 2011; Sheludchenko et al., 2010; Wiehlmann et al., 2007). In particular, SNP genotyping methods for various bacterial pathogens have been developed by our research group using the bioinformatics program ‘Minimum SNPs’ (Honsa et al., 2008; Hussain et al., 2011; Huygens et al., 2006; Price, Inman-Bamber, Thiruvenkataswamy, Huygens, & Giffard, 2007; Price et al., 2006; Rathnayake et al., 2011; Robertson et al., 2004; Sheludchenko et al., 2010; Stephens et al., 2006). The ‘Minimum SNPs’ software package previously described by Robertson et al. (2004) derives SNP sets from MLST housekeeping gene sequences with optimised resolving power based on Simpson’s index of diversity (Hunter & Gaston, 1988). The SNP sets used to genotype bacterial strains in previous studies have demonstrated high discriminatory power: S. aureus  D-value of 0.95 (Robertson et al., 2004), Campylobacter jejuni D-value 0.98 (Price et al., 2006), Escherichia 
coli D-value of 0.96 (Sheludchenko et al., 2010); Enterococcus faecalis D-value of 0.96, E. faecium D-value of 0.91(Rathnayake et al., 2011), S. epidermidis D-value 0.95 (Hussain et al., 2011).   
2.8.7 High Resolution Melt Analysis (HRMA) Real-time polymerase chain reaction (RT-PCR) is an ideal platform for high-throughput bacterial genotyping (Price, Smith, Huygens, & Giffard, 2007). Recent developments involve the coupling of RT-PCR with HRMA, using a single instrument (Stephens, Inman-Bamber, Giffard, & Huygens, 2008). In HRMA the fluorescence produced by a DNA intercalating dye (eg SybrGreen) is monitored during strand dissociation events during the melt phase. The PCR amplicon is 
 
aroE (159 alleles)  
acsA 145 alleles* 
trpE (161 alleles) ppsA (116 alleles) 
guaA (125 alleles)  
nuoD (87 alleles) 
mutL (136 alleles) 
P. aeruginosa MLST 
Housekeeping Genes 
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subjected to small temperature increments. At high temperatures, the strands of DNA denature releasing the dye and a drop in fluorescence can be observed (Erali, Voelkerding, & Wittwer, 2008). While meltcurves are principally used to establish the melting temperature (Tm) of an amplified DNA fragment, the shape of the melt curve is representative of the DNA sequence undergoing melting, allowing amplicons to be distinguished based on their melt curve shape, even if they share the same Tm value (Stephens et al., 2008). Shape differences in the melting curves can be displayed with normalization and comparison software (Price, Smith, et al., 2007), allowing the degree of sequence relatedness to be observed from which the sequence relatedness can be inferred. The high resolving power of HRMA means that even a single polymorphism can influence the melt curve, facilitating the detection of SNPs (Price et al., 2006; Reed, Kent, & Wittwer, 2007). In comparison to other counterparts, the advantages associated with HRMA make it a superior method for genotyping studies. This method is quicker, cheaper and is performed on a generic instrument. No separation or processing of samples is required and a closed-tube method decreases the risk of contamination (Reed et al., 2007).   HRMA has been used traditionally in gene mutation analysis (Dufresne, Belloni, Wells, & Tsongalis, 2006; Graham, Liew, Meadows, Lyon, & Wittwer, 2005). Some recent microbiological applications that have used this technology have been reported. Odell et al. (2005) demonstrated the potential of HRMA to rapidly differentiate between bacterial species. This technology was applied successfully to the Mycobacteria spp. Price et al. (2007) emphasized the genotyping capability of HRMA technology when analyzing clustered regularly interspaced short-palindromic repeat (CRISPR) loci from Campylobacter jejuni. This study established that the resolving power of HRMA was equal to or exceeded that of PFGE and that HRMA could potentially be applied to any polymorphic DNA region, ranging from SNPs to entire genes (Price et al., 2007b). Soon after Stephens et al.  (2008) applied HRMA to differentiate spa sequence variants of S. aureus successfully and demonstrated the portability and potential of HRM technology for library based schemes. More recently, Merchant-Patel et al. (2010) used HRMA to interrogate the flaA gene of Camplyobacter jejuni and Campylobacter coli and found that the method could even successfully resolve large fragments of highly variable genes.  Numerous studies have used HRMA to interrogate high D-value ‘minimum’ SNPs to facilitate strain differentiation in several bacteria (Hussain et al., 2011; Lilliebridge, Tong, Giffard, & Holt, 2011; Richardson et al., 2011). Minimum SNP technology in conjunction with HRMA has not yet been applied to assess the genetic relatedness of P. aeruginosa strains isolated from different sources. 
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 Anuj et al. (2010) developed a SNP typing system for P. aeruginosa without the aid of a bioinformatics software package.  A set of 10 SNPs were derived from several housekeeping genes and were interrogated with HRMA. The 10SNPs HRM assay was able to discriminate AES-I, AES-II and P42 from a selection of cystic fibrosis P. aeruginosa strains.  The ability however, of this method to differentiate additional clonal strains (e.g AES-III, LES, MES) from unique strains and to differentiate a collection of unique isolates from each other was not established. The authors identified a limitation in their study because some SNPs could not be identified with HRM presumably due to sequence variations within the PCR amplicon. This indicates that this method cannot be applied easily for functions other than detection of a few Australian clonal strains. Clonal strain specific PCR assays for the LES (Panagea et al. 2003), MES (Lewis et al., 2005), Midlands epidemic strain (Smart, Walshaw, Hart, & Winstanley, 2006)and AES-1 (Williams et al., 2010) have already been developed. The clonal specific PCR assays target 1-2 genes compared with the 10SNP HRM assays which targets 10 regions per strain, therefore this method is less efficient at detecting these strains.  In addition, a few issues with respect to methods were recognised. No environmental strains were included in their collection of isolates and therefore the extent of sequence variation was not elucidated. In addition, HRM analysis is highly sensitive to DNA concentration, DNA was extracted using a heat treatment method and no standardisation of DNA concentration was performed.  Moreover, temperature increments during the high resolution melt phase were large at 0.5 ⁰C/s and therefore a high degree of resolution cannot be achieved. Greater resolution can be achieved using smaller temperature increments (i.e 0.02 – 0.05) (QIAGEN, 2011). Figures 6 and 7 demonstrate typical HRM curves generated with the QIAGEN Rotor-Gene Q instrument.         
Figure 6: Normalised graph analysis demonstrating C/T SNP differentiation in S. epidermidis (Hussain, 2011)  
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Figure 7: Difference graph analysis demonstrating C/T SNP differentiation in S. Epidermidis (Hussain, 2011)  
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2.9 Project hypothesis and specific aims 
Project Hypothesis: That the novel SNP genotyping method, interrogated by HRMA, can be applied to assess the genetic relatedness and population structure of CF clonal and environmental strains of P. 
aeruginosa.  
Aims and Objectives: 
The aims of this thesis are:  
Aim 1 To develop a culture collection of environmental P. aeruginosa strains  
Objective 1 To collect water samples from South-East Queensland  
Objective 2 To isolate and characterise P. aeruginosa from water and soil samples    (provided) using phenotypic and genotypic typing methods 
 
Aim 2  To develop a novel P. aeruginosa SNP genotyping system to assess genetic   relatedness between environmental and CF clonal strains 
Objective 1 To identify highly discriminatory SNPs in P. aeruginosa housekeeping genes    using the software program ‘Minimum SNPs’ 
Objective 2 To design primers to amplify the D-value SNPs and to optimise Real-time    PCR and HRMA conditions for genotyping P. aeruginosa strains 
 
Aim 3 To apply the SNP HRMA system to differentiate P . aeruginosa CF clonal environmental strains 
 
Objective 1 To generate SNP HRM profiles for P .aeruginosa CF clonal and environmental   strains 
Objective 2  To perform in silico SNP analysis of STs from the P. aeruginosa pubMLST    database and to study the population structure of CF strains in relation to   environmental strains  
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CHAPTER 3 
3.0 Methods and materials 
3.1 Collection of environmental samples: 
3.1.1 Water samples: Water samples (n=60) were collected from various locations and water body types in South East Queensland (SEQ). Sampling occurred over a four-month period before and after the December 2010 - January 2011 Queensland floods. Samples were collected in sterile Polyethylene terephthalate (PET) bottles, filled to a volume of 600 mL and stored at room temperature in dark and dry conditions to prevent overgrowth of psychotropic organisms. Table 6 lists the samples collected, together with their respective locations, dates of collection, and water body types.  
Table 6: Water sampling dates, geographical locations and water body types. 
Sample 
number 
Date 
collected Sample Location Sample Type 1 5/12/2010 Colleges crossing recreation reserve, Chuwar River 2 5/12/2010 Colleges crossing recreation reserve, Chuwar River 3 5/12/2010 Moggill Ferry east, Brisbane river River 4 6/12/2010 Brisbane River, Fig Tree Pocket River 5 6/12/2010 Brisbane River, Fig Tree Pocket River 6 6/12/2010 Biambi Yumba Park, Fig Tree Pocket Pond 7 6/12/2010 Residential Pond, Fig Tree Pocket Pond 8 8/12/2010 Botanical Gardens, CBD Pond 9 8/12/2010 Brisbane River, Botanical gardens CBD River 10 9/12/2010 1Fig Tree Pocket Pony Club, Fig Tree Pocket Puddle 11 11/12/2010 Cubberla street,  Fig Tree Pocket Pond 12 11/12/2010 1Fig Tree Pocket State School, Fig Tree Pocket Marsh 13 17/12/2010 Warrill creek, Warrill View Creek 14 17/12/2010 1Kital Road, Allora Puddle 15 18/12/2010 Darymple creek,  Allora Creek 16 18/12/2010 Dam (spring water), Farmland Allora Dam 17 18/12/2010 1Spring water, Farmland Allora Spring water puddle 18 18/12/2010 Top Dam, Farmland Allora Dam 19 18/12/2010 Farmland, Allora Borewater 20 18/12/2010 Farmland, Allora Borewater 21 18/12/2010 Farmland, Allora Rainwater Tank 22 31/12/2010 Cornmeal creek, Sunshine Plaza, Maroochydore Creek 23 31/12/2010 Cotton Cove, Maroochydore Seawater 24 31/12/2010 Cotton Cove, Maroochydore Seawater 25 31/12/2010 1Cotton Cove Maroochydore Seawater puddle 26 31/12/2010 Coolum beach, Coolum Seawater rock pools 
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Sample 
number Date collected Sample Location Sample Type 27 31/12/2010 1Coolum beach, Coolum Drain water 28 3/01/2011 Cubberla creek, Marist Bros College Rosalie Lavalla Sports Fields, Fig Tree Pocket Creek 29 3/01/2011 Witton Creek, Indooroopilly Creek 30 3/01/2011 Sandy Creek, Indooroopilly Creek 31 3/01/2011 Brisbane River, Indooroopilly  River 32 20/02/2011 Brisbane River, Fig Tree Pocket  River 33 20/02/2011 Pond adjacent Hardwood Drive, Mt cotton Pond 34 20/02/2011 Brisbane River, Fig Tree Pocket River 35 20/02/2011 Brisbane River, Fig Tree Pocket River 36 20/01/2011 Cubberla creek, Chapel Hill Creek 37 21/02/2011 Residential pond, Algester Pond 38 27/02/2011 Oxley creek, Rocklea Creek 39 27/02/2011 1King Arthur Terrace, Tennyson Puddle 40 27/02/2011 Brisbane River, Fig Tree Pocket River 41 27/02/2011 Scrubby Creek, Borina Heights Creek 42 27/02/2011 Caboolture river, Caboolture South River 43 27/02/2011 Couthords Creek, Strathpine Creek 44 27/02/2011 Brisbane river, Fig Tree Pocket River 45 27/02/2011 Brisbane River, Walter Taylor Bridge Indooroopilly River 46 27/02/2011 Mt Ommaney Creek, Mt Ommaney Creek 47 27/02.2011 Southpine River, Strathpine River 48 16/03/2011 Brisbane River, Botanical Gardens CBD River 49 28/03/2011 Brisbane River, CBD River 50 29/03/2011 Brisbane River, CBD River 51 28/03/2011 Brisbane River,  New Farm Park  River 52 28/03/2011 Brisbane River, Riverside CBD  River 53 28/03/2011 Brisbane River, Southbank River 54 28/03/2011 Cubberla creek, Chapel Hill Creek 55 29/03/2011 Westlake, Westlake  Lake 56 30/03/2011 Coomera river catchment River 57 30/03/2011 Coomera river catchment River 58 30/03/2011 Coomera river catchment River 59 30/03/2011 Coomera river catchment River 60 30/03/2011 Coomera river catchment River 1Lower volumes of water were collected at some locations due to limited availability of water.  
3.1.2 Soil Samples: Soil samples were collected by Prof Jim Smith and Maree Corkeron from Northern Queensland, proceeding heavy rainfall events. These samples were provided in the form of soil slurries (10 g of soil in 20 mL of sterile distilled water) in sterile plastic containers. Soil samples were taken at depths of 0-10 cm, 10-20 cm and 20-30 cm. To reduce the number of samples to process, the 10-
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20 cm and 20-30 cm subsections of each sample were mixed together.  All samples were stored at room temperature prior to testing.  Table 7 lists the samples collected together with their respective locations, geographical co-ordinates and dates of collection. The geographic location of the soil sample sites are illustrated in Figure 8.  
Table 7: Soil collection dates, geographical locations and geographic co-ordinates. 
Sample 
number 
Date 
Collected Location 
1 (UTM) GR Co-
ordinates 1 7/02/2011 SES; Sidney Street, West End 0478124; 7870476 2 7/02/2011 Adjacent Cemetery; Mary Street, West End 0478960; 7869687 3 7/02/2011 Cnr Stanton/Hale Street, Townsville 0480246; 7870581 4 7/02/2011 Stanton Terrace, Townsville 0479788; 7870549 5 8/02/2011 Adjacent Fantome Street, Rowes Park 0477859; 7872396 6 8/02/2011 Crn Knapp/Walker Street, Townsville 0479670; 7869661 7 8/02/2011 Yarrawonga Drive, Castle Hill 0478812; 7871372 8 9/02/2011 Rowes Bay Reserve, Townsville 0477523; 7872254 9 9/02/2011 Hibiscus Park, Kirwan 0469910; 7865509 10 9/02/2011 Heatley Park, Heatley 0474475; 7867242 11 9/02/2011 Biara Street, Aitkenvale 0474974; 7866593 12 9/02/2011 Aitkenvale Park, Aitkenvale 0477336; 77867874 13 9/02/2011 Gill Park, Gulliver 0477087; 7867553 14 9/02/2011 Anderson Park Botanical Gardens, Mundingburra 0477048; 7866887 15 9/02/2011 Regal Park, Kirwan 0469610; 7865168 16 10/02/2011 Marabou Drive, Annandale 0475961; 7864687 17 10/02/2011 Karvella street, Annandale 0478180; 7865406 18 10/02/2011 James Cook University Campus, Douglas 0474457; 7863036 19 10/02/2011 Townsville Hospital Site 1, Douglas 0475430; 7863551 20 10/02/2011 Townsville Hospital Site 2, Douglas 0475323; 7863578 21 10/02/2011 Townsville Hospital Site 3, Douglas 0475252; 7863593 22 10/02/2011 Townsville Hospital Site 4, Douglas 0475119; 7863575 23 10/02/2011 Townsville Hospital Site 5, Douglas 0475452; 7863518 1 GR (UTM) Universal Transverse Mercator (UTM) Grid Reference (GR). The UTM grid coordinates are expressed as “easting” and “northing”.         
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Figure 8: Google earth image illustrating the soil sampling locations (as indicated by the red pins).   
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3.2 Isolation and phenotypic identification of P. aeruginosa from water and 
soil samples: Traditionally, presumptive identification of P. aeruginosa is determined using the following phenotypic traits: - Fluorescent growth under UV on Cetrimide agar (Oxoid, Australia) - Growth at 42 ⁰C - Non-lactose fermentation - A positive result to Kovac’s oxidase test   A detailed description of the methods used to isolate and identify P. aeruginosa from environmental samples can be found in Appendix A.  
3.3 Vegetable P. aeruginosa strains: Vegetable strains were sourced from the Molecular Genetics Research Facility culture collection at QUT Gardens Point campus. These strains were derived from plant materials; specifically lettuce, sprouts, tomatoes and mushrooms and were genotyped with ERIC-PCR prior to commencement of this study (Minion, 2010). All isolates were stored in 15 % glycerol at   -80 ⁰C (Minion, 2010).  
3.4 Cystic Fibrosis Clonal strains: Clonal strains are defined as strains that are derived from the same ancestral line, which are established through molecular testing. Each molecular test applies set criteria to determine clonality. The clonal strains examined in this study are known to be ‘shared’ amongst multiple CF patients, indicating transmission events.  The clonal strains, used in this study include: 
• Liverpool epidemic strains (LES431 and LESB58) 
• Manchester epidemic strains (8799, and C3373) 
• Midland clonal strains (8916 and 10066) 
• Stoke and Trent clonal strains  The LESB58 strain, identified in 1988, was the first LES isolated (Fothergill, Walshaw, & Winstanley, 2012). The LES431 clonal strain variant/isolate was derived from a parent (without CF) of a child with CF in 2000 (Fothergill et al., 2012).  The clonal strain variants of the Manchester epidemic strains, Midland epidemic strains and Stoke/Trent strains used in this study have been described previously (Scott & Pitt, 2004). Each clonal strain was derived from different CF patients and shared >80 % sequence similarity with each other (as determined by PFGE) (Scott & Pitt, 2004).   
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The clonal strains were isolated and characterised by Dr Craig Winstanley (Institute of Infection and Global Health, University of Liverpool, United Kingdom). The strains were obtained from Dr Cynthia Whitchurch (Ithree Institute, NSW), in the form of nutrient agar slants (Oxoid, Australia) in 1.5 mL tubes. On arrival, cultures were sub-cultured to determine purity and stored subsequently in 20 % glycerol at -80 ⁰C.  
3.5 DNA extraction: Preliminary DNA extractions were performed using a previously described method (Stephens, Huygens, & Giffard, 2007), briefly described as follows: 12-15 colonies of fresh culture (revived from glycerol stocks) were suspended in 180 µL of RNAase/DNAase free water (Roche, Australia) and DNA was extracted using the Corbett X-tractorGene following Core-protocol No.141404 version 02 (Corbett Robotics, Australia). No DNA output could be achieved initially due to membrane blockage with bacterial cells.   A series of optimisations were performed targeting different experimental variables to develop a method for successful DNA extraction. A full list of the experimental optimisations and a brief outline of the method are represented in Table 8. All experiments were replicated, with the inclusion of an environmental isolate to account for different cell morphology types.    
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Table 8: Methods for experimental optimisations 
Optimisation 
number Optimisation  Brief method description 
1 
Bacterial culture grown in 
broth1 for different 
periods of time. Pelleted 
and suspended in water.  
1. A single colony of P. aeruginosa was inoculated into 4 mL of  Luria broth (LB)1 (in 15 mL falcon tubes) and incubated in a shaking incubator at 37 ⁰C/200 rpm for different time intervals of 3 h/4 h/5 h.  2. Broths were centrifuged at 3,800 rpm for 10 min at 4 
⁰C, to pellet the bacteria 3. Pellets were re-suspended in 180 µL of RNAase/DNAse free water (Roche, Australia) and transferred to 96-well sample plate (Qiagen, Australia) for extraction 
Bacterial culture grown in 
broth overnight in 
microtubes in different  
broth volumes. Pelleted 
and suspended in water 
1. A single colony of P. aeruginosa was inoculated into different volumes of LB broth1 [1 mL; 0.5 mL;0.25 mL] in microtubes and incubated overnight at 37 ⁰C with the lids slightly loosened . 2. Microtubes were centrifuged at 13,000 rpm for 5 min to pellet the bacteria.   3. The pellet was then re-suspended in 180 µL of RNAse/DNAase free water (Roche, Australia), and transferred to the sample plate for extraction.  
2 
Bacterial culture grown 
overnight in 500 µL broth. 
Halved, pelleted and 
suspended in water 
1. A single colony of P. aeruginosa was inoculated into 500 µL of LB broth1 in microtubes and incubated overnight at 37 ⁰C with the lids slightly loosened. 2. 250 µL of the broth was discarded. The remainder of the broth was centrifuged at 13,000 rpm for 5 min to pellet the bacteria. 3. The pellet was then re-suspended in 180 µL of RNAse/DNAase free water (Roche, Australia), and transferred to the sample plate for extraction.  
12-15 colonies of fresh 
culture suspended in 
lysozyme2 
1. 12-15 colonies of fresh culture was suspended in 180 µL of lysozyme buffer* in the sample plate and incubated at 37 ⁰C for 30 min for subsequent extraction. 
Bacterial culture grown in 
500 µL of broth overnight. 
Pelleted and suspended in 
lysozyme 
1. A single colony was inoculated into 500 mL of LB broth1 in a microtube and incubated at 37 ⁰C overnight.  2. Microtubes were centrifuged at 13,000 rpm for 5 min to pellet the bacteria.   3. The pellet was re-suspended in 180 µL of lysozyme buffer2, incubated at 37 ⁰C for 30 min and then transferred to the sample plate for extraction. 
Bacterial culture grown in 
broth for 3 h. Pelleted and 
suspended in lysozyme.  
1. A single colony of P. aeruginosa was inoculated into 4 mL of LB broth1 (in 15 mL falcon tube) at 37 ⁰C for 4 h shaking at 200 rpm.  2. Broths were centrifuged at 3,500 rpm for 10 min at 4 ⁰C to pellet bacteria. 3. The pellet was re-suspended in 180 µL of lysozyme buffer2 and incubated at 37 ⁰C for 30 min. The lysates were then transferred to the sample plate for extraction. 
Grown in broth for 4 h. 
Pelleted and suspended in 
lysozyme 
1. Method is the same as above except broths were incubated for an extra hour. 
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1 Luria Broth (LB): Bacteriological peptone (10 g) NaCl (10 g) Yeast extract (5 g) (Oxoid, Australia) sterile distilled water, up to volume of 1 L.  2Lysozyme buffer (50 mM Tris HCl pH 8; 25 mM NaCl; 2 mM EDTA; 0.1 % triton X-100; lysozyme from egg white added fresh (Sigma-Aldrich, USA) 0.1 mg/mL) and filter (0.45 µM) sterilised.  To evaluate which was the most effective method, the quality and quantity of resulting DNA was assessed using a NanoDrop ND-1000 UV-Vis spectrophotomer (NanoDrop, USA). Based on these results, protocol number five (Bacterial culture grown in 500 µL of broth overnight, pelleted and suspended in lysozyme) was selected as the best method and was used for all subsequent DNA extractions.   DNA extraction of clonal strains was performed using the QIagen DNeasy Blood and Tissue Mini Kit (Qiagen, Australia) to avoid potential cross-contamination. The quality and quantity of all DNA extracts was assessed using a NanoDrop ND-1000 UV-Vis spectrophotomer (NanoDrop, USA). DNA extractions were stored at -20 ⁰C.  
3.6 Selection of strains for genotyping: Water and soil sampling methods produced a large number of isolates from each sample. Given the resources available it was not feasible to genotype all isolates. Due to the broth-based enrichment methods used it was likely that a large number of the isolates within each sample would share the same genotype. It was estimated that three or four HRM runs could be performed per SNP (9) this equates to 300-400 isolates in total. To ensure that the culture collection was genotypically diverse, seven or eight isolates were randomly selected from each sample for further testing. 
3.7 Species-specific PCR: Initially, a Real-time PCR (RT-PCR) method adapted from the published literature targeting a region within the ecfX gene was employed to confirm an isolates’ identity as P. aeruginosa (Cattoir et al., 2010). Changes to the published protocol included the addition of a 72 ⁰C hold step for amplicon extension and the exclusion of fluorescent probes due to the high cost. Further optimisation of this method included using gradient PCR to optimise primer annealing temperature to eliminate non-specific product formation, and adjusting MgCl2 concentration to eliminate non-specific products.  Despite a series of optimisations, this method could not provide confirmatory identification of the isolates tested.   
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A literature search was conducted to review all methods for speciating P. aeruginosa. A set of criteria based on desirable characteristics was developed to select the most appropriate method.  Each method was reviewed against the following criteria: gene targeted, specificity and sensitivity of the assay, cost, sample types tested, conventional vs. RT-PCR and critical analysis made by other published works.   A conventional PCR method published by Lavenir et al. (2007) targeting the ecfX gene was selected as the most appropriate method and was applied to speciate isolates. The following primer sequences were synthesised (Sigma-Aldrich, Australia) (1,000 pmol/µL) for PCR reactions:     Forward 5’ATGGATGAGCGCTTCCGTG3’  Reverse 5’TCATCCTTCGCCTCCCTC3’  Briefly, each 25 µL reaction contained 5 µL of MyTaq Red Buffer (Bioline, Australia), 0.5 µL of both forward and reverse primer (20 uM), 0.25 µL of Mytaq HS polymerase (Bioline, Australia), 2.5 µL of DMSO (Sigma Aldrich, Australia), 14.25 µL of RNAse/DNAse free water (Roche, Australia) and 2 µL of diluted DNA template (5 ng/µL). All PCR amplifications were performed on the Mastercycler EP gradient S (Eppendorf, Australia) instrument with the following cycling conditions:  initial denaturation step at 95 ⁰C for 5 min followed by 35 cycles of 94 ⁰C for 45 s, 58 ⁰C for 45 s, 72⁰C for 45 s and a final extension step at 72 ⁰C for 5 min.  PCR products (5 µL) were subjected to agarose gel electrophoresis on a 2 % gel using 1 X TBE buffer at 90 V for 50 min and stained with Gel Red (Bioline, Australia). Hyperladder IV marker (Bioline, Australia) was run alongside the PCR products to approximate product size and quantity. PCR amplification bands were visualised on a Gel Doc system (ChemiDoc XRS; Bio-Rad Laboratories, USA) using Quantity One software (v 4.6.3; Bio-Rad Laboratories, USA). Isolates that produced amplicons of 528 bp in size, were identified as P. aeruginosa. Those showing no bands or band sizes other than 528 bp were not considered to be P. aeruginosa isolates.    All PCR experiments used P. aeruginosa ATCC 27853 as a positive control and Escherichia coli ATCC 25922 and Staphylococus aureus ATCC 25923 as negative controls. No-template controls were also included to check for DNA contamination.  
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3.8 SNP Identification: MLST Allele sequence data was downloaded from the MLST database (http://pubMLST.org/paeruginosa/) in the form of multiple sequence alignments in FASTA format.  The ‘Minimum SNPs’ software package, run in D-Maximisation mode, used sequence alignments of housekeeping genes (MLST) to derive a set of SNPs with optimised resolving power. The D-Maximisation mode applies the Simpson’s Index of diversity algorithm to measure the resolving power of the SNPs (Robertson et al., 2004).  The ‘exclude’ function of the Minimum SNPs program was used to exclude and subsequently replace SNPs which proved difficult to design primers around.  
3.9 Primer design:  SNP-specific primers were designed from sequence alignments in the MLST database.  P. 
aeruginosa housekeeping genes are highly diverse in nature, thus limiting primer-binding sites. Areas of conservation around the SNPs were sought for potential primer placement.  A set of criteria was developed and applied to primer design to assist with designing and selecting primers. Primers must not contain more than three degenerate bases and must be 17-23 bp in length. Potential primer pairs were also analysed using a web based program, Net Primer (http://www.premierbiosoft.com) for hairpins and primer-dimer formation, Tm and GC content. Each primer option was also analysed using the Basic Local Alignment Search Tool (BLAST) (blast.ncbi.nlm.nih.gov) to determine the specificity of the primers.    When primers could not be designed due to limited conserved sites, MLST amplification primers from the MLST database (http://pubMLST.org/paeruginosa/) and from additional publications (van Mansfeld, Willems, et al., 2009) were included as options.  A web based program ‘Insilico PCR amplification’ (Bikandi, San Millán, Rementeria, & Garaizar, 2004); http://insilico.ehu.es/PCR/) was used to confirm that primer amplification produced a PCR product of the correct size.   Degenerate bases were incorporated into primer sequences where mismatches occurred between the primer binding site and the DNA template.  Table 9 lists the symbols used to indicate degenerate bases in the primers.  
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Table 9: Degenerate base symbols 
Symbol Base represented W A;T S C;G M A ;C K G;T R A;G Y C;T B C;G;T D A;G;T H A;C;T V A;C;G N A;C;G;T  Following in silico analysis of the primers, a list of primer options for each SNP was generated.  The primer pairs considered the most optimal for each SNP were selected.  After testing, if any primer pairs were not optimal, new primers were selected from the list until all SNPs were optimised. Primers were synthesised by Sigma-Aldrich (Australia). Figure 9 illustrates the primer design process followed. 
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Figure 9: Flow diagram illustrating the primer design process used in this study.  
Primers designed manually  
from MLST sequence  
alignments Published MLST primers for  MLST database 
First list of primer options and  
analysis 
First selection of primers  
trialled 
Successful Unsuccessful 
Final set of optimised primers Second selection of primers  trialled 
Literature search: 
Other MLST primers found 
Analysis performed 
Unsuccessful 
Third selection of primers  
trialled 
Successful 
Successful 
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3.10 Primer optimisation for PCR and HRM: Gradient PCR was performed on all SNP specific primer pairs to determine their optimal annealing temperatures and to detect non-specific product formation. P. aeruginosa ATCC27853 was used throughout as a positive control strain. Each 50 µL PCR reaction contained 5 µL of PCR buffer (with Mg2+)(Invitrogen, Australia), 36.3 µL of RNAse/DNAse free water (Roche, Australia), 1 µL of 10 mM dNTPs (Invitrogen, Australia), 1.25 µL of both forward and reverse primer (20 
μM) (Sigma Aldrich, Australia), 0.2 µL of Taq polymerase (Invitrogen, Australia) and 5 μL of DNA template. All PCR amplifications were performed on the Mastercycler EP gradient S (Eppendorf, Australia) instrument with the following cycling conditions: initial denaturation at 95 ⁰C for 5 mins, followed by 30 cycles of 95 ⁰C for 30 s, annealing gradient at (50-62 ⁰C) for 30 s, 72 ⁰C for 30 s and a final extension at 72 ⁰C for 10 min.    
PCR products (5 μL) were subjected to gel electrophoresis on a 2 % gel using 1 X TBE buffer at 90 V for 50 min and stained with Gel Red (Bioline, Australia). Hyperladder IV marker (Bioline, Australia) was used to approximate product size and quantity. PCR amplicons were visualised on a Gel Doc (ChemiDoc XRS; Bio-Rad Laboratories, USA) using Quantity One software (v 4.6.3; Bio-Rad Laboratories, USA). The band intensities at each annealing temperature were compared to determine the optimal annealing temperature range for each primer pair.  An annealing temperature that showed optimal amplification was selected for subsequent RT-PCR and HRM experiments.  
3.11 Optimisation of Real-time PCR and HRMA: 
3.11.1  RT-PCR: Control strains were incorporated into a RT-PCR assay to assess the specificity and sensitivity of the SNP specific primer pairs.  P. aeruginosa ATCC 27853 and two wild type environmental strains were used as positive controls. Escherichia coli ATCC 25922 and Staphylococus aureus ATCC 25923 were used as negative controls.  No-template controls were also included to test for DNA contamination.    Each 20µL RT-PCR reaction was conducted in duplicate and optimised to contain 10 µL of 2X HRM PCR Master Mix (Qiagen, Australia), 0.7 µL of both forward and reverse primer (20 µM) (Sigma Aldrich, Australia), 6.6 µL of RNase/DNase free water (Roche, Australia) and 2 µL of DNA template (5 ng/µL).  Each SNP was amplified with the following optimised cycling conditions: initial denaturation step at 95 ⁰C for 5 min, followed by 40 cycles of 95 ⁰C for 30 s, 58 ⁰C for 30 s, 72 ⁰C for 30 s, followed by hold at 72 ⁰C for 10 min, melt (72 – 99 ⁰C) rising by 1 ⁰C followed by HRM at 80-99 ⁰C rising by 0.05 ⁰C per step.  All RT-PCR/ HRM were performed on a Rotor-Gene 
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6000 instrument (Qiagen, Australia), and data was analysed using the Rotor-Gene software v1.7 (Qiagen, Australia).   Quantitative analysis was performed on all controls. Positive controls were analysed for efficient PCR product formation and reproducibility of duplicates. Negative controls were checked for specificity, indicated by late amplification compared with the positive controls. Conventional melt analysis was also performed to ensure that the positive and negative controls exhibited different amplicon melt patterns.  
3.11.2 High resolution melt analysis: (HRMA): Normalised and difference graphs were generated to assess the ability of the HRMA method to differentiate between bacterial strains. The criteria for designating a pair of melt curves “same” or “different” has been described previously (Price et al., 2006; Stephens et al., 2008). In difference graph format, difference curves were considered the same if they fell within +/-5 units and did not cross the control line more than once.  The negative control strains were compared with positive control strains to ensure that they were classified as “different”. The different curves of P. aeruginosa ATCC27853 and environmental control strains were compared to each other to test the sensitivity of the method.  
3.11.3 Sequencing validation of selected control and environmental strains: The P. aeruginosa control strains (P. aeruginosa ATCC27853, Environmental 1 and Environmental 2) were sequenced to determine the effectiveness of the HRM method criteria to differentiate between D-value SNPs. When two control strains were classified with the criteria as the "same" at a particular SNP, only one strain was sequenced to represent the D-value SNP. 
3.12 Application of HRMA to:  
3.12.1 Environmental P. aeruginosa strains Each SNP was interrogated in 47 environmental P. aeruginosa isolates, performed in duplicate using optimised conditions described earlier. Positive controls P. aeruginosa ATCC27853 and two wild type strains (used in optimisation) and negative controls E. coli (ATCC 25922), S. 
aureus (ATCC 25923) and NTC were included in every run.    Normalised graphs were generated in replicate view to examine melt dissociation patterns. Normalised graphs were converted to difference graph format to determine which isolates were the “same” or “different” to each other.  Strains exhibiting abnormal amplification or melt patterns, possibly due to mismatches in primer binding, were excluded from further analysis 
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3.12.2 Clonal Strains: Clonal strains were tested separately from the environmental strains to prevent any cross-contamination events from occurring. The clonal strains were analysed together with sequenced environmental control strains. All isolates were performed in duplicate.  Both normalised and difference graph analysis was performed, as described above.  
3.13 ScreenClust Analysis: ScreenClust analysis was performed as per manufacturers guidelines outlined in the ScreenClust software user guide (Qiagen, Australia). Briefly, The Rotor-Gene ScreenClust HRM software (Qiagen, Australia) performs independent analysis of HRM data produced by Rotor-Gene 6000 cyclers.  ScreenClust software (Qiagen, Australia) groups isolates into clusters based on their melt dissociation behaviour. Analysis of input HRM data is performed using a series of steps. Initially, raw melt data is converted to a normalised plot. Next, a residual plot is constructed from a composite median curve. Principal Component Analysis (PCA) is performed based on individual sample characteristics extracted from the residual plot.  PCA recognises patterns in 3-dimensional data and subsequently generates cluster plots that display separation between samples.  Posterior probability and typicality scores are applied to each sample to determine the probability that the sample belongs, and how well it fits into the assigned clusters (0-1 scale: 1 being the greatest). The ScreenClust software operates in both supervised and unsupervised mode.  In supervised mode, known controls are used to define the number of clusters. In unsupervised mode, the software determines the number of clusters automatically without the use of controls.  ScreenClust analysis was performed on all environmental and clonal HRM runs in the unsupervised mode.    
3.14 SNP validation by DNA sequencing: 
3.14.1 Selection of sequence representatives from the entire collection of strains: The HRM run data for each SNP was converted into normalised graph format and analysed manually. For amplicons that produced well-defined melt patterns, 1-2 sequence isolates that showed reproducible melt curves for each group, were selected as sequence representatives.   ScreenClust results were used for amplicons that did not produce distinguishable melt groups in the normalised HRM plots.  The number of isolates belonging to each cluster was calculated (isolates that belonged to more than one cluster were excluded) and clusters with a high proportion of isolates were selected. Isolates with the highest typicality and probability (if available) scores for both replicates, were selected to represent their assigned cluster.   
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3.14.2 Sequencing protocol: 
3.14.2.1 Primers: Both PCR amplification and sequencing were performed with previously described MLST primers (Curran et al., 2004).  The primer sequences used are as follows, [primers were synthesised by Sigma-Aldrich (Australia) (1000 pmol/µL) 
3.14.2.1.1 PCR amplification: 
Table 10: List of primers used for PCR amplification 
Primer Sequence (5’-3’) Amplicon size(bp) 
acsAForward: ACCTGGTGTACGCCTCGCTGAC 842 acsA Reverse: GACATAGATGCCCTGCCCCTTGAT 
aroE Forward: TGGGGCTATGACTGGAAACC 825 
aroE Reverse: TAACCCGGTTTTGTGATTCCTACA 
mutL Forward: CCAGATCGCCGCCGGTGAGGTG 940 
mutL Reverse: CAGGGTGCCATAGAGGAAGTC 
nuoD Forward: ACCGCCACCCGTACTG 1042  nuoD Reverse: TCTCGCCCATCTTGACCA 
ppsA Forward: GGTCGCTCGGTCAAGGTAGTGG 989 
ppsA Reverse: GGGTTCTCTTCTTCCGGCTCGTAG 
trpE Forward: GCGGCCCAGGGTCGTGAG 811 
trpE Reverse: CCCGGCGCTTGTTGATGGTT  
3.14.2.1.2 Sequencing: 
Table 11: List of primers used for sequencing  
Primer Sequence (5’-3’) Amplicon size(bp) 
acsA Forward: GCCACACCTACATCGTCTAT 390 
acsA Reverse: AGGTTGCCGAGGTTGTCCAC 
aroE Forward: ATGTCACCGTGCCGTTCAAG 495 
aroE Reverse: TGAAGGCAGTCGGTTCCTTG 
mutL Forward: AGAAGACCGAGTTCGACCAT 441 
mutL Reverse: GGTGCCATAGAGGAAGTCAT 
nuoD Forward: ACGGCGAGAACGAGGACTAC 366 
nuoD Reverse: TGGCGGTCGGTGAAGGTGAA 
ppsA Forward: GGTGACGACGGCAAGCTGTA 369 
ppsA Reverse: GTATCGCCTTCGGCACAGGA 
trpE Forward: TTCAACTTCGGCGACTTCCA 441 
trpE Reverse: GGTGTCCATGTTGCCGTTCC 
3.14.2.2 PCR amplification:  Changes were made to the MLST PCR amplification protocol previously described (Curran et al. 2004) due to non-specific product formation.  Each 50 µL reaction was optimised to contain 10 
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µL MyTaq Red Buffer (Bioline, Australia), 0.4 µL of Mytaq HS polymerase (Bioline, Australia), 1 µL of both forward and reverse primer (10 µM) (Sigma Aldrich, Australia), 3 µL of DNA template and 34.6 µL of RNAase/DNAase free water (Roche, Australia). All PCR amplifications were performed on the Mastercycler EP gradient S instrument (Eppendorf, Australia) with the following modified cycling conditions:  initial denaturation step at 95 ⁰C for 1 min followed by 30 cycles of 96 ⁰C for 1 min, 66 ⁰C (except nuoD at 60 ⁰C) for 15 s, 72 ⁰C for 1 min and a final extension step at 72 ⁰C for 10 min.   
3.14.2.3 Gel purification of PCR products: All PCR products were electrophoresed on a 1.8 % gel, stained with Gel Red, using 1X TBE buffer. All gels were run at 90 V for 4-5 h (depending on PCR product size).  PCR amplification bands were visualised on a UV transilluminator instrument (Spectronics Corporation, USA). The PCR bands of interest were excised from agarose gels using a fresh sterile scalpel (1 per sample), being careful to cut within the middle of the band. All PCR gel purifications were performed using QIAquick Gel extraction kit (Qiagen, Australia), following the manufacturer’s instructions. All purified products were confirmed for purity by agarose gel electrophoresis and quantified using the Nanodrop  ND-1000 UV-Vis spectrophotomer (NanoDrop,  USA).  
3.14.2.4 Sequencing reaction and cleanup: All sequencing procedures were adapted from The Griffith University DNA Sequencing Facility (GUDSF) protocol (see appendix C). Each 20 µL sequencing reaction contained 0.5 µL Big Dye Terminator (v3.1) (Applied Biosystems,  USA), 3 µL sequencing buffer (Applied Biosystems,  USA), 1 µL of either forward or reverse primer (3.2 pmol) (Sigma Aldrich, Australia), 1 µL of template (10 ng/µL) and 14.5 µL of RNAase/DNAase free water (Roche, Australia).  Sequencing reactions were done on a Mastercycler EP gradient S instrument (Eppendorf, Australia) with the following cycling conditions: 96 ⁰C for 1 min, followed by 30 cycles of 96 ⁰C for 10 s, 50 ⁰C for 5 s and 60 ⁰C for 4 min.  The PCR products were subjected to post-sequence cleanup using the GUDSF protocol (http://www.griffith.edu.au/science-aviation/dna-sequencing-facility/pdf/ethanoledtaprotocol.pdf).  Following post-sequence cleanup, samples were submitted to the QUT Molecular Genetics Research Facility for analysis using the 3500 series Genetic Analyser instrument (Applied Biosystems, USA). 
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3.14.2.5 Sequencing result analysis: All sequencing results were imported to the Bioedit sequence alignment editor software package (Hall, 1999) and aligned with Clustal W software (Larkin et al., 2007) against a known MLST allele.  The sequence alignments allowed the detection of the SNP nucleotide base as well as other polymorphisms present within the PCR amplicons.     
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CHAPTER 4 
4.0 Results 
4.1 Isolation of P. aeruginosa from water samples: Three different methods for isolating P. aeruginosa from water samples were trialled to streamline the isolation process and to maximise the recovery rate.  The asparagine broth method was found to be the most effective out of the three trialled. Pre-filtering the water samples to remove debris and fine sediment meant that the resulting filtrate could pass through the 0.45 um filter at a much faster rate. Unlike the previous methods, bacteria attached to sediment particles were accounted for as both the pre-filter and membrane filter were submerged in the broth. The recovery rate of P. aeruginosa isolation was improved via addition of the pre-filter and the use of the whole membrane filter instead of simply streaking across its diameter.  The highly selective agents used in the asparagine broth meant that fewer phenotypic tests (ie growth on MCA) were required to give presumptive P. aeruginosa identification.  
4.2 DNA extraction:  Elution of DNA from the Corbett X-tractor Gene was not achieved using the previously described method (Stephens et al., 2007) due to excess bacterial cells blocking the filter membrane apparatus. The first series of optimisations was performed to determine the optimal concentration of bacterial cells that could be applied to the X-tractor Gene to produce a high quantity and quality DNA output. To determine the optimal concentration of bacterial cells, the variables: incubation time and broth volume were explored. Variations to the incubation time did not yield good quality or quantity of DNA. Alterations to the volume of broth were more successful. Cultures grown in 0.5 mL of broth achieved a high quantity of DNA (ave. 163.2 ng/µL) and an ideal quality of DNA (ave 1.865 ng/ µL). However, only a small eluant volume was attained and therefore further optimisations were required.       
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Table 12: X-tractor Gene DNA extraction optimisation series one 
Method Isolate Elution 
DNA 
quantity 
(ng/µL) 
DNA quality 
(260:280) 
Bacterial culture grown 
in broth for 3 h.  
P. aeruginosa ATCC27853 None N/A N/A Environmental isolate (replicate #1) Partial 16.2 1.37 Environmental isolate (replicate #2) Partial 16.6 1.14 
Bacterial culture grown 
in broth for 4 h.  
P. aeruginosa ATCC27853 (replicate #1) None N/A N/A 
P. aeruginosa ATCC27853 (replicate #2) None N/A N/A Environmental isolate (replicate #1) Partial 64 1.33 Environmental isolate (replicate #2) Partial 57.4 1.48 
Bacterial culture grown 
in broth for 5 h.  
P. aeruginosa ATCC27853 Partial 12.5 1.45 Environmental isolate (replicate #1) Partial 10.4 1.19 Environmental isolate (replicate #2) None N/A N/A 
Bacterial culture grown 
in 0.25 mL LB broth in 
Microtube overnight.  
P. aeruginosa ATCC27853 Partial 39.3 1.78 Environmental isolate Partial 33.6 1.65 
Bacterial culture grown 
in 0.5 mL LB broth in 
Microtube overnight.  
P. aeruginosa ATCC27853 Very low volume 167.7 1.85 
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Environmental isolate Very low volume 158.8 1.88 
Bacterial culture grown 
in 1 mL LB broth in 
Microtube overnight.  
P. aeruginosa ATCC27853 None N/A N/A 
Environmental isolate Partial 10.5 2.1  A second set of optimization trails that explored other variables were performed to produce a higher elution volume. The results of this optimisation series are detailed in Table 13. Despite reducing the concentration of bacterial cells further, suspending the pellet in water did not achieve a high quality or quantity of DNA. As an alternative, different concentrations of bacterial cells were treated with lyosozyme buffer to assist lysis of cell material and to prevent the membrane filter being blocked.  Overall, the addition of lysozyme buffer improved the elution volume and quality of DNA eluted in the majority of tests performed.  Cultures grown in 0.5 mL of broth overnight and 4 h in 4 mL broth achieved the highest quality and quantity of DNA on average for all isolates. Elution volumes were also comparable in both experiments. Cultures grown in 0.5 mL of broth overnight with lysozyme treatment was selected as the best method to use due to the convenience of growing cultures overnight and ease of centrifugation in 2 mL microtubes compared with 15 mL Falcon tubes (required for incubation of 4 mL  broth).  
Table 13: X-tractor gene DNA extraction optimisation series two 
Method Isolate Elution 
DNA 
quantity 
(ng/µL) 
DNA quality 
(260:280) 
Bacterial culture 
grown overnight in 
500 µL broth 
overnight. Halved, 
pelleted and 
suspended in water 
P. aeruginosa ATCC27853 Full 19.8 1.71 Environmental isolate (replicate #1) Full 35.3 1.82 Environmental isolate (replicate #2) Full 20 1.44 
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12-15 colonies of fresh 
culture suspended in 
lysozyme 
P. aeruginosa ATCC27853 Full  69.9 1.7 Environmental isolate None N/A N/A 
Bacterial culture 
grown in 0.5 mL of 
broth overnight. 
Pelleted and 
suspended in 
lysozyme 
P. aeruginosa ATCC27853 Full 113.9 1.92 Environmental isolate (replicate #1) Full 113.8 1.94 Environmental isolate (replicate #2) Very low volume  90.4 1.68 
Bacterial culture 
grown in broth for 3 h. 
Pelleted and 
suspended in 
lysozyme. 
P. aeruginosa ATCC27853 Full 66.1 1.7 Environmental isolate (replicate #1) Partial 62 1.7 Environmental isolate (replicate #2) Very low volume 82 1.88 
Bacterial culture 
grown in broth for 4 h. 
Pelleted and  
suspended in 
lysozyme 
P. aeruginosa ATCC27853 Partial 255.8 2.01 Environmental isolate (replicate #1) Full 117.2 1.98 Environmental isolate (replicate #2) Full 139.2 1.96 
4.3 Species-Specific PCR: A recently published RT-PCR method targeting a region within the ecfX gene was applied to confirm the collection of isolates identity as P. aeruginosa (Cattoir et al., 2010). Despite a series of optimization trails, this method could not speciate the collection of isolates successfully without fluorescent probes.  As shown in Figure 10, no clear distinction between positive and negative isolates could be made.       
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Figure 10: Real Time-PCR analysis of P. aeruginosa isolates targeting the ecfX gene  To select a new confirmatory identification method, a critical literature review of published methods was performed. Fifteen papers were analysed for their specificity, sensitivity, gene target, cost of assay, sample types tested and assessment in other published works. The results of this analysis are detailed in Table 55 in Appendix B.    In the majority of the RT-PCR methods reviewed, expensive fluorescent probes were included in the assays. Review of the literature revealed that the sensitivity and specificity statistics assigned to each method with the use of probes are not transferable when the probes are excluded.  Due to the expense of fluorescent probes and the ease of result interpretation by conventional PCR, only conventional PCR methods were explored further.   A conventional PCR method published by Lavenir et al. (2007) was selected as the most appropriate method for isolate speciation (Lavenir et al., 2007). This method is cost effective and requires only the use of primers, standard PCR reagents and gel electrophoresis materials. Unlike many other published methods, this method was tested directly on water and soil samples (known to host a diverse range of bacteria) and was found to be 100% specific and sensitive for P. aeruginosa.  
4.4 Identification of SNPs: In the preliminary Minimum SNPs run, the cumulative D-value began to plateau after SNP number nine with a D-value of 0.99. Therefore, only 9 SNPs were needed to achieve a SNP set with a high level of discrimination.   A second run excluding SNPs gua6 and acs7 was performed, as these SNPs are located at the beginning of the guaA and acsA genes respectively, hindering forward primer design. SNPs 
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pps268 and trp331 replaced the previously excluded SNPs, and the outcome still reached a high cumulative D-value of 0.99.  After analysis of MLST gene alignments, it was evident that SNP aro491 had to be excluded. This SNP was located towards the end of the aroE gene with no conserved sites available for primer design.  After a third and final run of the Minimum SNPs program, aro491 was replaced with 
aro47, achieving a total cumulative D-value of 0.991.  
Table 14: List of SNP sets derived from ‘Minimum SNPs’ with their respective cumulative D-value 
Run Minimum SNP Cumulative D-value Accepted 
1 
gua6 0.5136             
acs7 0.7579  
mut36 0.8792  
acs336 0.9374  
trp112 0.9664  
pps100 0.9803  
nuo255 0.9875  
aro491 0.9918  
acs78 0.9936  
 
mut36 0.5003  
2 
acs336 0.7498  
trp112 0.8752  
pps100 0.9319  
nuo255 0.9613  
aro491 0.9752  
 
acs78 0.9814  
pps268 0.9881  
trp331 0.9913  
3 
mut36 0.5003  
acs336 0.7498  
trp112 0.8752  
pps100 0.9319  
nuo255 0.9613  
acs78 0.9739  
pps268 0.9831  
trp331 0.9873  
aro47 0.9910   
4.5 Primer design: A list of primer options was designed from MLST sequence alignments to amplify each D-value SNP. Areas of homology (>17 bp) around the SNPs with fewer than four polymorphisms were 
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selected as primer sites. Degenerate base pairs were incorporated into the primers with less than four polymorphisms. MLST PCR amplification primers were incorporated into the primer options list if few nested primers could be designed.  The primer sequences including the positioning of the degenerate bases are listed in Table 15.   
Table 15: Initial list of primer options and the incorporation of degenerate base pairs into primer sequences 
SNP Primer Sequence  (5’- 3’) Base change 
mut36 
MLST Forward F1 CCAGATCGCCGCCGGTGAGGTG NONE Reverse Complement R1 GGTCTTGCCGTTRTGGCGCAVRT G->A | G->C&A | G->A Reverse Complement R2 ACCCARCCCCACARGYGCAG G->A | G->A | T->C Forward F2 CAGGARGTSRTCAAGCG A->G | C->G | A->G 
acs336 
Forward F3 CCGGAAGCSTGGYAGTGGT C->G | C->T MLST Reverse R3 GACATAGATGCCCTGCCCCTTGAT NONE Forward F4 CGYTGCCCGATCGTCGAYAC C->T | C->T Forward F5 TGGTGGCARACCGARACCGG G->A | G->A  Reverse Complement R4 GCBGCRGAGCCCGGYTTC C->G&T | G->A | C->T Reverse Complement R5 CCACVCCGAAGAAYGGCY G->A&C | C->T | T->C 
trp112 
MLST Forward F6 GCGGCCCAGGGTCGTGAG NONE Reverse Complement R6 AGCATCARGTGCTCGGCGA G->A Forward F7 GYAGCTCKCCGGARGTGCT C->T | G->T | G->A Forward F8 RGTRCGCCCGATCGCYGG G->A | G->A | C-> T Reverse Complement R7 ACGATGYGCATGACRTTGGARTA T->C|G->A|G->A Reverse Complement R8 GTGCTCGGCGAYYTCCTTGGC T->C|C->T 
pps100 
MLST Forward F9 GGTCGCTCGGTCAAGGTAGTGG NONE Reverse Complement R9 GATGGCGCTRGCGCGCTTCATCA G->A Forward F10 ATGGARCGCTAYYTGCT G->A | C->T | C-> T Reverse Complement R10 CCGATRCGCTGRCCRATGGC G->A | G-> A | G->A 
nuo 255 
Forward F11 GGCGCCGAGARGATGGCCGA A-> G Reverse Complement R11 TAGGTGCSCAGRWACAGCAGGTG C->G | G->A | T->A Forward F12 ACCGACCGYATCGACTAYCT C->T | C->T Forward F13 CGACTAYCTHGGYGGGGTGAT C->T |C->A&T |C->T Forward F14 GGGGTGATGAAYAAYCTGCC C->T| C->T 
Reverse Complement R12 GATRCGGAAGAACTCBG A->G | C->G&T 
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SNP Primer Sequence  (5’- 3’) Base change 
acs78 
MLST Forward F15 ACCTGGTGTACGCCTCGCTGAC NONE Reverse Complement R13 ACCACTRCCASGCTTCCGG G->A | G->C Forward F16 TGTTCGARGGYGTRCCGAACT G->A | C->T | G->A Reverse Complement R14 CRGCCATSATCGCGCTTA G->A | C->G  Reverse Complement R15 GGTRTAGAGGATRTTRACCTTGTG G->A | G->A | G->A  Reverse Complement  R16  ACGCAGRCTGGARCCRTCGG  G->A | G->A | G->A 
pps268 
Forward F17 TGATGAAGCGCGCYAGCGCCATC C->T MLST Reverse R17 GGGTTCTCTTCTTCCGGCTCGTAG NONE Forward F18 GAYCCGGACTGGGAGCCRGT C->T | G->A Reverse Complement R18 TCRCGDGCGATGATCGC G->A | A->T&G Reverse Complement R19 CGATGATCGCVGCGTGGCA C->A&G 
trp331 
Forward F19 TACTCCAAYGTCATGCRCATCGT C-> T | A-> G MLST Reverse R20 CCCGGCGCTTGTTGATGGTT NONE Forward F20 ATGCRCATCGTKTCCAACGTC A->G | G->T Reverse Complement R21 GCGCGGATCTTYGGCGCRCC C->T | G->A Reverse Complement R22 GCGCGGATCTTYGGCGC C->T 
aro47 MLST Forward F21 TGGGGCTATGACTGGAAACC NONE Reverse Complement R23 VCCRTCGGTGTTGTCRCC G->A&C | G->A | G->A Forward F22 GTCACYGTKCCSTTCAAGGA C-> T | G->T | G->C #Degenerate bases are bolded in red as per Table 9.  Table 18 lists the first selection of primers used for Real-time PCR and HRM. For each primer pair, selection was based on: I. Annealing temperature (Tm) of the primer II. Hairpin formation III. Number of degenerate base pairs IV. Primer-dimerisation An example on how each primer pair was selected is shown for SNP trp112: Forward#3 was excluded from further analysis as the Tm was too high. The first primer option was selected as the best choice for a number of reasons.  All options were predicted to form primer-dimers. However, primer option 1 had the least number of strong dimer-bonds compared with other options.  The Tm values of both the forward and the reverse primers were within a close range of each other. Both primers in this option had the least number of degenerate bases compared with other options. 
 
  
Table 16: trp112 analysis of primer options 
 
Primer 
option 
Location 
within MLST 
gene (bp) 
No. 
Degenerate 
bases 
Sequence (5'-3') [RC denotes reverse 
complement] Tm 
%GC 
content Hairpins Forward #1 Published MLST 0 GCGGCCCAGGGTCGTGAG 66.59 77.78 nil Forward #2 9-27 3 GCAGCTCGCCGGAGGTGCT 68.06 73.68 
 
Forward #3 55-72 3 GGTGCGCCCGATCGCCGG 74.06 83.33 
 
Reverse #1 147-165 1 TCGCCGAGCACCTGATGCT 64.64 63.16   RC: AGCATCAGGTGCTCGGCGA Reverse #2 248-270 2 TACTCCAACGTCATGCACATCGT 62.78 47.83   RC: ACGATGTGCATGACGTTGGAGTA Reverse #3 137-157 2 GCCAAGGAGATCGCCGAGCAC 68.71 66.67 nil GTGCTCGGCGATCTCCTTGGC 
 
  
Table 17: trp112 analysis of primer pairs 
 
Primer 
pair Primer Sequence Primer-Dimer 
1 
Forward #1 GCGGCCCAGGGTCGTGAG 
 
 
Reverse #1 RC: AGCATCAGGTGCTCGGCGA 
2 Forward #1 GCGGCCCAGGGTCGTGAG 
 
 
Reverse #2 RC: ACGATGTGCATGACGTTGGAGTA 
3 
Forward #1 GCGGCCCAGGGTCGTGAG 
 
 
Reverse #3 GTGCTCGGCGATCTCCTTGGC 
4 Forward #2 GCAGCTCGCCGGAGGTGCT 
 
 
Reverse #1 RC: AGCATCAGGTGCTCGGCGA 
5 Forward #2 GCAGCTCGCCGGAGGTGCT 
 
 
Reverse #2 RC: ACGATGTGCATGACGTTGGAGTA 
6 
Forward #2 GCAGCTCGCCGGAGGTGCT   
Reverse #3 GTGCTCGGCGATCTCCTTGGC 
 
  As shown in Table 18, four of the nine SNPs had ineffective primer pairs, as they formed faint/no PCR product or produced non-specific products. Therefore, new primer options were explored for these SNPs.  
Table 18: First selection of primers for optimisation  
SNP Primer Sequence (5'-3') Successful primer pair achieved 
mut36 Foward F1 CCAGATCGCCGCCGGTGAGGTG No Reverse R2 ACCCARCCCCACARGYGCAG 
acs336 Foward F4 CGYTGCCCGATCGTCGAYAC No Reverse R3 GACATAGATGCCCTGCCCCTTGAT 
trp112 Foward F6 GCGGCCCAGGGTCGTGAG Yes Reverse R6 AGCATCARGTGCTCGGCGA 
pps100 Foward F9 GGTCGCTCGGTCAAGGTAGTGG No Reverse R9 GATGGCGCTRGCGCGCTTCATCA 
nuo255 Foward F11 GGCGCCGAGARGATGGCCGA Yes Reverse R11 TAGGTGCSCAGRWACAGCAGGTG 
acs78 Foward F15 ACCTGGTGTACGCCTCGCTGAC No Reverse R14 CRGCCATSATCGCGCTTA 
pps268 Foward F17 TGATGAAGCGCGCYAGCGCCATC Yes Reverse R17 GGGTTCTCTTCTTCCGGCTCGTAG 
trp331 Foward F20 ATGCRCATCGTKTCCAACGTC Yes Reverse R22 GCGCGGATCTTYGGCGC 
aro47 Forward F22 GTCACYGTKCCSTTCAAGGA Yes Reverse R23 VCCRTCGGTGTTGTCRCC 
 For the unsuccessful primer pairs (forward/reverse), an alternative primer was selected from the initial list of primer options (Table 18) and trialled. The list of primers used in the second series of optimisations is listed in Table 19. The primer pair for pps100 was the only successful primer combination.  
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Table 19:  Second selection of primers for optimisation  
1SNP Primer Sequence (5'-3') Origin Tested with 
Successful 
primer pair 
achieved 
mut36 Reverse R24 CAGGGTGCCATAGAGGAAGTC MLST PCR Primer F1 No 
pps100 Reverse R10 CCGATRCGCTGRCCRATGGC Initial primer options list  F9 Yes 
acs78 Reverse R15 GGTRTAGAGGATRTTRACCTTGTG Initial primer options list  F15 No 1 acs336 was not analysed in the second round of optimisations. Primers for this SNP were subsequently designed in the final optimisation series.   Primer pairs for SNPs mut36, acs78 and acs336 could not be optimised using the primers designed from the MLST sequence alignments and the MLST database PCR amplification primers (Curran et al., 2004). After further investigation of the literature, a study using new MLST PCR amplification primers for P. aeruginosa MLST reactions (van Mansfeld et al., 2009b) was identified. The primers from this study were tested along with the primers designed previously, to develop optimal primer pairs for the SNPs.  The next set of primer options that were tested are listed in Table 20. This table also indicates the primer combinations used.  
Table 20: Final selection of primers for optimisation  
SNP Primer Sequence (5'-3') Origin Tested with  
Successful 
primer pair 
achieved 
mut36 Forward F23 AGCCTGGCAGGTGGAAACCC van Mansfeld et al. (2009) R2; R24;R1 yes 
acs336 Forward F3 CCGGAAGCSTGGYAGTGGT 
Primer options list one R25 yes Forward F5 TGGTGGCARACCGARACCGG Primer options list one R25 Reverse R25 CGGCCAGGAGTCGAGGATC van Mansfeld et al. (2009) F3;F5;F4 
acs78 Forward F24 AAGGGCGTGCTGCATACCA 
 van Mansfeld et al. (2009) R13; R16; R15;R14 yes Reverse R13 ACCACTRCCASGCTTCCGG Primer options list one F24 Reverse R14 ACGCAGRCTGGARCCRTCGG Primer options list one F24 
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Table 21: Optimised SNP specific primer pairs 
SNP Primer Sequence (3'-5') Amplicon size (bp) 
mut36 Forward F23 AGCCCTGGCAGGTGGAAACC 618 Reverse R24 CAGGGTGCCATAGAGGAAGTC 
acs336 Forward F5 TGGTGGCARACCGARACCGG 177 Reverse R25 CGGCCAGGAGTCGAGGATC 
trp112 Forward F6 GCGGCCCAGGGTCGTGAG 392 Reverse R6 AGCATCARGTGCTCGGCGA 
pps100 Forward F9 GGTCGCTCGGTCAAGGTAGTGG 290 Reverse R10 CCGATRCGCTGRCCRATGGC 
nuo255 Forward F11 GGCGCCGAGARGATGGCCGA 215 Reverse R11 TAGGTGCSCAGRWACAGCAGGTG 
acs78 Forward F24 AAGGGCGTGCTGCATACCA 255 Reverse R15 GGTRTAGAGGATRTTRACCTTGTG 
pps268 Forward F17 TGATGAAGCGCGCYAGCGCCATC 598 Reverse R17 GGGTTCTCTTCTTCCGGCTCGTAG 
trp331 Forward F20 ATGCRCATCGTKTCCAACGTC 113 Reverse R22 GCGCGGATCTTYGGCGC 
aro47 Forward F22 GTCACYGTKCCSTTCAAGGA 132 Reverse R23 VCCRTCGGTGTTGTCRCC            
 
  
4.6 Primer optimisation for PCR and HRM: Primer pairs that produced strong clear bands by conventional PCR without non-specific PCR product formation were tested for optimal annealing temperatures. An annealing temperature of 58 ⁰C was selected for all subsequent PCR experiments.  
Table 22: Optimal annealing temperature range for each primer pair determined by gradient conventional 
PCR 
Final SNP specific primer pairs Optimal annealing temperature range 
mut36 50-62⁰C 
acs336 55-62⁰C 
trp112 50-62⁰C pps100 50-62⁰C 
nuo255 50-62⁰C 
acs78 50-62⁰C 
pps268 58.1-62⁰C 
trp331 50-60.7⁰C 
aro47 50-62⁰C 
 
4.7 Optimisation of RT-PCR and HRMA using ATCC and environmental 
control strains: Real-time PCR and standard DNA melt analysis was performed to evaluate the robustness of the RT-PCR method. In this assay, P. aeruginosa ATCC 27853 and two environmental strains were used as positive controls and E. coli (ATCC 25922) and S. aureus (ATCC 25923) were used as negative controls.  Some amplification and melt curve formation of the negative controls was expected, as housekeeping genes are universal in many bacterial species. As shown in Figure 11, the positive controls reached the cycle threshold (Ct) before cycle 17 compared with the negative controls that reached the Ct after 30 cycles. Standard melt analysis performed on all SNPs showed that the negative controls produced a minimal fluorescence signal (if any), indicating non-specific product formation and melted at lower temperatures compared with the positive controls.  An example of the melt curve produced by the positive and negative controls is illustrated in Figure 12.  Based on this analysis, the RT-PCR assay was considered to be robust. 
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Figure 11: Real-time PCR analysis of the ATCC and environmental controls compared to the ATCC negative 
controls (Data was exported to TeeChart to provide a clearer representation of melt curves). 
 
 
Figure 12: Standard melt analysis of the positive controls in comparison to the negative controls HRMA was performed on all positive controls to determine the sensitivity of the method. Each control strain was classified as the “same” or “different” to each other using the HRMA criteria described previously (Price et al,. 2006; Stephens et al., 2008).  The control strains could be differentiated, verifying the sensitivity of the method.  An example of the criteria applied to controls is shown in Figure 13.  In this example, the ATCC is considered different from the environmental controls as it crosses over the +5 U threshold and both environmental control strains are considered the same as each other as they fall within the -+5 U threshold and do not cross the line more than once.   
Positive controls 
Negative controls 
Positive controls (P. aeruginosa ATCC27853; Env. cont 1 & 2) 
Negative controls (E. 
coli ATCC25922 & S. 
aureus ATCC 25923) 
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Figure 13: Difference graph of the ATCC and environmental control strains (Data exported to TeeChart) 
 
4.8 Sequencing validation of selected control and environmental strains: 
Table 23: Sequence validation of HRMA 
SNP ATCC 
27853 
Environmental 
1 
Environmental 
2 
mut36 C C 1ns 
acs336 C T C 
trp112 A A 1ns 
pps100 G G G 
nuo255 G C 1ns 
acs78 A A A 
pps268 C C T 
trp331 T C 1ns 
aro47 G 1ns G 1(ns) not sequenced.  Control strains shaded grey were considered the “same” based on the previously developed HRMA criteria. When two controls were the “same” for a particular SNP, only one strain was selected for sequence validation of the polymorphism present at each SNP position. In the event where two SNPs were located within the same gene, the sequence alignment provided results for both SNPs.   As shown in Table 23 there were incidences were the HRMA criteria classed all strains as “different” but sequencing demonstrated that they shared the same SNP. In cases where no clear differentiation between melt curves could be established, an alternative melt curve analysis was performed.  
P. aeruginosa ATCC27853 
Environmental control 1 
Environmental control 2 
+5 U control  
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4.9 Application and sequence validation of HRMA: 
4.9.1 Environmental strains: Analysis of normalised graphs was performed as an alternative means for differentiating strains by their SNP profile.  Strains that exhibited abnormal melt patterns possibly due to mismatches in primer binding were excluded from this analysis. Figure 14 depicts an example of where strains were excluded from analysis due to abnormal melt patterns.  
 
Figure 14: Exclusion of Strains from Normalised Graph Analysis (Data exported to TeeChart) In normalised graph analysis, four out of nine SNP PCR amplicons produced well-defined melt patterns that separated into individual melt groups. The other five SNP PCR amplicons produced melt patterns with very little definition. The melt patterns appeared spread out with no grouping or clustered tightly together.  An example of a SNP amplicon that produced tightly clustered melt curves is displayed in Figure 15. 
 
Figure 15: Normalised graph of SNP MUT36 displaying no separation into separate melt groups  
Excluded (see green and orange lines) 
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  The normalised graphs that displayed well-defined melt groups included trp331, pps268, 
acs336 and acs78, these were analysed further by sequencing the PCR products/amplicons.  Representative strains selected from each melt group were sequenced to assess the ability of the method to differentiate strains according to the nucleotide type ie A/T/G/C present at each SNP position.    
4.9.1.2 trp331: In normalised graph analysis, the amplicon for SNP trp331 displays four well-defined melt groups with melt group 3 representing the majority of the strains. Melt groups 1, 2 and 4, located on opposites of the melt region, have a C nucleotide at position 331. Therefore, the melt groups are not differentiated at trp331 only.  
 
Figure 16: Melt groups produced by SNP trp331 
 
 
 
 
 
 
 
 
 
 
1 
2 3 4 
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Table 24: Sequencing result of melt group representatives 
Melt 
group 
Number of isolates in 
group 
Representative 
isolate 
Sequencing 
result 1 7 S52 C V1 2 13 Environmental control 1 C 
3 23 
Environmental control 2 T P. aeruginosa ATCC27853 S23/24 S69 4 1 V2 C  V1, S23/24 and S69 were sequence representatives for another SNP (trp112) located within the same gene. The sequence alignments provided results for both SNPs.   The sequence alignments of the trp331 PCR region with strain representatives from each melt group, represented in Figure 17, clearly demonstrate how the melt groups separate from each other based on the combination of polymorphisms present in the PCR region. Table 25 provides an overview the polymorphisms present in relation to the melt groups.  
Table 25: Overview of the polymorphisms present within each melt group 
Melt 
grou’p 
Position of SNP in trp gene 
283 331 337 343 346 349 
1 C C G T G G 
2 C C G C T A 
3 C T G C T A 
4 T C A C T A 
C;T;A T T;C;A 
Difference 
 
                  
Figure 17: Sequence alignment of trp331 sequence representatives demonstrating the location of polymorphisms within the amplicon 
1 The sequence for allele 1 and allele 10 controls are the same for the length of this fragment.
 
  
4.9.1.3 pps268: The normalised graph analysis of the pps268 PCR amplicon produced two distinct melt groups as shown in Figure 18. Melt group 2 had the highest proportion of isolates belonging to it.  From the 7 representative isolates sequenced, it appears that the split between the groups could be the result of a T/C base change at SNP268. Table 26 details the melt groups and their representative isolates and sequencing results.  
 
Figure 18: Melt groups produced by SNP pps268 
Table 26: Sequencing results of melt group strain representatives for pps268 
 
       C14, V3 and V4 were sequence representatives for another SNP (pps100) located within the same gene. The sequence alignments provided results for both SNPs 
 
Melt 
group 
Number of isolates 
in group 
Representative 
isolate 
Sequencing 
result 
1 14 ATCC27853 C Environmental control 1 R50 
2 27 
Environmental control 2 
T 
S67 C14 V3 V4 
1 2 
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4.9.1.4 acs336: The normalised graph for acs336 PCR amplicon produced eight individual melt groups as illustrated in Figure 19. Melt groups 3 and 4 had the majority of strains assigned to it. The results displayed in Table 27 suggest that there is no correlation between melt group and the SNP acs336.  Melt groups 2, 3 and 4 had isolates belonging to the same group but share different SNP nucleotides at position 336.  
 
Figure 19: Melt groups produced by SNP acs336 
Table 27: Sequencing results of melt group representatives for acs336 
Melt group Number of isolates in group Representative isolate Sequencing result 
1 6 Co1 C R52 2 9 S58 T C29 C 3 10 Environmental control 1 T V2 C 4 10 Environmental control 2 C S69 C V5 T 5 7 S67 C 6 1 ATCC27853 C 7 1 V1 C 8 1 R56 C R52, C29 and V5 were sequence representatives for another SNP (acs78) located within the same gene. The sequence alignments provided results for both SNPs 
 
1 
2 
3 
8 
7 
6 4 
5 
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4.9.1.5 acs78: Four distinctive melt groups were produced by the acs78 PCR amplicon as represented in the normalised graph, Figure 20.  Both melt groups 2 and 3 included the highest proportion of strains.  
 
Figure 20: Melt groups produced by SNP acs78 
Table 28: Presents the melt group number and its associated sequence result.  
Melt 
group 
Number of isolates in  
group 
Representative 
isolate Sequencing result 1 1 R4 A 2 20 Environmental control 2 A C29 
3 20 Environmental control 1 A ATCC27853 R52 4 2 V5 G  The results in this Table suggest that the melt groups could not be separated solely using acs78.   
4.9.2 ScreenClust: ScreenClust analysis was performed on SNP amplicons that did not produce well-defined melt groups in normalised graph analysis. An example of a typical ScreenClust output is shown in Figures 21-23. SNP amplicons that were analysed with ScreenClust included trp112, aro47, 
mut36, nuo255 and pps100. Sequence representatives were selected from clusters that contained a high proportion of isolates.   
1 
2 
3 
4 
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    Probabilities 
ID Name Cluster Typicality Cluster 1 Cluster 2 Cluster 3 1 c14 Cluster 1 0.50347647 0.9935 0.0000 0.0065 2 c14 Cluster 1 0.66016502 0.9994 0.0000 0.0006 3 r3 Cluster 3 0.71074305 0.0000 0.0063 0.9937 4 r3 Cluster 3 0.83965566 0.0000 0.0025 0.9975 5 s26/27 Cluster 1 0.53161513 1.0000 0.0000 0.0000 6 s26/27 Cluster 1 0.54268291 1.0000 0.0000 0.0000 9 p7 Cluster 3 0.07390495 0.0000 0.0147 0.9853 10 p7 Cluster 3 0.48327192 0.0000 0.0097 0.9903 11 s34 Cluster 2 0.33460424 0.0000 1.0000 0.0000 12 s34 Cluster 2 0.46203531 0.0000 1.0000 0.0000 13 c12 Cluster 1 0.66749565 0.9978 0.0000 0.0022 14 c12 Cluster 1 0.20748580 0.9512 0.0000 0.0488 15 c29 Cluster 2 0.55325155 0.0000 0.9998 0.0002 16 c29 Cluster 2 0.37973243 0.0000 1.0000 0.0000 17 s58 Cluster 1 0.50937907 0.9837 0.0000 0.0163 18 s58 Cluster 1 0.45407958 1.0000 0.0000 0.0000 19 r2 Cluster 1 0.69544537 1.0000 0.0000 0.0000 20 r2 Cluster 1 0.61314257 1.0000 0.0000 0.0000 21 s16 Cluster 1 0.45812737 0.9995 0.0000 0.0005 22 s16 Cluster 1 0.68165497 1.0000 0.0000 0.0000 23 s23/24 Cluster 2 0.44191636 0.0000 0.9999 0.0001 24 s23/24 Cluster 2 0.10075687 0.0000 0.8930 0.1070 25 s14/15 Cluster 1 0.96393729 1.0000 0.0000 0.0000 26 s14/15 Cluster 1 0.86237661 1.0000 0.0000 0.0000 27 r45 Cluster 1 0.89786159 1.0000 0.0000 0.0000 28 r45 Cluster 1 0.74325660 1.0000 0.0000 0.0000 29 c48 Cluster 3 0.38407881 0.0000 0.0021 0.9979 30 c48 Cluster 3 0.44199941 0.0000 0.0005 0.9995  
Figure 21: Assignment to clusters and statistical analysis Table 
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Figure 22: Raw Data Plot 
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Figure 23: Cluster Plot 
4.9.2.1 trp112: ScreenClust analysis divided the collection of environmental isolates into eight clusters with the majority of isolates belonging to cluster 1. The clusters mostly overlapped each other with little separation between groups. The cluster number and their respective sequence results are displayed in Table 29. Based on the number of clusters produced, tight formation of the clusters, and the sequencing results, it is clear that ScreenClust is not capable of differentiating the strains using SNP trp112.   
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Table 29: Sequence results of cluster representatives for trp112 
Cluster No of isolates in cluster 
Isolate(s) 
sequenced 
Typicality score 
(replicates) 
Sequencing 
result 
1 10 S23/24 0.955; 0.9144 A 
2 6 V1 0.61; 0.59 G 
3 2 None N/A N/A 
4 2 1V2 0.522; 0.522 G 
5 6 V6 0.717; 0.776 A 
6 6 S69 0.946; 0.866 G 1S52 0.837; 0.778 G 
7 1 None N/A N/A 
8 7 2ATCC 27853 0.876; 0.474 A 2,3Environmental control 1 0.817; 0.704 A 1V2 and S52 were sequence representatives from another SNP (trp331) within the same gene.  2ATCC 27853 and Environmental control 1 were sequenced previously.  3Environmental control 1 strain has the highest typicality for cluster 8.  
4.9.2.2 aro47: ScreenClust analysis performed on the environmental isolates divided the population into nine highly overlapping clusters. Clusters 2 and 3 represent the majority of the isolates; the remaining clusters had only a few isolates per cluster.  Of the isolates sequenced, only a G nucleotide base at position 47 in the aroE gene was represented.   
Table 30: Sequence results of cluster representatives for aro47 
Cluster No of isolates in cluster 
Isolate(s) 
sequenced 
Typicality score 
(replicates) 
Sequencing 
result 
1 1 None N/A N/A 
2 10 Co1 0.974; 0.924 G 
3 7 S23/24 0.683; 0.784 G 
4 4 None N/A N/A 
5 3 None N/A N/A 
6 3 1Environmental control 2 0.207; 0.298 G 
7 1 None N/A N/A 
8 1 None N/A N/A 
9 1 None N/A N/A 1The environmental control 2 strain was sequenced previously and does not have the highest typicality of isolates belonging to cluster 6 
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4.9.2.3 mut36: ScreenClust analysis divided the environmental HRM data into three well-defined clusters with the majority of isolates in cluster 1. In cluster 3 both strains sequenced had a C nucleotide base at position mut36.  
Table 31: Sequence results of cluster representatives for mut36 
Cluster 
No of 
isolates in 
cluster 
Isolate(s) 
sequenced 
Typicality 
Score 
(replicates) 
Probability 
Score 
(replicates) 
Sequencing 
result 
1 21 V1 0.977; 0.783 0.9999; 0.9994 C 
2 9 V7 0.964; 0.732 1.0000;1.0000 T 
3 15 1ATCC 27853 0.222; 0.155 1.0000; 1.0000 C 1Environmental control 1 0.261; 0.486 1.0000; 1.0000 C 
1P. aeruginosa ATCC27853 and environmental 1 control strains were sequenced previously.  Neither strains have the highest typicality score of their respective cluster.  
4.9.2.4 pps100 ScreenClust analysis separated the environmental isolates into seven individual groups that overlapped slightly. The majority of isolates grouped into clusters 5 and 6. Clusters 1 and 6 both had more than one strain assigned to the cluster.  Sequence results of these clusters showed that two isolates could belong to the same cluster but share a different SNP.   
Table 32: Sequence results of cluster representatives for pps100 
1Environmental 1 and 2 control strains were sequenced previously.  2S67 and R50 were sequence representatives from another SNP (pps268) located within the same gene.   
 
Cluster 
No of 
isolates in 
cluster 
Isolate(s) 
sequenced 
Typicality 
score 
(replicates) 
Probability 
score 
(replicates) 
Sequencing 
result 
1 7 V4 0.645; 0.684 1.0000; 1.0000 G 2S67 0.336; 0.913 1.0000; 1.0000 A 2 2 none N/A N/A N/A 3 6 V3 0.962; 0.780 1.0000; 1.0000 A 4 2 none N/A N/A N/A 5 8 1Environmental 2 control 0.529; 0.880 0.9991; 0.9997 G 6 8 C14 0.707; 0.621 0.9959; 1.0000 A 2R50 0.875; 0.585 1.0000; 1.0000 G 7 3 1Environmental 1 control 0.321; 0.310 0.9996; 0.9929 G 
93  
4.9.2.5 nuo255 ScreenClust analysis of the HRM data divided the population into four overlapping clusters. The majority of isolates were assigned to cluster 2. As shown in Table 33, cluster differentiation is not soley based on the type of polymorphism at position nuo255.  
Table 33: Sequence results of cluster representatives for nuo255 
Cluster 
No of 
isolates in 
cluster 
Isolate(s) 
sequenced 
Typicality 
Score 
(replicates) 
Probability 
Score 
(replicates) 
Sequencing 
result 1 8 1ATCC 27853 0.613; 0.913 1.0000; 1.0000 G 2 25 2Environmental control 1 0.244; 0.262 1.0000; 1.0000 C 3 4 S13 0.928; 0.643 1.0000; 1.0000 C 4 4 C29 0.896; 0.435 1.0000; 1.0000 G 1ATCC27853 was sequenced previously and does not have the highest typicality of isolates belonging to cluster 1.  2Environmental control 1 was sequenced previously and does not have the highest typicality of isolates belonging to cluster 2.  
   
 
  
                                    
                        ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
nuo allele 1            GGCGCCGAGAAGATGGCCGAGCGCCAGTCCTGGCACAGTTTCATCCCCTACACCGACCGCATCGACTACCTCGGCGGGGTGATGAACAACCTGCCCTACGT  
C29                     .....................................................................................................  
S13                     ............................................T........................................................  
Environmental control 1 .....................................................................................................  
ATCC 27853              ............................................T........................................................  
          
                        ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
nuo allele 1            ACTCTCGGTGGAGAAGCTCGCCGGGATCAAGGTGCCGCAGCGGGTCGACGTGATCCGGATCATGATGGCGGAGTTCTTCCGTATCCTGAACCACCTGCTG  
C29                     ....................................................................................................  
S13                     ....................................C...............................................................  
Environmental control 1 ....................................C...............................................................  
ATCC 27853              ....................................................................................................  
  
                                       
                        ....|....|....| 
nuo allele 1            TACCTGGGCACCTAT 
C29                     ............... 
S13                     ............... 
Environmental control 1 ............... 
ATCC 27853              ...............  
 
Figure 24: Sequence alignment for nuo255 sequence representatives demonstrating additional polymorphisms within PCR amplicon    
nuo255 
 
  As shown in Figure 24 and Table 34 additional polymorphisms present within the PCR fragment affect cluster differentiation when using the ScreenClust program.     
Table 34: Combination of polymorphisms within nuo255 PCR amplicon 
Cluster Position of SNP in nuo gene 
162 255 
1 T G 
2 C C 
3 T C 
4 C G   
4.9.3 Clonal strains  The P. aeruginosa clonal strains that originated from the United Kingdom, were subjected to HRMA together with previously sequenced controls for each SNP. As shown in Figure 25, the melt curves generated by the environmental strains were similar to the melt curves for the clonal strains. Table 35, clearly demonstrates that the environmental strains can belong to the same cluster or melt group as the clonal strains. Both ScreenClust and normalised graph analysis confirmed the sequence similarity between the clonal strain variants (eg MID8916 and MID10066). In each SNP except for trp112 and aro47, each clonal variant belonged to the same cluster or melt group. Figure 26 demonstrates that at SNP trp331 when MID10066 was defined as the control, MID8916 fell within 1.1 Fluorescent unit (FU) but crossed the control line more than twice, indicating other polymorphisms could be present within the amplicon.           
Figure 25: Normalised graph analysis of melt patterns produced by the clonal strains and environmental 
strains for SNP trp331. The environmental strains are in red 
V1;  MANC3373;  MAN8799 
Environmental control 1;  Stoke;   ATCC27853; MID8916; LES431; MID10066; LESB58 
V2 
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Figure 26: Difference graph analysis of control MID10066 against MID8916 for SNP trp331 (Data exported to 
TeeChart)     
MID10066 
MID8916 
 
  
Control strains are coloured in red. Strains that had duplicates that were grouped into two different clusters are not shown in this Table  
Table 35: Grouping of Environmental and CF Clonal strains 
Cluster /  
Melt 
group 
mut36 acs336 trp112 pps100 nuo255 acs78 pps268 trp331 aro47 
1 
ATCC27853; 
MID8916; 
MID10066; 
LESB58; 
LES431; 
TRENT 
Co1 V2 
Environmental 
control 2; Stoke; 
MAN8799; 
MANC3373; 
LES431; LESB58 
S13 R4 
ATCC27853; 
Environmental 
control 1; 
MAN8799; Stoke; 
MANC3373 
V1; MANc3373; 
MAN8799 Trent 
2 Environmental control 2 
V2; LES431; C29; 
S58; LESB58 
MANC3373; 
LESB58 V4 
Environmental 
control 1 
Environmental 
control 2; 
MID8916; 
MID10066; Stoke 
Environmental 
control 2; 
MID8916; Trent; 
MID10066 
Environmental 
control 1; Stoke; 
Trent 
ATCC27853; 
Environmental 
control 2; 
Environmental 
control 1; Stoke; 
MAN8799; 
MANC3373; 
MID8916; MID10066 
3 V7 Environmental control 1 S52; LES431 
ATCC27853; 
R50; Trent 
MID8916; 
MID10066; 
LES431; Trent 
ATCC27853; 
MAN8799; 
MANCD3373; 
LES431; LESb58; 
Trent 
LES431; LESB58 
ATCC27853; 
MID8916; LES431; 
MID10066; LESB58 
LES431; Co1 
4 
V1; R8; Stoke; 
MAN8799; 
MANC3373 
V5 Stoke V3; S67 ATCC27853 V5   V2   
5   Environmental control 2 ATCC27853; V6 
MID10066; 
MID8916 C29         
6   
MID8916; 
MID10066; Stoke; 
S67 
Environmental 
control 1 C14           
7   
V1; Trent; 
MAN8799; 
MANC3373 
MID10066             
8   ATCC27853               
9   R56               
 
  
4.10 Length of PCR amplicon size and cluster formation 
 As shown in Table 36, the size of the PCR amplicon does not predict the level of separation into clusters or groups.  
Table 36: Size of PCR amplicon vs separation into melt groups. 
SNP 
Length of 
amplicon 
(bp) 
Normalised graph 
clusters 
Number of ScreenClust 
clusters 
trp331 113 4 well separated groups 9 clusters  
aro47 132 No strong separation of groups 9 clusters many overlapping 
acs336 177 5 well separated groups and 3 well separated singles 7 clusters  
nuo255 215 No strong separation of groups 4 clusters overlapping 
acs78 255 2 major melt groups. And 3 well separated singles 6 clusters overlapping 
pps100 290 No strong separation of groups 7 clusters some overlapping 
trp112 392 No strong separation of groups 8 clusters overlapping 
pps268 598 2-3 groups  4 overlapping clusters 
mut36 610 No strong separation of groups 3 clusters, some overlapping Highlighted orange: example of SNPs with short amplicons lengths and produced little separation into groups or SNPs that had longer PCR amplicons but separated well into groups.  
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CHAPTER 5 
5.0 In silico investigation of P. aeruginosa population structure:  a 
bioinformatics analysis 
5.1 Introduction A key objective of the bioinformatics analysis was to investigate diversity in P. aeruginosa housekeeping alleles from an extensive collection of isolates. This analysis aims to support and build upon outcomes in Chapter 4, that indentified additional polymorphisms within SNP PCR amplicons and described their melt curve behavior.   Another purpose of this chapter was to expand on the HRM results in Chapter 4, that demonstrated similarity between the UK clonal and environmental P. aeruginosa strains. eBURST (based upon related sequence types) analysis of pubMLST isolates can provide insights into P. aeruginosa population structure as a whole, and allow further inferences to be made about relationships between CF clonal and environmental strains to be made.   
5.2 Methods 
5.2.1 Polymorphic site analysis of MLST genes 
5.2.1.1 Number of polymorphic sites START2  version 0.9.0 beta software program (http://pubmlst.org/software/analysis/start2/) (Jolley, Feil, Chan, & Maiden, 2001) was used to determine the number of polymorphic sites in each MLST gene. All allelic profiles and sequences were downloaded from the pubMLST database (http://pubmlst.org/paeruginosa/) in FASTA format and used as input data for analysis with START2 version 0.9.0 beta software  program  (Jolley, Feil, Chan, & Maiden, 2001). 
5.2.1.2 Visual analysis of polymorphic sites and prevalance The ‘locus explorer’ function in the P. aeruginosa pubMLST database (http://pubmlst.org/paeruginosa/)  was used to determine the location of known polymorphic sites and to determine the percentage prevalance of each nucleotide base at each polymorphic position. Coloured bars indicate the categories of prevalance percentages for each nucleotide base. Each MLST gene alignment was based on the following allele reference sequences: 
acs  allele 1 
aro allele 19 (99.60 % identical – differences at nt 224: T->C and nt 337: A->G) 
gua allele 12 
mut allele 31 
nuo allele 1 
pps  allele 4 
trp  allele 10 
100  
5.2.2 Polymorphic site analysis of PCR amplicons MLST allele sequences were downloaded from the MLST database and aligned with Clustal W (Larkin et al., 2007) using Bioedit software (Hall, 1999). The location of each polymorphism, the alleles containing the polymorphism and the nucleotide base change were noted. For SNPs 
pps268, trp112, pps100, acs78, acs336, primers were located outside of the MLST sequence region and therefore the whole PCR amplicon could not be analysed.  Analysis was performed on MLST data downloaded from the pubMLST database (http://pubmlst.org/paeruginosa/) on the 22nd February 2012.  
5.2.3 MLST database statistics Data downloaded from the ‘isolates database’ of the pubMLST database was used to determine the proportion of isolates published in the P. aeruginosa MLST database that belonged to the following groups: CF, Environmental, Clinical (Human: non-CF), Other (ie from animal sources) and the number records. 1630 isolates in total were analysed. Isolates without ST values were excluded from analysis. 
5.2.4 eBURST v3 analysis Conventional and comparative eBURST analysis was performed using the eBURST v3 programme (http://eburst.mlst.net) (Feil, Li, Aanensen, Hanage, & Spratt, 2004). The eBURST algorithm, developed specifically for MLST data, estimates the evolution of each clonal complex from its ancestral genotype (or primary founder). A conserved eBURST group (or clonal complex) is defined as all STs assigned to a specific group that share identical alleles at 6/7 loci with at least one other ST in the group. Each ST can only be assigned to a single group. The primary founder of the group is defined as the ST with the greatest number of Single Locus Variants (SLVs) (or Double Locus Variants (DLVs) when more than one ST has the same number of SLV) and has the lowest average distance from all other STs in the group.  
5.2.4.1 Conventional eBURST analysis All STs with complete allelic profiles in the entire pubMLST database (http://pubmlst.org/paeruginosa/) were downloaded and submitted for eBURST analysis (http://eburst.mlst.net). Complete allelic profiles on the pubMLST database without STs values, 
were also included in the analysis and were assigned abritary numbers (≥4000) so that they can be distinguished from all other assigned STs. STs described in the publication by Khan et al. (2008), that did not possess ST values but had complete allelic profiles were assigned arbitrary 
numbers (≥8000) and submitted for eBURST analysis. In total, 1360 different STs were submitted for eBURST analysis. Descriptions of SLVs for selected clonal strains were sourced from the MLST database and from published literature.  
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5.2.4.2 Comparative eBURST analysis The comparative eBURST function compares two datasets and coloured the STs  differently depending if they were unique to the dataset (green and black) or if they were present in both datasets (pink). STs that were described on the MLST database or in publications as being derived from either ‘CF patients’ (n=351) or the ‘environment’ (n=134)  were submitted for comparative eBURST analysis. Descriptions of shared STs were sourced from the MLST database and from published literature.  
5.3 Results 
5.3.1 Polymorphic site analysis of MLST genes 
5.3.1.1 Number of polymorphic sites The proportion of polymorphic sites within each individual MLST housekeeping gene was high with 35.36 % of polymorphic sites on average.  As shown in Table 37, the nuoD gene had the lowest proportion of polymorphic sites at 22.68 % and also had the lowest number of unique alleles. The guaA gene had the highest proportion of polymorphic sites at 51.34 % combined with lower than average number of unique alleles.  The aroE gene had the greatest number of unique alleles.   
Table 37: MLST gene and the number of unique alleles and proportion of polymorphic sites 
Gene 
Size of 
fragment 
sequenced 
(bp) 
Number of 
unique 
alleles 
Number of 
polymorphic 
sites 
Proportion of 
polymorphic 
sites (%) 
acsA 390 133 124 31.79 
aroE 495 152 237 47.88 
guaA 372 120 191 51.34 
mutL 441 128 155 35.15 
nuoD 366 82 83 22.68 
ppsA 369 107 99 26.83 
trpE 441 151 153 34.69 Mean 410.57 124.71 148.86 35.77  
5.3.1.2 Visual analysis of polymorphic sites and prevalance As shown in Figures 27 to 33 MLST genes possess many polymorphic sites. A large proportion of polymorphisms were not common as demonstrated by only 10% of alleles encoding a SNP.     
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 Figure 27: Polymorphic sites within the MLST alleles in the acsA gene  
 
Figure 28: Polymorphic sites within the MLST alleles in the aroE gene 
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Figure 29: Polymorphic sites within the MLST alleles in the guaA gene  
 
Figure 30: Polymorphic sites within the MLST alleles in the mutL gene 
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Figure 31: Polymorphic sites within the MLST alleles in the nuoD gene 
 
Figure 32: Polymorphic sites within the MLST alleles in the ppsA gene 
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Figure 33: Polymorphic sites within the MLST alleles in the trpE gene 
 
5.3.2 Polymorphic site analysis of PCR amplicons Tables 38 to 46 indicate the location of known polymorphisms (from the database) in PCR amplicons.  The high D-value SNPs are coloured coded yellow.  
Table 38: PCR amplicon for SNP mut36 
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 1 24, 39, 53, 86, 92, 100, 105, 125 C-> T&A 3 24 G->A 
9 2, 3, 4, 6, 8, 9, 10, 14, 15, 17,18, 19, 21-23, 25, 27, 38, 41-43, 46, 48, 54-55, 59, 61, 63, 67-68, 72, 76, 77, 81-83, 58, 88, 97, 102, 110, 115-116, 118-119, 124, 126, 129, 131, 134 A->G 12 91 C->G 13 122 A->G 16 110 A->C 17 110 A-> G 21 39, 56, 58, 69, 86, 92, 100, 110, 125, 136,  C->T 22 58, 69, 136  C->T 24 39, 53, 86, 92, 100, 110, 125 G->C 26 79 C->A 27 27, 49, 50, 52, 57, 104-112  G-> A&C 33 39, 53, 86, 92, 100, 110, 125 C-> T&G 
106  
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 
36 (D=0.5003) 
2-4, 6, 10, 14-15, 17-19, 22-23, 26-27, 31, 38-39, 41-43, 46-50, 52-61, 63, 67-69, 72, 76-78, 81-82, 85-86, 88-90, 92-94, 97, 100, 102, 104-112, 115, 116, 118-119, 124-126, 129, 131, 134, 136  T-> C&G 40 22 G->A 42 91, 110, 119 C->T 45 91 G->C 47 91 C-> G 48 35, 49-50, 52, 57, 60, 89, 91, 104-112 T->C 51 91, 93 C->T 54 85, 115 C-> T&G 55 39, 53, 86, 92, 100, 125 C->T 57 110 G->T 60 106 C->T 63 39, 53, 86, 91-92, 100, 125 C->T 69 58 C->T 75 91, 110 C->G 76 91, 110 A->G &A 82 49-50, 52, 57, 91, 104-109, 111-112 G->A 83 49, 50, 52, 57, 91, 104-109, 111-112 C->G 84 110 C->G 85 30, 46, 72, 77, 118, 122 C->T 89 81 A->T 90 104, 110 C->T 92 49, 50, 52, 57, 74, 79, 104-112, 131 G-> C&T 97 49, 50, 52, 57, 60, 91, 104-109, 111-112 C-> A&T 98 6, 17, 49, 50, 52, 57, 59, 99, 104-109, 111-112 G-> A&C 99 35, 37, 49-50, 52, 57, 60, 80, 87, 89, 91, 104-112, 123  A-> C,G,T 102 52 C->T 105 49, 65, 115, 118 G->A 106 49, 50, 52, 57, 91, 104-112, 120 C->G&A&T 107 50, 52, 104, 106, 109  T->C 108 49, 50, 52, 57, 91, 104-112 G->C&T 109 91, 110 G-> A&T 110 110 C->G 111 35, 60, 70, 89, 111, 102, 111, 123, 132 C->G&T 114 2-16, 18-24, 26-90, 92-105, 107-136 T-> C&A 117 38 G->A 120 71, 88, 91, 110  C->G 121 77, 126 C->A 
107  
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 123 49, 50, 52, 57, 91, 104-112 G->T&C 125 84, 117 T->G 126 110 C->T 128 91, 110, 126 G-> C&T 129 96 C->T 130 91, 110 G-> T&A 131 110 C->G 132 44, 49, 50, 52, 57, 91, 104-112 G-> A&C 135 91 G->T 138 39, 75 C->T 141 17, 91, 101  C->T&G 142 110, 113 C->T 143 49, 50, 52, 57, 91, 104-112 A->C 146 68 C->T 147 35, 37, 49, 50, 52, 57, 60, 78, 80, 87, 89, 91, 104-112, 123, 136 A->G&C&T 150 91 C->T 153 32, 89, 91, 110  C->T&G 156 104-105 G->A 163 35, 37, 60, 67, 73, 80, 87, 123 C->T 165 49, 106, 110, 111 G->A 168 49, 50, 52, 57, 104-112 G->C 171 20, 62, 90 C->T 172 110 G->C 174 15 G->A 175 49, 50, 52, 57, 91, 104-109, 111-112 G->A 177 110 C->G 183 108 C->T 184 91 A->G 185 91 A->G 186 35, 37, 60, 80, 87, 89, 91, 110, 123 C->T 187 40 G->A 189 2, 9, 13, 32-33, 91, 119, 127,  C->T 194 91 A->G 196 91 C->T 202 125 G->T 204 7, 8, 11, 29, 36, 40, 44, 45, 51, 65, 70, 74, 75, 77, 79, 91, 95, 96, 98, 101, 103, 110, 113-114, 117, 127, 130, 132, 135 C->T&G 210 110, 90 C->G&T 213 87, 110 C->G & T 214 49-50, 52, 57, 104-112 T->C 217 45 C->T 218 103, 128 C->T 
108  
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 221 76 C->T 222 110 C->G 228 7, 8, 36, 40, 45, 50, 51, 57, 91, 94, 96, 103, 106, 109, 112-113, 127, 130, 132, 135 C-> T&G 231 63-64 C->T 237 35, 37, 60, 80, 87, 89, 123 G->A 238 91, 110 C->G 240 112 G->A 243 35, 37, 60, 80, 87, 89, 91, 123 C->T 246 39, 53, 55, 86, 92, 100,125 G->A 252 35, 37, 60,80, 87, 89, 91, 110, 123 C->T 255 34, 83 C-> T 258 50, 52, 57, 91,104-112 T->C 261 49, 50, 52, 57, 91, 104-109, 111-112 G->C 263 114 A->G 267 49, 50, 52, 57, 91, 104-112 G->C&T 269 95 G->A 270 18, 110 C-> T&G 276 39, 53, 86, 92, 100, 125 G->A 279 110 C->G 280 129 G->T 285 49, 104, 109 G-> A 288 14, 131 G->A 291 110 C->G 292 134 G->T 293 110 C->T 294 90-91, 110 C->T 297 23, 39, 91-92, 100, 110 C-> G&T 298 103 G->C 303 26, 47, 56, 58, 69, 78, 90, 136 G->A 309 65, 98, 121 G->A 312 35, 37, 49- 50, 52, 57, 60, 87, 91, 104-112, 123 T->C&G 315 49-50, 52, 57, 104-109, 111,112 T->C 321 110 C->T 323 135 T->C 327 49-50, 52, 57, 104-109, 111,112 G->C 329 91 A->T 331 48 A->C 332 41 A->G 333 91 C->T 336 55, 110 C->T 339 49-50, 52, 57, 104-112 G->C 
109  
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 340 51 A->T 
342 10, 12, 24, 26, 33, 35, 37-39, 47, 49-50, 52-53, 56-58, 60, 69, 78, 80, 86-87, 89-92, 100, 104-109, 111, 112, 123, 125, 136 T->C 345 38 G->T 347 101 C->G 351 46, 61, 91 C->T 353 36 T->C 354 53, 86, 125 G->A 360 91, 110 C->T 361 49,50, 52, 57, 91, 104-112 T->C 363 49, 50, 52, 57, 91, 104-112 C->G 366 29, 35, 37, 49-50, 52, 57, 60, 80, 87, 89, 95, 97, 104-112, 123 A->G 367 91, 110 G-> C&A 369 16, 20, 110, 124 C->T&G 372 52, 104,106-111 T->C 375 47, 52, 110 G->A 376 91 G->A 377 91 C->G 378 91 G->C 379 49, 50, 52, 57, 91, 104-109, 111-112 G->A 380 49-50, 52, 57, 91, 104-112 T->C 381 100 G->A 382 42 G->A 384 35, 37, 60, 80, 87, 89, 123 G->C 387 53, 66, 82, 91, 130 C->T 390 110 C->G 393 26, 38, 47, 56, 58, 69, 78, 90, 136 C->T 396 91 G->T 399 35, 37, 80, 87, 89, 123 C->T 402 110 G->C 407 44 A->T 414 110 A->G 417 35, 37-38, 49, 50, 52, 57, 60, 80, 87, 89, 91, 104-112, 123 T->G&C 420 110 C->T 423 19, 54, 59, 88  C->T 426 35, 37, 49, 50, 52, 57, 60, 80, 87, 89, 104, 106-109, 111, 112, 123 T->C 429 110 C->G 430 110 A->G 432 56, 58, 110 C->T 
110  
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 433 133 C->T 435 16, 20, 28, 43, 49, 50, 52, 57, 91, 104-112, 124 G-> T&C&A 437 110 T->C 438 43, 110 G->A&C 439 4 G->A 440 116 T->C 441 91 C->G  
Table 39: PCR amplicon for SNP acs336 
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 291 58, 128 G->A 297 120 G->A 303 120 C->T 315 52 G->A 318 10, 103 C->A&T 321 50 G->A 
322 4-6,8-9, 11, 14, 18, 21, 23, 26-27, 29, 31, 33-34, 40, 42, 44, 48, 50-52, 57, 59, 65, 66, 81, 85, 86, 91, 97, 99, 103, 105-106, 108-109, 112, 115-116, 122-125, 127 C->T 324 120 G->A 327 120 G->A 330 120 C->T 333 120 C->T 
336 (D=0.7498) 
4,5, 6, 8, 9, 11, 14, 18, 23, 27, 29, 31, 33-34, 36-37, 40, 42, 44-46, 48, 50-52, 54, 57, 59, 61, 65-66, 81, 85-88, 90-91, 97, 99, 103, 105-106, 108-109, 112, 115-116, 122-125, 127 C->T 338 120 C->G 339 120 G->C 340 120, 129, 132, 133, 135-139, 143-144 A->C 345 29, 65, 97 G->A 350 66 G->A 354 7, 15, 17, 28, 30, 39, 42, 46, 54-56, 62-64, 101-102, 114, 121, 135, 145 C->T 
357 7, 15, 17, 28, 30, 39, 55-56, 62-64, 95, 101-102, 114, 120-121, 129, 132-133, 135-139, 143-145 G->A&C 360 120 C->A 
111  
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 361 120 A->C 362 120 A->G 366 51 G->A 375 91, 112, 135 C->T&G 379 120 G->C 380 120 T->A 
381 
3, 7, 10, 15, 17, 19-22, 25-26, 28, 38, 39, 41, 43, 45-46, 49, 53-56, 58, 62-64, 82, 87, 89-90, 92, 95, 96, 98, 101-102, 108-111, 118, 120-121, 128-129, 132, 133, 135, 136, 137, 138, 139, 140, 141, 143, 144, 145 
C->A&T&G 
387 3, 12-13, 17,19, 21-22, 24, 26, 28, 32, 35, 38, 39, 41, 47, 54, 56, 60, 62-64, 67, 82, 95, 98, 101-102, 104, 107-109, 113, 114, 119, 121-122, 126, 137, 139, 145 G->A&C 
 
Table 40: PCR amplicon for SNP trp112 
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 1 97, 99-106, 108 T->C 2 112 G->A 4 71-72, 90, 93, 97, 99-106, 108, 123, 126, 129, 135 C-> A&G 7 29 G->T 
10 5-6, 11, 15, 21-23, 25-26, 28, 32-33, 36, 40, 48-49, 54-55, 73, 78, 81, 89, 96, 98, 118, 122, 125, 128, 130, 132-133, 140 C->T 
13 126, 129, 135 C->T 16 24, 47, 50, 131 G->T 22 101, 104, 126, 129, 135 G->A 25 126, 129, 135 G->A 28 127 G-> 31 97, 99-106, 108, 126, 129, 135 A->G 34 97, 99-100, 102, 104, 106, 108, 138 G->C&A 37 97, 99-106, 108 C->G 40 122 G->A 
112  
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 
43 14, 17, 24, 32, 34-35, 42, 47-48, 50, 55, 61-62, 71-72, 77, 80-81, 84, 87-88, 90, 93, 96-106, 108, 119, 120, 123-124, 126-127, 129, 131, 135, 139, 140 T->C 
46 43 C->G 47 97, 99-106, 108 C->G 48 97, 99-106, 108 T->A 49 34, 35, 77 G->A 
52 4-6, 11, 15, 21-24, 26, 28, 32-36, 40,42, 46-51, 55, 61-62, 71-73, 77-78, 80-81, 84, 87, 89, 90, 93, 96-106, 108, 118-120, 122-124, 126-129, 131-133, 135, 139-140 G->C&A 54 58 C->T 55 110, 126, 129, 135 G->A 58 101, 103 ? 64 126, 129, 135 G->C 70 86 C->T 
73 5, 21-25, 28, 34, 40, 42, 46-47, 49-50, 54, 62, 77-78, 87, 97-106, 108, 118, 122, 124-127, 129-133, 135 T->C 77 137 C->T 79 71, 72, 90, 93, 97, 99-106, 108, 123, 126, 129, 135 T->A&C 85 23, 46, 50, 78, 124, 133 C->G 88 97, 99-106, 108 G->C 89 97, 99-106, 108 A->G 90 97, 99-106, 108 T->C 93 97, 99-106, 108 A->C 94 79 C->T 97 97, 99-106, 108 A->G 100 97, 99-106, 108 G->A 103 9, 56 C->A&T 105 29 A->G 108 97, 99-106, 108 T->G 109 97, 99-106, 108 G->C 110 46 G->A 
113  
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 
112 (D=0.8752) 1, 7, 12, 14, 17-18, 20, 29-30, 37-39, 41, 45, 52, 57-60, 63, 65, 68, 74, 76, 79, 82, 85, 86, 91, 94, 97, 99-106, 108, 115-166, 121, 134, 136-137 G->A&C 
113 37 C->T 122 81 G->A 124 97, 99-106, 108, 126, 129, 135 T->C 128 32, 48, 81, 96 C->T 
130 5, 11, 22-24, 28, 34, 40, 42, 46-47, 49-50, 54, 77-78, 84, 87, 98, 117, 122, 124-127, 129-131, 133, 135, 139 G->A&T 132 107 C->T 133 97, 99-106, 108 G->C 136 66, 126, 129, 131, 135 C->T 145 97, 99-106, 108 G->A 146 49, 62, 119 A->G 158 125 C->T  
Table 41: PCR amplicon for SNP pps100 
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 1 8-9, 48, 73, 93, 97, 99, 100 C->T 2 30, 49 A->G 7 8-9, 29, 32, 42, 48, 68, 93, 97, 99-100 C->T 13 8,9,24,44,48,49,54,59,73,77-84,93,97,99-100 A->C&G 16 24, 44, 54, 59, 73 C->T&A 19 8-9, 48, 93, 97, 99-100 G->C 22 8-9, 48, 93, 97, 99-100 A->G 31 74, 99 G->A 32 50 A->G 37 8-9, 48, 77-84, 93, 99-100 C->T 38 77-84 G->T 43 29, 32, 42, 68, 88 C->T 44 70 G->A 46 69 C->A 49 8-9, 48, 77-84, 93, 97, 99-100 C->C 
114  
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 52 77-84, 89 C->G&T 58 77, 78, 80-82, 84, 94 G->A 64 24, 44, 59 C->T 65 24, 44, 59 C->T 70 77-84 G->C 72 5 A->C 73 77-84 A->G 82 9, 59, 77-84, 97 G->C&T 83 37, 51, 58 A->G 84 46, 48, 77-84 C->A&G 85 71, 77-84 C->G&T 89 27, 43 C->T 94 8-9, 48, 54, 73, 93, 97, 99-100 G->C 96 34 A->T 97 8-9, 48, 53, 58, 64, 86, 90-91, 93, 97, 99-100 A->G 
100 (D=0.9319) 3-5, 8-10, 12-15, 21-25, 28, 30-31, 33-34, 41, 44, 46, 48-51, 54, 56-57, 59, 61-63, 66, 70, 72-73, 76-85, 87, 89, 92-97, 99-100,  A->C&G&T 103 8-9, 48, 77-84, 93, 97, 99-100 T->C 109 11 C->T 112 14. 20, 57, 60, 65, 75,  C->T 118 8-9, 48, 93, 97, 99-100 C->T  
Table 42: PCR amplicon for SNP nuo255 
Position 
within gene  Alleles with SNP 
Nucleotide 
base 
change 128 66 A->G 138 65 G->A 141 65 C->G 145 65 T->A 146 65 C->G 153 84 C->T 156 86, 80, 79, 65, 53, 41, 38, 37, 36, 35, 34, 33, 32, 17,  T->C 162 2-3, 7, 27, 29, 44, 55-56, 74-75, 81, 84,  C->T 165 6, 18, 80 C->T 168 16, 57, 60 C->T 177 59 C->T 186 56 C->T 
115  
Position 
within gene  Alleles with SNP 
Nucleotide 
base 
change 189 16, 36 C-> A&T 192 7, 12, 57 C->T 204 41 C->T 207 51 C->T 211 23 C->T 213 32-34, 36-38, 41, 77, 79, 80 C-> G&T 216 26, 36, 65 C->T 219 17, 32-39, 53, 57, 60, 65, 68, 76, 77, 80, 86 A->G 222 20, 28, 30, 47, 48, 54, 78, 79 C-> T&G 223 79 T->G 225 79 G->C 228 79 G->C 234 65 G->A 240 33, 37, 41, 51, 85 C->A 243 20, 28, 30, 32-34, 36, 38, 47, 48, 54, 62, 65, 77, 78, 79, 80  G-> A&C&T 246 79 C->T 247 79 A->C 251 67 T->C 252 86, 79 G->A 253 31 C->T 255 (D=0.9613) 4, 9, 19, 21, 26, 27, 29, 31, 43, 45-47, 49, 56, 59, 61, 67, 69, 82, 83 G->C 256 65 C->G 257 65 A->C 258 65 G->C 259 79 C->A 260 79 G->A 261 80, 79, 77, 65, 36, 37, 38, 41 G->C&A&T 268 65, 79 G->T&A 269 79 T->C 270 32-34, 36-38, 41, 65, 68, 77, 79-80 G->C 276 32-34, 36-38, 41, 44, 55, 65, 77, 79-80 G-> C&A 277 65 A->G 
116  
Position 
within gene  Alleles with SNP 
Nucleotide 
base 
change 283 65, 79 A->C 285 65 G->C 286 32-34, 36-38, 41, 77, 80 G->T 288 9, 46, 65 G-> A&C 300 8, 15, 17, 28, 32-38, 41, 53, 58, 64-65, 77, 79-80, 86 T->C 304 65, 79 C->A 305 79, 65 T->C 306 79, 65 G->C 308 79, 65 A->G 309 65 C->T 320 65, 79 A->T 321 35, 37-38 C->T 324 65 G->C 327 79 C->T  
Table 43: PCR amplicon for SNP acs78 
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 3 26,33, 40, 43, 49, 63, 97-99, 105, 120 C->T&G 4 57, 83, 88 C->T 6 126 G->T 
7 2-7, 9, 12-14, 16, 19, 23, 28-33, 35, 37, 42, 44, 47, 48, 50-51, 56-57, 59, 61, 64, 67, 81-83, 85-86, 91, 92, 95-909, 103-104, 106-108, 110, 113, 119, 121, 123, 125-126, 141 C-> T&A 10 120 G->T 11 117 C->T 12 121 C->A 15 9 C->T 21 2,9,31,48,107,113,119,132,139, 143,  C->T&G 24 96, 120, 141 C->T 28 120, 129, 132, 133, 135, 136, 137, 138, 139, 143-144 A->C&G 30 120, 129, 132, 133, 135, 136, 137-139, 143-144 T->G 31 120 C->A 39 129, 132, 133, 135, 136, 137-139, 143-144 G->A 
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Position 
within gene  Alleles with SNP 
Nucleotide base 
change 42 127 C->T 45 4-5, 12-13, 27, 29, 32, 33, 35, 44, 50-51, 59, 61, 85, 86, 91, 97, 103-104, 123 G->A 54 58, 118, 120, 128 C->T 57 120, 129, 132, 133, 135, 136-139, 143-144 C->G 60 123 C->T 61 62, 129, 132, 133, 135, 136, 137, 138, 139, 143, 144 G->A 63 129, 132, 133, 135, 136, 137, 138, 139, 143-144 G->C 64 120 A->C 65 120 C->G 66 53, 120 C->T 67 90 C->T 72 129, 132, 133, 135, 136, 137, 138, 139, 143, 144 G->C 75 129, 132, 133, 135, 136, 137, 138, 139, 143, 144 G->C 76 120 A->C 77 129, 139 A->G 
78 (D=0.9739) 
3-5, 10, 12-13, 18-20, 24, 27, 29, 32-33, 38-39, 41, 43-45, 49-51, 53, 58-59, 61, 67, 81-82, 85-87, 89-91, 95-97, 103-104, 107, 111, 114, 118, 120, 123, 127-129, 139-140,  A->G 82 120, 129, 132, 133, 135, 136, 137, 138, 139, 143-144 A->G 84 12 C->G 90 135, 143-144 G->A 99 4, 104 C->T 102 132, 137, 144 C->T 111 120 C->T  
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Table 44: PCR amplicon for SNP pps268 
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 232 78 G->A 238 93, 100 C->T 259 8-9, 48, 93, 97, 99-100 C->T 262 82 C->T 
268 (D=0.9831) 2-9, 12, 14, 16-20, 22-25, 27, 29, 31, 33, 34, 36-40, 42-26, 48, 50, 53-57, 59, 62-63, 65-75, 77-85, 87-89, 93-95, 97-100 C->T 
271 96 C->T 280 8-9, 36, 40, 48, 69, 74, 93, 97, 99-100 G->C&T 292 8-9, 48, 77-84, 93, 97, 99-100 T->A&C 295 77-84 C->T 298 8-9, 48, 77, 82-84, 93, 97, 99-100 A->G 301 12, 56, 70 G->A 304 62, 82, 84 C->T 307 8-9, 38, 48, 93, 97-100 C->T 309 95 C->T 313 9, 48, 59, 77-84, 93, 97, 99-100 G->C&A 317 23 G->T 322 77-84 T->C 325 8-9, 48, 93, 97, 99-100   328 16, 54, 73 C->T 
331 2-6, 8-9, 12-16, 18-19, 21-32, 34, 36-40, 42, 44, 46-51, 53-56, 58-59, 61-62, 66-85, 87-94, 96-100 T->C 335 22, 98 A->G 338 77-84 C->G 339 77-84 A->C 340 77-84 G->C 341 8-9, 48, 77-84, 93, 97, 99-100 A->G 343 57, 77-84 C->T 347 77-84 C->A 349 8, 99 G->A 352 8-9, 48, 77-84, 93, 97, 99-100 T->C 
119  
Position 
within gene  Alleles with SNP 
Nucleotide base 
change 
355 2, 6, 19, 25-27, 36-37, 39-40, 42, 54, 55, 67-69, 71, 73-74, 76,  C->G&A 357 87 A->T 359 77-84 G->C 360 77-84 G->A 361 8-9, 21, 48, 93, 97, 99-100,  G->A&C 364 77-84 G->C 367 8-9, 48, 93, 97, 99-100 C->G 370 77-84 T->G&A  
Table 45: PCR amplicon for SNP trp331 
Position 
within gene  Alleles with SNP 
Nucleotide 
base 
change 264 82 A-> G 271 97,99-106,108, 126, 129, 135 G->T 282 97, 99-106, 108 C->A 283 20, 67, 113 C->T 268 6,97,99-106, 108, 126, 129, 135 G->A&C 289 62, 97, 99-106, 108, 126, 129, 135 A->G&C 290 97, 99-106, 108, 126, 129, 135 T->C 292 97, 99-106, 108 G->C 293 76, 97, 99-106, 108 C-> T &A 294 97, 99-106, 108, 140 G-> A&T 295 84, 97, 99-106, 108  C-> T & G 296 97, 99-106, 108 G -> C 297 97, 99-106, 108 A->C 298 30, 97, 99-106, 108 G-> T&C 300 97, 99-106, 108, 121 G-> A&T 301 93, 123 G->A 304 18,99,100, 105 C-> T, G 305 126, 129, 135 A->G 306 116 G->T 307 24, 33, 87, 126, 129, 135 C->T 308 69 G->A 310 71, 72, 90, 97, 99-106, 108 G-> A&C 314 29 G->C 319 97, 99-108 G->C 321 29 T->G 
120  
Position 
within gene  Alleles with SNP 
Nucleotide 
base 
change 325 97, 99-106, 108 G->C 
331 (D=0.9873) 2-5, 8-13, 15-16, 19, 21-28, 31-34, 36-37, 40, 42-44, 46-49, 51, 54-57, 59-67, 70-72, 75, 78, 80-81, 83-109, 111-115, 117-120, 122-123, 125-126, 128-136, 139-140 T-> C&A 334 99, 101, 105 G->C 337 6, 32, 35, 48, 50, 55, 73, 77, 81, 96, 124, 127, 140,  G->T&A 340 97, 99-106, 108 G->C 
343 3-5, 8,9,11,13,15,16,22-28,33-34,36,40,42,46-47,49,51-52,54,60,62,64,67,70,75,78,80,87,89,98,109,114,117-120,122,125,128,130-131,133,139 C->T 
346 3-5, 8-9, 11,13,15-16,22-28,33-34,36,40,42,46-47,49,51-52,54,60,62,64,67,70-72,75,78,80,87,89-90,93,97-106,108-109, 114, 117-120, 122-123, 125-126,128-131, 133, 135, 139 T->G&C 
349 3-5, 8-9, 11, 13, 15-16, 22-28, 33-36, 40, 42, 46-47, 49, 51-52, 54, 60, 62, 64, 67, 70-72, 75, 78, 80, 87, 89-90, 93, 97-106, 108-109, 114, 117-120, 122-123, 125-126 A->G 352 85 C->T 355 97, 106 C->T 361 361, 120 G->A  
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Table 46: PCR amplicon for SNP aro47 
Position within gene  Alleles with SNP Nucleotide base change 8 39 C->T 11 32 G->T 23 34, 42, 70 G->C 24 126 A->G 25 126 A->T 26 15, 21, 34, 42, 68, 70, 79, 82, 84, 104, 106, 108, 109-111, 113-119, 138-139, 144 G-> A&C&T 27 89 G->A 28 35 C->A 31 90 A->T 32 109-111, 113-119 T->C 35 20, 34, 42, 70, 79, 90, 104, 106, 108, 109-111, 113-119, 129, 144 T-> C&G 39 109-111, 113-119 G->T 40 90, 109-111, 113-119 T-> C&G 41 90, 109-111, 113-119 G->C 43 109-111, 113-119 A->G 44 25, 109-111, 113-119 C->T 
47 (D=0.9910) 
2,5,6,10,18,20,24,25,27-28,31,32,33,35,40,41,44,45,47-49,53,55,57,60,63,65,66,68-69,71-73,76,80,83-85,88-89,94,97,100-101,103,105,107,110-111,113-114,116-120,123,125,127,129-130,132-133,135-136,138-140,143,145 
A->G 
48 34, 42, 70, 90, 109-111, 113-119,  T->C 50 90, 109-111, 113-119 G->C 52 90, 109-111, 113-119 G->C 53 42, 49, 124 C->T 56 25, 71, 115 G->A 57 132 C->T 59 90, 109-111, 113-119 G->C&T 63 90, 109-111, 113-119 A->C 64 38, 90, 109-111, 113-119 C->T&G 65 90 C->T 68 34, 42, 70, 90, 109-111, 113-119 G->C&C 71 109 C->T 
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Position within gene  Alleles with SNP Nucleotide base change 74 34, 42, 70, 90, 109-111, 113-119 G->C&T 83 90 C->T 86 109, 111 C->G 89 121 G->C 90 34, 42, 70 A->G 91 90, 109-111, 113-119 T->A 92 90, 109-111, 113-119 C->G 93 90, 109-111, 113-119 C->A 94 90, 109, 111, 115 G->A 95 90, 109-111, 113-119 C->A&G 
98 
5-6, 9-10, 12, 14-15, 18-21, 24-25, 27-30, 32-33, 35-36, 40-41, 44-49, 53, 55, 57, 60, 63, 65-69, 71-73, 76, 79-89, 94-101, 103-111, 113-120, 122-123, 125-133, 135-141, 143-146 
G->C&T 
100 34, 42, 70, 109-111, 113-119 C->A 101 9, 12, 14-36, 67, 77, 81, 87, 98, 128, 141, 146 C->T 103 34, 42, 70 A->G 106 134 G->A 107 34, 42, 70, 93, 109-111, 113-119,  T->C 110 9, 12, 14, 56, 67, 81, 87, 98, 141, 146 C->T 111 141 C->T 115 90, 109-111, 113-119 G->T 116 90, 109-111, 113-119,  C->G 119 59, 72, 89, 34, 42, 70,90, 119 C->T&G  Figures 34 and 35 document the physical locations of known polymorphic sites (from MLST data) within the trp331 and nuo255 PCR amplicons and describe the polymorphic sites within the P. aeruginosa representatives sequenced. Eight sequence representatives for SNP trp331 contained six out of 39 total polymorphic sites and 48 total polymorphisms (Figure 34).  For the 
nuo255 PCR amplicon, four sequence representatives possessed two out of 59 total polymorphic sites and 69 total polymorphisms.    
123  
     
Figure 34: Polymorphic sites within the trp331 PCR amplicon.  The arrows indicate the location of the 
polymorphic sites. The red arrow represents the D-value SNP (trp331) 
 
Figure 35: polymorphic sites within the nuo255 PCR amplicon.  The arrows indicate the location of the 
polymorphic sites. The red arrow represents the D-value SNP (nuo255) 
5.3.3 MLST database statistics CF isolates (40 % total) represented the greatest proportion of isolates recorded on the MLST online database (Figure 36). This was followed closely by other clinical isolates at 38 %.  Environmental strains represented only 9 % of isolates recorded on the database. 6 % of isolates did not have any corresponding source information in the database.  
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Figure 36: Proportion of isolates on the online pubMLST database 
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5.3.4 Prevalence of minimum-SNPs in different population groups Table 47 demonstrates the separation of different population groups based on minimum SNP type.  Minimum- SNP types that were more prevalent in a specific population group are highlighted in yellow.  
Table 47: Application of 9 SNP method to resolve population groups 
SNP Base 
Percent 
STs in 
Database  
Percent 
CF STs 
Percent 
Environmental 
STs  
Percent 
difference: CF 
and 
environmental 
Percent 
difference: 
CF and 
database  
Percent 
difference: 
environmental 
and database 
acs78 
A 73.87 83.79 67.97 15.82 9.92 5.90 G 26.13 16.21 32.03 
acs336 
C 50.95 50.82 43.75 7.07 0.13 6.84 T 49.05 49.18 56.25 
aro47 
A 34.61 23.63 39.84 16.22 10.98 5.23 G 65.39 76.37 60.16 
mut36 
C 50.11 48.08 50.00 1.92 2.03 0.11 T 49.89 51.92 50.00 
nuo255 
G 63.18 55.77 69.53 13.76 7.41 6.35 C 36.82 44.23 30.47 
pps100 
A 38.35 29.95 36.72 6.77 8.40 1.63 C 0.76 0.27 0.00 0.27 0.49 0.76 G 59.97 68.96 62.50 6.46 8.99 2.53 T 0.92 0.82% 0.78 0.04 0.10 0.14 
pps268 
C 24.22 34.34 25.78 8.56 10.12 1.56 T 75.78 65.66 74.22 
trp112 
A 41.79 50.27 35.94 14.34 8.48 5.85 G 57.45 49.73 64.06 7.22 6.61 C 0.76 0.00 0.00 0.76 0.76 
trp331 
C 60.5 51.92 68.75 16.83 8.58 8.25 T 39.42 48.08 31.25 8.66 8.17 A 0.08 0.00 0.00 0.08 0.08 Highlighted orange: Greater than 15% difference between the groups  
 
5.3.5 Comparitive eBURST analysis of CF and environmental P. aeruginosa isolates 30 STs were present in both the environment and CF populations (Figure 37).  In addition, a number of the environmentally sourced STs were SLVs of STs derived from CF patients. The majority of CF isolates (n=251) however, were not linked to strains derived from the environment, as seen in the eBURST analysis. Table 48, presents the results of an analysis of the geographical distribution and sources of the shared STs. Most of the shared STs (n=22) were isolated from different countries and diverse sources.  
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Table 48: Global distribution of shared STs 
ST CF isolates Environmental isolates Other 9 Canada Australia (QLD) River water and Japan Coastal water France  16 Australia (QLD) Australia (QLD) River water Australia(QLD) Feline nasal biopsy & Australia (QLD) Human ear 
27 Australia (QLD, VIC) UK water & Australia (QLD) household sink 
UK (Croydon, Boston, Studi, Glasgow, Stourbridge, Queen Marys, Mid-Glamorgan) & Canada & Australia (QLD) various human sources 147 Australia (QLD)  Australia (QLD) River water Australia (QLD) Human UTI and Ear 
179 Canada & Australia (QLD, WA, VIC, NSW, SA) Australia (QLD) River water and Japan River water UK & Spain & Australia (QLD) Human and Canine infections 207 Canada Australia (QLD) Household sink Australia (QLD) 219 Canada Kuwait Crude oil contaminated soil NA 241 Australia (QLD) Japan (Tokyo) Pond water   252 Australia (NSW) Australia (QLD) River water Australia (QLD) human soft tissue infection 
253 Australia (QLD, VIC) Australia (QLD) River water, Tap water and Endoscopy; UK Soil 
Australia (QLD) Various human and Canine infections and avian crop swab 257 Australia (QLD) Australia (QLD) River water Croatia (Dalmatia) 
266 Australia (QLD) Australia (QLD) River water Australia (QLD) Human UTI and Canine ear 313 Australia (QLD) Australia (QLD) Household sink and municipal pool Hungary (Budapest) Soft tissue infection & Australia (QLD) soft tissue infection 381 Australia (QLD) Australia (QLD) River water Spain (Balearic island) & Australia (QLD) human, canine, feline infections 
385 Australia (QLD, NSW) Australia (QLD) River water Australia (QLD) & Spain (Balearic island)  
389 Australia (QLD) Australia (QLD) River water N/A  
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ST CF isolates Environmental isolates Other 395 no value (labelled CFPA) Australia (QLD) River water and Japan coastal sea water China & Australia (QLD) various human infections 471 Australia (QLD)  Australia (QLD) River water and household sink Australia (QLD) canine ear 499 The Netherlands Australia (QLD) River water NA 553 The Netherlands Australia (QLD) River water NA 555 The Netherlands and Australia (VIC) Australia (QLD) River water NA 560 The Netherlands & Australia (QLD) China Drainage water Spain (Balearic island) & Australia (QLD) human and canine infections 564 The Netherlands Australia (QLD) River water NA 
633 France Australia (QLD) household sink Czech republic blood isolate 645 Australia (VIC) Australia (QLD) municipal pool Czech republic blood isolate 794 Australia (WA) Australia (QLD) River water Croatia (Dalmatia) 802 Australia (QLD) Australia (QLD) River water NA 810 Australia (QLD, NSW) Australia (QLD) River water NA 870 Australia (QLD) Australia (QLD) River water NA 
155 Australia (QLD, VIC, WA) & France & Spain (Balearic islands) & Canada Australia (QLD) River water Australia (QLD) Human and Canine ear infections   
 
  
                
Figure 37: Comparative eBURST image of STs grouped into environmental only (Green text), Both CF and environmental (Pink text) and CF only (Black text).  The dots 
represent STs. Dots connected by lines indicate single locus variants. The length of lines and placement of singleton and ST groups is random.  
 
  
5.3.6 Conventional eBURST analysis of Australian and Global CF clonal strains eBURST analysis represented the population structure of P. aeruginosa STs, derived from the MLST database and other published literature (n=1360), with 214 groups and 558 singletons.  As shown in Figure 38, the LES and AES-II are part of the same clonal complex. ST833 was assigned as the primary founder of the group 1 clonal complex. Six SLVs of AES-II were isolated from Australian CF patients, a non-CF patient, a canine wound and pond water in Tokyo (Table 49). LES had five SLVs only two of which have isolate descriptions (Table 50). One of these SLVs was labelled ‘CFPA’ the other was isolated from a canine wound in Australia.  
 
Figure 38: eBURST diagram of STs belonging to group 1 clonal complex.  The dots represent STs and the lines 
connecting the dots indicate SLVs. The pink and purple lines indicate SLVs of ST775 and ST146. The length of 
the lines connecting STs is arbitrary.   
Table 49: AES-II (ST775) SLV isolate descriptions SLV Isolate descriptions 241 CF patient Australia (QLD) and pond water (Tokyo, Japan) 653 Canine wound Australia (QLD) & CF patient Australia (VIC) 247 No value 808 CF patient Australia (QLD) 914 Human non-CF patient Australia (QLD) 833 CF patient Australia (QLD)  
Table 50: LES (ST146) SLV isolate descriptions LES SLV Isolate descriptions 374 No value 681 No value 414 Labelled CFPA 680 No value 683 Canine foot wound Australia (QLD) 
AES-II 
LES ST833 
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 AES-III (ST242) belongs to a small clonal complex consisting of three STs. ST242 was assigned as the primary founder of the complex. No available isolate descriptions were available for the two ST242, SLVs.             
Figure 39: eBURST diagram of group 70 clonal complex. The dots represent STs. The purple lines indicate 
SLVs of ST242. The length of the lines connecting STs is arbitrary.  Clone C (ST17) was assigned to clonal complex group two, that consists of 26 STs. Group two tied with group three, as the second largest clonal complex. Clone C was considered to be the primary founder of the complex. The majority of the 12 SLVs of Clone C do not have any isolate descriptions (Table 51).  The majority of the described STs were isolated from CF patients in Canada, Australia and the Czech Republic. A single SLVs was isolated from a non-CF patient in Australia.  
AES-III 
131  
 
Figure 40: eBURST diagram of group 2. The dots represent STs and the lines connecting the dots indicate 
SLVs. The purple lines indicate SLVs of ST 17. The length of the lines connecting STs is arbitrary. 
Table 51: Clone C (ST17) SLV isolate descriptions Clone C SLV Isolate Details 318 No record 339 No record 445 No record 157 No record 187 CF patient Canada 1163 No record 636 CF patient Czech republic 327 No record 202 Canada CF patient Canada & UK unknown source   958 No record 688 No record 845 Australia (QLD) CF patients &  Australia (QLD) non-CF patient  The Midlands epidemic strain (ST148) was a member of the eBURST group 18, that contained seven STs. ST148 was identified as the primary founder of the clonal complex. Table 52 shows that one of the six SLVs had corresponding isolate data, and it derived from a CF patient in the Netherlands.       
Clone C 
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Figure 41: eBURST diagram of group 18. The purple lines indicate SLVs of ST148. The length of the lines 
connecting STs is arbitrary. 
Table 52: Midlands epidemic strain (ST148) SLV isolate descriptions MID SLV Isolate Descriptions 371 No records 140 No records 952 No records 682 No records 568 The Netherlands CF patient 956 No records  The Manchester epidemic strain (ST217) was part of eBURST group 10, that consisted of ten STs. ST217 was assigned as the primary founder of this clonal complex. The Manchester epidemic strain had four SLVs that were derived from diverse sources (Table 53). Two SLVs were derived from CF patients and the other was isolated from river water in France.  
 
 
Figure 42: eBURST diagram of group 10. The dots represent STs and the lines connecting the dots indicate 
SLVs. The purple lines indicate SLVs of ST217. The length of the lines connecting STs is arbitrary. 
Midlands epidemic strain 
Manchester epidemic Strain 
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Table 53: The Manchester epidemic strain (ST217) SLV isolate descriptions MES SLV Isolate descriptions 14 Australia (QLD) CF patient 950 No record 417 ID is ‘CFPA’ 1134 France (Rhone) River water  eBURST described the AES-I as a singleton; it did not belong to any clonal complex. AES-1 was the only major epidemic strain described that did not belong to a clonal complex.  
  
5.3.7 In silico SNP analysis of clonal strains Each of the major CF clonal strains had an in silico SNP profile that was unique (Table 54). Analysis of the records on the MLST database and other published works demonstrated that the AES-I, AES-III and Clone C have been isolated from sources other than CF patients. This analysis also shows that LES, AES-1, AES-III and Clone C have been isolated from a number of countries. None of the CF clonal strains recorded in the MLST database were isolated from environmental sources.  
 
  
  Allele Number Insilico SNP profile ST Details 
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acs7
8 
acs33
6 
aro4
7 
mut3
6 
nuo25
5 
pps10
0 
pps26
8 
trp11
2 
trp33
1 Location(s) Source Comments 
146 15 6 5 11 3 4 23 1 A T G C C G T G T Australia (QLD); UK (most); Canada ; Spain(Balearic islands) sputum 
CF strain in Canadian, Australian 
(QLD) and Spanian patients. Canadia 
strains (see Aaron et al. (2010)) 
Liverpool epidemic strain 
649 23 11 84 11 3 4 4 7 A T G C C G T A T Czech republic; Australia (VIC, WA, QLD, NSW) 
Blood, sputum and 
broncial lavage 
All aus strains from CF. AES 1/ P1/ 
M16. Blood isolate from the Czech 
Republic (see Nemec et al. (2010)) 
775 17 28 5 11 5 4 4 7 A C G T C G T A T Australia (WA and QLD).  sputum and upper respiratory tract CF and AES II 
148 5 17 5 1 3 13 6 7 A C G C G A T A T UK (Midlands and Birmingham) sputum Midlands 1 epidemic.  
217 3 28 5 11 18 4 13 3 A C G C C G C G C UK sputum (all) Manchester epidemic 
242 11 28 5 5 11 3 15 44 A C G T G G C G C Australia (TAS, QLD, VIC) and Sweden (stockholm) 
Sputum, Equine 
clitoral swab, 
Bronchial lavage, 
upper respiratory 
tract 
AES III. Stockholm CF patients 
(Karpati et al. (2008)) detected after a 
summer camp 2005 for teens from 
the Stockholm CF centre . Found in 5 
patients and is AKA J- cluster Also 
found in non-CF sputum and in an 
equine clitorial swab in Australia 
(QLD) 
17 15 11 5 1 7 9 4 7 A T G T C G T A T Canada; UK; Netherlands; Aus(QLD), Spain (Baleric Islands) 
sputum, Blood, Soft 
tissue infection 
Clone C genotype P10118; Clone C 
genotype P10119; Clone C. Found 
in CF patients in the Netherlands 
(van Mansfeld et al.(2009b)) in 
Canadian CF patients (Speert et al., 
(2002)), Australia (QLD) Found in 
Human-non CF patient - Australia 
(QLD) 
Table 54: in silico SNP analysis of CF clonal strains 
1 SNP barcodes are ordered according to the MLST genes and not by D-value.   
  
 
  
5.4 Conclusion Major findings of the analyses presented in this chapter include:  In silico analyses of the MLST database alleles demonstrated that P. aeruginosa housekeeping genes are highly diverse and that there are many other polymorphisms within the SNP PCR amplicons other than the D-value SNP (some of which were not detected within the sequence representatives). The eBURST and 
in silico SNP analysis of the P. aeruginosa population structure identified a relationship between several of the CF clonal strains and environmentally sourced strains. A detailed discussion of the 
P. aeruginosa population structure (as defined by the in silico analysis performed in this study) is included in the Discussion chapter.   
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CHAPTER 6 
6.0 General Discussion 
 
P. aeruginosa is the most common and important pathogenic organism that infects CF patients and when it colonises the CF lungs, it is seldom eradicated and is often responsible for an increase in patient morbidity and mortality rates (McCallum et al., 2001). The development of genomic fingerprinting methods over the last few decades has permitted detection of clonal P. aeruginosa strains that are present within selected CF clinics across Europe, Canada and Australia. The Liverpool epidemic strain, Midlands epidemic strain, Manchester epidemic strain and Australian epidemic strains (AES-I, AES-II and AES-III) have generated much concern within the CF community due to their high transmissibility and the associated health complications following infection. In particular, infection with LES has been linked to an increased need for hospitalisation (Al-Aloul et al., 2004), greater loss of lung function (Aaron et al., 2010), multiple antibiotic resistance (Chambers et al., 2005) and even death (Aaron et al., 2010).    The transmission route for P. aeruginosa clonal strains is still currently unknown. Current theories include acquisition from an environmental source or transmission through patient-to-patient spread. The latter theory is currently the most widely supported as the importance of close contact between patients and the ability of CF patients to spread infection has been demonstrated in a number of studies.  Specifically, a number of epidemiological investigations performed at multiple CF centres have shown that when CF patients were segregated based on clonal strain status, new incidences of infection were reduced (Jones et al., 2005, Morris et al., 2009, Griffiths et al., 2005). Moreover, the studies demonstrated transmission of LES between CF patients and non-CF individuals that had spent time in close proximity to each other (McCallum et al., 2002; Wallace et al., 2005).  Support for CF patients’ as a possible source of clonal strain dissemination is indicated by identification of LES on patients’ hands and in biological cough aerosols produced by CF patients (Panagea et al., 2005). Despite evidence suggesting that CF patients can be responsible for spread of clonal strains, the mechanisms for how the clonal strains were originally introduced into the CF community has not been established. Therefore, it is important to consider the potential of the environment as the original reservoir for clonal strains.   Therefore, it is important to identify the clonal strains harboured by CF patients and also to undertake epidemiological studies that examine the potential routes of clonal strain 
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transmission. To facilitate these studies, fast, cost-effective, highly discriminatory and robust genotyping methods need to be developed.  
6.1 P. aeruginosa Environmental strains and clinical infection  The natural environment is the primary habitat for P. aeruginosa and has been shown to host a genetically diverse collection of strains including clonal complexes that are responsible for various clinical infections (Pirnay et al., 2005). As an opportunistic pathogen P. aeruginosa has an impressive repertoire of intrinsic virulence factors and a highly adaptable genome that enables the organism to acquire additional pathogenicity determinants that allows the organism to cause serious infections in humans.  In addition, P. aeruginosa has high metabolic versatility that enables it to use a wide range of compounds as energy sources (Palleroni et al., 1984) and the ability to use alternative biochemical pathways for growth in low-oxygen environments (Vander Wauven et al., 1984)  These factors make environmental strains of P. aeruginosa well adapted to initiate infection and to adapt to a variety of niche environments, including the CF lung. This is demonstrated in early CF P. aeruginosa infections, presumably resulting from infection by environmental strains (Jelsbak et al., 2007; Speert et al., 2002; Burns et al., 2001). The ability of P. aeruginosa environmental strains to produce CF infections is supported by the comparative eBURST analysis of unique CF and environmental strains that demonstrated that many environmental strains (n=30) share the same ST as those isolated from CF patients. Moreover, our analysis of the online MLST database revealed that many environmental strains also have the same ST as strains isolated from other sources including from urinary tract infections, septicaemia and soft-tissue infections.  
6.2 The environment as a reservoir for clonal strains   Despite the known link between the environment and unique P. aeruginosa CF strains, the relationship between CF clonal strains and environmental strains has yet to be established. With the exception of Clone C, that has been demonstrated to be ubiquitous in the natural environment via molecular testing, no other CF clonal strains have been isolated from the natural environment. Our studies here using HRM analysis of the UK clonal strains and bioinformatic investigations of MLST data suggests clonal strains and the environmental strains are similar genetically.   
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The HRM analysis performed on the UK clonal strains and environmental strains demonstrated that the clonal strains could belong to the same melt group or ScreenClust group as the environmental strains. Thus, environmental strains could belong to the same clonal complex as the clonal strains tested. Full MLST sequencing however, of the environmental and UK clonal strains would need to be performed to confirm this.    The MLST database and published literature demonstrate that several CF clonal strains have been isolated from sources other than CF patients and in locations separate from where the clonal strains were originally isolated. Specifically, the AES-I (ST649) strain has been isolated from a blood culture sample in the Czech Republic, the AES-III (ST242) strain was isolated from an animal source (QLD), clinical infections in non-CF individuals and from CF patients in Stockholm (Karpati, Meyer, Adermark, Johansson, & Welinder-Olsson, 2008) and Spain (García-Castillo et al., 2012). These findings indicate multiple routes for clonal strain acquisition and that an environmental or other reservoir, while not yet identified, may exist. Indeed, many studies performed on P. aeruginosa strains have been predominantly clinically sourced. Only 9 % of sequence types listed in the MLST database, originate from environmental sources.  
 
6.3 eBURST representation of P. aeruginosa population structure and the 
relationship between environmental and CF clonal strains 
   eBURST analysis was performed on the entire collection of strains in the MLST database to gain a better understanding of how each clonal strain may have evolved and diversified, and this analysis showed 214 ST clonal complexes and 558 ST singletons (STs not related to any other strain in the database). Interestingly, the LES and the AES-II  were both assigned by eBURST to the largest clonal complex: CC1 (although eBURST represented these clones as distantly related). The primary founder ST833 is not abundant among the STs submitted to the database  (a feature often seen with  group founders) there being only one record as a CF isolate from Australia.  Of all of the CF clonal strains examined here, AES-I was the only clonal strain to be represented as a singleton ST.  In addition, the eBURST analysis revealed that many of the CF clonal strains were single locus variants (SLVs) with strains widely geographically distributed and/or isolated from sources other than CF infections, including the environment. Specifically, AES-II and the Manchester epidemic strains had SLVs that were isolated from water sources in countries different from 
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the clonal strains’ country of origin. This indicates a possible evolutionary relationship between the environmental STs and some CF clonal strains. In the majority of cases however, the clonal strains were assigned as the primary founders of the clonal complex, and therefore, the SLVs (isolated from the environment) had most likely diverged from the CF clonal strains. As this event would be unlikely, it is more reasonable to suggest that these clonal complexes are more abundant in the pool of P. aeruginosa genotypes, which explains their wide geographical distribution, and that diversification of the clonal complex may have occurred prior to their introduction into the CF community.   
6.4 Limitations of eBURST analysis  Although eBURST analysis has suggested an evolutionary relationship between specific CF clonal and environmental strains based on MLST housekeeping gene sequences, screening of different genes or using alternative methods, could suggest a different ancestral relationship between strains. This was suggested in a study by Wiehlmann et al. (2007) who used eBURST to interrogate 15 core genome markers to establish that the Midlands epidemic strain and the Liverpool epidemic strain belonged to the same clonal complex. These findings conflict with our MLST eBURST results which indicated the LES and Midlands epidemic strain belong to distinct clonal complexes.  Turner et al. (2007) assessed the reliability of eBURST to discern true evolutionary relationships between STs. This study concluded that eBURST performed well for populations undergoing low or moderate levels of recombination, but the accuracy of eBURST representations  ‘declined with increasing recombination to mutation ratio’ (Turner, Hanage, Fraser, Connor, & Spratt, 2007). A recent study performed on a substantial collection of P. aeruginosa strains from a variety of sources, identified frequent recombination events in 
P. aeruginosa housekeeping genes and that recombination generated novel alleles at a rate  3.5 times faster than by mutation (Kidd et al., 2012). Whether or not this level of recombination would affect the ability of eBURST to elucidate true patterns of ancestral descent is unclear.  
6.5 Development of the SNP genotyping method 
 The current methods used to study P. aeruginosa clonal strains that include: PFGE, RAPD and MLST are either costly, time-consuming or have limited ability to be applied universally across laboratories. To address this problem, a SNP based HRM method would allow efficient and cost-effective differentiation of clinical, environmental and clonal strains.  
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 The Minimum SNPs program applied here was used to derive high D-value SNPs capable of resolving P. aeruginosa strains. Despite repeated runs of the program, excluding unsuitable D-value SNPs based on issues with primer design, a high cumulative D-value of 0.991 was reached. This level of discrimination is comparable with D-values calculated using other molecular methods used to genotype P. aeruginosa strains: PFGE (0.965), MLST (0.972) and ERIC-PCR (0.965) (Kidd et al., 2011). Assessment of discriminatory value (using Simpson’s index of diversity algorithm) however, is influenced by the number of strains assessed. As the D-value SNPs identified here were derived from the MLST sequence data, theoretically it is not possible for our SNP method to achieve a greater level of discrimination than is possible with MLST, without incorporation of additional markers. In spite of this, the high cumulative D-value achieved with the nine SNPs identified here, highlights the capacity of the Minimum SNPs software to derive SNP sets with a high level of discrimination compared to other methods.   Anuj et al. (2011) identified SNPs within P. aeruginosa housekeeping genes, without using a bioinformatics approach to interrogate using HRMA. Their 20SNPHRM assay had a discriminatory power of 0.941 while the 10SNPHRM assay had a discriminatory power of 0.921 (Anuj et al., 2011). The Minimum SNPs software program used here, identified only nine SNPs with a cumulative D-value of 0.991 and therefore is a more discriminatory method of typing P. aeruginosa strains compared to previous studies. Moreover, Anuj and et al. (2011) used only 10 MLST sequenced CF isolates to calculate their D-value, whereas here the entire collection of P. aeruginosa sequence data listed in the MLST database (n=1006; 10th October 2010) were included. This included isolates from a diverse range of sources including environmental strains, CF strains, clonal strains and other clinical strains. Therefore, in general the D-value SNPs developed here can be considered to be a more robust and definitive means to resolve the P. aeruginosa population structure.   The HRM same/difference criteria used to interrogate the high D-value SNPs has been applied successfully to other bacterial species (Price et al., 2006; Stephens et al., 2008). Here, sequence validation confirmed however that this criterion could not be applied to interrogate the high D-value SNPs adjacent to the high D-value SNPs (within the PCR amplicon) produced a ‘cancelling out’ effect.  Previous work published by our research group used bacterial species that had more conserved housekeeping genes with fewer numbers of polymorphisms in the area surrounding the high D-value SNPs. The reason why the HRM method was 
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successful in previous applications was due to a higher level of housekeeping gene conservation in other organisms (S. aureus) compared to P. aeruginosa.  As an alternative approach to HRMA D-value SNP interrogation, normalised HRM graphs were analysed. Normalised HRM graph analysis of SNPs trp331; pps268; acs336; acs78 produced well-defined melt groups while SNPs trp112; mut36; aro47; pps100; nuo255 showed no separation into distinct melt groups. PCR amplicons that showed nil separation were interrogated with the ScreenClust software. Sequence validation performed on the melt groups demonstrated that HRM and ScreenClust were not efficient at separating melt groups based on D-value SNP only, and that other polymorphisms present within the amplicon influenced melt group assignment due to the ‘cancelling out’ effect.  Table 36 shows that size of the PCR amplicon is not associated with the level of separation. This is exemplified with the mut36 amplicon which had the longest PCR amplicon but produced only three well defined ScreenClust melt groups while the aro47 amplicon that had a shorter amplicon length and showed no separation into groups using normalised graph analysis.  The number of melt groups formed is in general, largely influenced by the combination of polymorphisms present and the total melting temperature (influenced by the number of GC bonds in the amplicon sequence).  In cases where there was nil separation into groups using normalised graph analysis, it is likely that polymorphisms within the amplicon cancelled each other out and differences in Tm between strains were limited. Moreover, ScreenClust software simply applies statistical algorithms to raw HRM data to generate ‘clusters’ and therefore, as seen with the normalised HRM graph analysis, can also be influenced by the presence of additional polymorphisms in the sequence.  This idea is supported by in silico polymorphic site analysis of the MLST genes that showed that P. aeruginosa MLST housekeeping genes were highly diverse, containing approximately 35 % SNPs on average. A large proportion of the SNPs present in these genes are found in less than 10 % of alleles. As a result, designing primers to flank the D-value SNPs proved difficult. PCR amplicons could not be designed without often incorporating additional polymorphisms.  The issue of the presence of other SNPs within the PCR amplicon affecting the ability of HRM to differentiate SNPs has also been reported in other studies (Anuj et al., 2011; Hussain,  2011)  
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6.7 MLST: Selection of housekeeping genes  There are two MLST schemes that have been developed for P. aeruginosa. The first was developed in 2004 (Curran et al., 2004) followed by the second scheme in 2005 (Vernez et al., 2005). Both schemes differ in the housekeeping gene selection process, genes chosen, and collection of strains used to test the method. The MLST scheme developed by Curran et al. (2004) is used more often for MLST studies, presumably due to more robust/diverse selection of strains used to test the method, the availability of an online database, and unlike its counterpart did not experience issues with null PCR amplification of MLST genes. Both MLST schemes sought housekeeping genes with sequence variability presumably so that a high level of discrimination comparable to other current methods (eg PFGE) could be achieved. When selecting genes for their MLST scheme, Curran et al. (2004) also evaluated each gene from a technical design approach. Therefore, more conserved genes may be been excluded on the basis that they were unsuitable for primer design. Curran et al. (2004) assessed the degree of selective pressure operating on the chosen MLST genes using the dN/Ds calculation (number of synonymous to non-synonymous substitutions) on a collection of 143 isolates. The dN/Ds ratio was considered to be low and therefore the loci examined were not considered to be under ‘strong positive selective pressure’ (Curran et al., 2004). Since the introduction of the MLST typing scheme, many more STs from diverse sources have been submitted to the database. Data generated here demonstrate a much higher percent average variable site number (approx. 35 %) for the MLST genes than previously calculated. This can be expected as a larger number of isolates were used in the analysis and from a wider selection of sources. Given however, the high diversity evident in MLST housekeeping genes and the considerably higher dN/Ds ratio (data not shown) detected, it is plausible to suggest that housekeeping genes may be under a greater selective pressure and be far more variable than initially thought. It is likely that the predominantly clinical selection of isolates used to assess the degree of selective pressure and the proportion of polymorphic sites in each gene was not a good representation of the global population of P. aeruginosa STs and that more conserved genes, although possibly less discriminatory, may provide a more accurate representation of the evolutionary patterns and clonal relationships between P. aeruginosa STs.  This theory is supported by a recent longitudinal study performed on isolates derived from a CF patient which observed nucleotide changes in the mutL gene (encodes mismatch repair protein) that gave rise to a new ST.  It was speculated that the selective pressure within the CF lung (i.e frequent antibiotic therapy) selected for the mutL hypermutable variant for the variants increased ability to adapt its genetic material. Kidd et al. (2012) also identified the presence of 
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single base pair insertion/deletion within the mutL gene for two STs in their collection. These STs were assumed to be hypermutator strains. These findings indicate therefore, possible heightened selective pressures acting on specific MLST housekeeping genes in P. aeruginosa that had been isolated from chronic CF infections and this also questions the choice of genes selected for use with the MLST method.     
Burkholderia cepacia was once classified as a member of the Pseudomonad genus (group II). Advancements in molecular biology supported B. cepacia’s reclassification under the new genus 
Burkholderia (Gitaitis and Nischwitz, 2006) and is currently known as as the BCC complex which consists of at least nine species. In comparison to other species published on the MLST database, the BCC is more closely related to P. aeruginosa.  The MLST scheme for BCC developed by Balwin et al. (2005), utilises seven housekeeping genes to differentiate all nine species. Analysis of the BCC MLST database records (data not shown) revealed that the housekeeping genes are considerably diverse with approx. 49 % variable sites on average, this compares with 
P. aeruginosa at approx. 35 %. Both P. aeruginosa and members of the BCC are opportunistic pathogens with enhanced metabolic capabilities that allow them to adapt to various niche environments (including the CF lung) and therefore this versatility may be reflected in the diversity observed in the housekeeping genes. The BCC MLST scheme examines a group of nine species which may indicate a higher level of diversity observed with BCC in comparison to P. 
aeruginosa.  A recent study using a multigenic approach (including non-MLST housekeeping genes), described P. aeruginosa relative to other Pseudomonads as a well-defined species with no ‘biovar, pathovar, serovar or genomovar’ (Mulet, Lalucat, & García-Valdés, 2010). This study however, used mostly clinical strains in their evaluation and our findings here demonstrate a significant level of diversity within the environmental isolates. Therefore, the degree of sequence homology identified by Mulet, Lalucat and Garcia-Valdes (2010) between P. 
aeruginosa strains may have been underestimated.  
6.8 Commercial viability/ Applicability of SNP assay and alternative 
methods of SNP interrogation  The purpose of the current study was to design a genotyping method with high resolution to study the population structure of environmental P. aeruginosa strains and to apply the in 
silico SNP method to investigate the population structure of CF strains in the MLST database to determine strain similarities and strain relationships. Although the high D-value SNPs provide the best level of strain discrimination in theory, using SybrGreen®/HRMA in practise 
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proved highly challenging and resulted in clear separation of only four SNP types based on distinguishable melt curves.  Despite this, a key finding of this study was that the ‘Minimum SNPs’ software proved highly effective in deriving highly discriminatory SNPs capable of resolving the population of P. 
aeruginosa. Table 47 shows that the nine SNP method is capable of revealing the population structure in P. aeruginosa and at separating different source groups (ie CF vs environmental strains).  In addition, in silico analysis of CF clonals revealed that the in silico SNP profiles are not shared by other CF clonal strains and therefore samples could be screened using a process of exclusion (i.e detection of a CF clonal strain in a particular sample).   However, further in silico analysis of the entire collection of STs on the MLST database would be required to confirm that the in silico SNP profiles for the clonal strains are not shared by other STs.  Other mechanisms such as matrix-assisted laser desorption/ionization time-of- flight mass spectrometry (MALDI-TOF MS), microarray and PCR with multiple primers could be explored as alternative means of SNP interrogation. However, accurate SNP detection using these methods would require targeting short sequence regions and therefore the issue of multiple polymorphisms still remains (e.g availability of primer binding sites).  
6.9 Other approaches for analysis of the relationship between 
environmental and CF clonal strains  .  MLST is currently considered the gold standard for studying bacterial populations and for documenting the evolution of clonal complexes. This method interrogates sequence data from several housekeeping genes present in the core genome and does not provide information on the accessory genome.  Whole genome sequencing of P. aeruginosa strains has established that, while the core genome is relatively conserved, elements of the accessory genome can vary widely between strains (Lee et al., 2006; Mathee et al., 2008). Variation of the accessory genome can also occur intra-clonally. This has been demonstrated for LES where different isolates have shown addition of various prophages and genomic islands, some of which may enhance the ability of the strain to establish infection (Fothergill et al., 2012; Winstanley et al., 2009). It is likely that the flexibility of the accessory genome facilitates adaption of P. 
aeruginosa to the CF lung environment and allows transformation to a more virulent and competitive strain. Therefore, strains isolated from the environment will vary greatly in their accessory genome compared to that of the CF niche-specialised clonal strains. As a result, studies that seek to understand the evolution of CF clonal strains should apply molecular methods that target both the core and accessory genome of P. aeruginosa. Wiehlmann et al. 
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(2007) developed a microarray genotyping system that targets various SNPs within the core genome (generates a hexadecimal barcode) and 38 genetic markers within the accessory genome. Alternatively, MLST could be performed with the addition of binary markers, perhaps targeting regions undergoing positive selection during CF infection (Chung et al., 2012; Cramer et al., 2011; Rau et al., 2010; Smith et al., 2006).   
6.10 Future Directions  This study would have benefited from the inclusion of the following clonal P. aeruginosa strains:  The Australian Epidemic Strains (AES-I, AES-II and AES-III), other international CF clonal strains (Clone C, Netherlands clonal strain (ST406) and the Copenhagen CF clonal strain), unique clinical CF strains and clinical strains derived from sources other than CF.  This would have allowed further insights into the relationship between environmental and CF strains and the P. 
aeruginosa population structure as a whole. Moreover, analysis of additional strains may have generated novel melt patterns allowing better characterisation of strain diversity.   Full MLST of the environmental and UK clonal strains could provide a link regarding the relationship between environmental and clonal strains. In addition, sequencing of regions outside the MLST specified genes could allow the full extent of sequence diversity (ie additional polymorphisms) to be determined.  As outlined earlier, screening with molecular methods capable of evaluating both the core and accessory genome of P. aeruginosa would improve our understanding of the origin and evolution of P.  aeruginosa clonal strains.       
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APPENDIX A 
Isolation and identification of P. aeruginosa from environmental samples 
Soil sampling and phenotyping: Soil slurries were mixed thoroughly using a vortex mixer (Vortex Genie 2; Scientific Industries, USA). Aliquots of 50 µL and 100 µL of sample were spread onto Cetrimide agar (CET) (Oxoid, Australia). Serial dilutions (10-1 to 10-6) of the remaining soil slurry was prepared with 100 µL of each dilution spread onto CET agar plates (Oxoid, Australia). The CET plates were incubated at 42 ⁰C/48 h. Preliminary testing showed very limited growth when samples were diluted, confirming that P. aeruginosa was present in low numbers in the soil samples. In subsequent 
169  
testing only direct sampling from soil slurries was performed.  After incubation, the CET plates were observed for fluorescence with a UV lamp. Plates from each sample with 15-30 fluorescent colonies were selected for further testing. Each fluorescent colony was inoculated onto MacConkey Agar #2 (MCA) (Oxoid, Australia) using the 16-streak method and incubated for 42 
⁰C /48 h.  Non-lactose fermenting colonies were inoculated onto nutrient agar plates (NA) (Oxoid, Australia) for oxidase testing and incubated at 37 ⁰C/24 h.  Oxidase tests were performed on a single colony from nutrient agar plates using Kovac’s Oxidase test. It was considered a positive reaction when isolates produced a violet purple reaction within 10 seconds. Oxidase positive isolates were stored on nutrient agar slants (stored at 4 ⁰C) and in 20 % glycerol at -80 ⁰C.      
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Figure 43:  Flow-diagram illustrating the steps used to isolate and identify P. aeruginosa in soil 
Soil Sample 
Cetrmide agar (spread plate) 
50 µL; 100 µL  
42 ⁰ C/ 48 h 
Select plate with 15-30 Fluorescent  
colonies 
All Fluorescent colonies 
MacConkey agar (16-streak) 
42 ⁰C/ 48 h 
Cetrimide agar (spread plates) 
42 ⁰ C/ 48 h 
Nutrient agar  
37 ⁰ C/ 24 h 
Positive oxidase reaction 
Stored on Glycerol/ nutrient agar slants 
Method discontinued after first batch  
due to minimal growth in serial dilutions 
Non-lactose fermenters 
Serial dilutions 
10-1 - 10-6 
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Water samples: The water samples collected were generally reasonably turbid in nature; this along with the high diversity of microorganisms present in the water samples caused many difficulties in attempting to isolate Pseudomonas sp. from water samples. A number of methods were trialled and optimised to overcome these issues.  
Method#1: 
Method#1: Water filtering and phenotyping  Water samples were mixed thoroughly and aseptically transferred into 500 mL centrifuge jars. The samples were centrifuged (Avanti J-26XPI, Beckman Coulter, Australia,) at 2,000 rpm for 10 min with a slow stop setting to settle the soil particles that would otherwise interfere with the filtering process. Centrifugation at 3,000 rpm was selected, as higher speeds would cause bacterial cells to precipitate. The supernatant was transferred and stored in sterile 500 mL Schott bottles.  Water samples were filtered through 0.45 µM 37 mm sterile gridded membrane filters (Millipore Corporation, USA)  in the following volumes: 1 mL ( plus 30 mL sterile distilled wash water), 10 mL (plus 30 mL sterile distilled wash water) and 100 mL of undiluted sample.  The membrane filters were aseptically applied to the surface of a CET agar plate (Oxoid, Australia) and incubated at 25 ⁰C/48 h.   During the Queensland flood events in December 2010 to January 2011, access to Queensland University of Technology Gardens Point campus was prohibited for approximately 14 days. During this period, the CET filter plates were stored at 4 ⁰C. On return to campus, a thick green mucoid growth covering the entire bottom part of the plates (and dropping onto the lids) was observed on the majority of the CET plates. This mucoid growth was fluorescent under a UV lamp.  A literature search indicated that the bacterial growth was likely to be Pseudomonas 
fluorescens as it is present in the environment, and exhibits strong growth and fluorescence on CET agar plates (Oxoid, Australia). Moreover, P. fluorescens grows at 4 ⁰C whereas P. aeruginosa cannot (Bergey's manual of systematic bacteriology volume 2: The proteobacteria, 1984) .  Using a sterile plastic loop, a diagonal streak was taken from overgrown plates and inoculated into 4 mLs of nutrient broth (Oxoid, Australia). The broth was mixed using a vortex mixer (Vortex Genie 2; Scientific Industries, USA), and incubated at 42 ⁰C/18 h. This aimed to support additional growth of P. aeruginosa whilst hindering the growth of P. fluorescens.  After overnight incubation, a loopfull of broth was 16-streaked onto CET agar plates (Oxoid, Australia) and incubated at 42 ⁰C/48 h. Fluorescent colonies observed under UV light were labelled accordingly.  Half of the single fluorescent colonies from each plate were selected and 16- streaked onto MCA (Oxoid, Australia) and incubated at 42 ⁰C/24 h. Non-lactose fermenting 
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colonies were subcultured onto NA (Oxoid, Australia) for subsequent oxidase testing and incubated at 37 ⁰C/24 h. Oxidase positive isolates were stored on nutrient agar slants (stored at 4 °C) and in 20 % glycerol and stored at -80 ⁰C.   
Further Development/Improvement Results of this experiment indicated that P.aeruginosa is not present in high numbers in water samples and is therefore unlikely to be detected in smaller filtered volumes.  Subsequent experiments should be performed by filtering at least 100 mL.                  
Figure 44: Flow-diagram illustrating the steps used to isolate and identify P. aeruginosa in water  
Pick 50 % of fluorescent colonies 
Water Sample Centrifugation 2000 rpm/ 10 min 
 
Cetrimide agar 25 ⁰C/24 h 
Queensland Floods: agar plates stored at 4 ⁰C 14 days Streak across plate diameter (100 mL plate) Nutrient broth 42 ⁰C/48 h 
Cetrimide agar (16-streak) 48 ⁰C/48 h MacConkey agar (16-streak) 42 ⁰C/24 h 
Non-lactose fermenters Nutrient agar (16-streak) 42 ⁰C/24 h Positive oxidase reaction 
Store on Glycerol/Slants 
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Method#2:  
Water filtering and phenotyping  Method#2 continues after centrifugation and storage of supernatant in Schott bottles outlined in method#1. 100 mLs of water was subjected to membrane filtration using a 45 µM 37 mm sterile gridded membrane filter (Millipore Corporation, USA). The membrane was subsequently applied to the surface of a CET agar plate (Oxoid, Australia), followed by incubation at 25 ⁰C/48 h. After incubation, a diagonal streak was taken, using a sterile plastic loop, from the overgrown plates, inoculated into 4 mLs nutrient broth (Oxoid, Australia) and incubated at 42 ⁰C/18 h. The broths were centrifuged at 3,000 rpm for 10 min to pellet the bacteria. The supernatant was poured off and the pellet re-suspended in 200 µL of sterile distilled water and mixed with a vortex mixer (Vortex Genie 2; Scientific Industries, USA) to yield a homogenous mix.  Serial dilutions (10-1 to 10-6) of this mix were prepared in sterile distilled water. 100 µL aliquots of each dilution were spread onto MCA agar surface. These plates were incubated at 42 ⁰C/24 h. The culture plate with the dilution that yielded 15-30 colonies was selected for sub-culture, with each individual colony from the selected dilution inoculated using the  16- streak  method onto NA plates (Oxoid, Australia), and  incubated at 37 ⁰C/24 h prior to oxidase testing. Oxidase-positive isolates were subcultured onto CET plates (Oxoid, Australia) and incubated for 37 
⁰C/24 h. Isolates that fluoresced under UV were subsequently stored on nutrient agar slants (stored at 4 °C) and in 20 % glycerol  stored at -80 ⁰C.   
Further Development/Improvement (methods 1 and 2) The centrifugation step minimised the larger particles in the water samples from interfering with the filtering process. However, it was unable to eliminate fine sedimentary particles, causing long delays in filtering progression.  It was noted that centrifuging the water samples might prevent the isolation of bacteria that were attached to the larger sediments in the water samples.     
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Figure 45: Flow-diagram illustrating the steps used in method 2 to isolate and identify P. aeruginosa in water    
Water Sample Filtration 100ml    
Cetrimide agar 25 °C/48 h    Streak across plate diameter    
Nutrient broth 42 °C/18 h    
Centrifugation 3000 rpm/10min    Resuspend pellet in sterile distilled H2O   
Serial dilutions 10-1 – 10-6    
Cetrimide agar 37 °C/24 h    
Select dilution with 15-30 colonies    
Nutrient agar (16-streak) 37 °C/24 h    
MacConkey agar (spread plate) 42 °C/24 h    
Positive Fluorescence   
Positive oxidase reaction    Stored on Glycerol/Nutrient agar slants   
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Method # 3: 
Preparation of asparagine broth: Reagents and diluents used in preparation of asparagine broth were adapted from the Australian standard for water microbiology (AS 4276.12-1995 Water microbiology - Pseudomonas aeruginosa - Estimation of most probable number (MPN)) and are as follows: - 1Asparagine, DL 3 g - Dipotassium hydrogen phosphate, (K2HPO) 1 g - Magnesium sulphate heptahydrate, (MgSO4.7H2O) 0.5 g - Distilled water 1 L 
1L-Asparagine (provided by Queensland Scientific Services laboratory, Coopers Plains; 10 g, company name not given) was used due to unavailability of the DL-Asparagine form.  Asparagine broth was prepared as previously described (Standards Australia, AS 4276.12-1995).  Briefly, each ingredient was dissolved separately in distilled water. Each reagent was added separately into 500 mL of water stirring between each addition, and topped-up with distilled water to 1 L. If necessary, the solution was adjusted to pH 6.9-7.2 and autoclaved to sterilise. This method was found to be ineffective as the salts precipitated out of the solution making the broth appear turbid. Other methods were used such as mixing, sonicating and re-autoclaving, but were not successful in dissolving the salts back into solution.  It is important that the broth remains transparent so that a false-positive result is not obtained due to turbidity.  To prevent salt precipitation caused by the autoclaving process, each ingredient was dissolved separately in sterile containers with sterile distilled water and heated in a water bath (at 45 ⁰C). 
Each ingredient was added separately and mixed into 500 mL of sterile distilled water (at 45 
⁰C). The solution was filled to a 1 L volume with sterile distilled water.  This method proved successful in ensuring a clear broth for P. aeruginosa isolation. Asparagine broth is selective for the isolation of  P. aeruginosa, as these bacteria are capable of utilising asparagine as the sole source of nitrogen (hydrolysing asparagine to aspartic acid), an ability limited to few microbes (http://www.condalab.com).  Positive control P. aeruginosa (ATCC 27853) and negative controls P. fluorescens (ATCC 13525) and E .coli (ATCC 25922) were used to confirm the selectivity and sensitivity of the asparagine broth.  
Water filtering and phenotyping:  Water samples were mixed thoroughly in PET bottles. The entire volume of the water sample was pre-filtered with glass fiber filters (Pall Corporation,  Australia) and subsequently  filtered through a 0.45 µM 37 mm sterile gridded membrane filter (Millipore Corporation,  USA). To 
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enrich P. aeruginosa, both the pre-filter and the membrane filter were submerged in 25 mL of asparagine broth (in 50 mL centrifuge tubes) and incubated in a shaking incubator at 200 rpm 42 ⁰C/48 h. Samples exhibiting turbidity compared to negative controls were considered 
positive for growth. The filters were removed and the broths were mixed thoroughly using a vortex mixer (Vortex Genie 2; Scientific Industries, USA). Aliquots (50 µL) of undiluted broth were spread onto CET agar (Oxoid, Australia) surface. Serial dilutions (10-1 to 10-6) were performed on the rest of the broth and 100 µL of each dilution was spread onto the surface of CET agar (Oxoid, Australia). CET plates were then incubated at 37 ⁰C/24 h. The dilution from 
each sample that yielded 15-30 colonies was selected and the colonies that fluoresced under UV light were marked.  All fluorescent positive colonies were subcultured onto NA (Oxoid, Australia) and incubated at 37 ⁰C/24 h for oxidase testing. Oxidase-positive colonies were subsequently stored on nutrient agar slants (stored at 4 °C) and 20 % glycerol  at -80 ⁰C.    
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Water Sample 
Pre-filtration 
600 mL 
Membrane filtration 
600 mL 
Asparagine broth 
200 rpm; 42 ⁰C/48 h 
Turbid samples 
Serial dilutions 
10-1 to 10-6 
Cetrimide agar (spread plates) 
37 ⁰C/24 h 
Select plates with 15-30 colonies 
Positive Fluorescence 
Nutrient agar 
37 ⁰C/24 h 
Undiluted broth 
 Positive oxidase reaction 
Stored on glycerol/ nutrient agar slants 
Figure 46: Flow diagram illustrating the steps used in method 3 to isolate and identify P. aeruginosa in water 
 
  
APPENDIX B 
Species-specific PCR: critical review of the literature 
Table 55: Critical review of literature to speciate P. aeruginosa 
Paper Gene Targeted Method details  Specificity (bacteria tested against) Cons Pros Cost Specificity/ Sensitivity Analysis by other literary works 
Spilker et al. 
(2004) 16S rDNA 
Based on 16S rDNA sequence 
alignments. Differenciate 
P.aeruginosa from other 
Pseudomonads. 
 
Conventional PCR 
14 P. aeruginosa strains (all ATCC's) P. agarici, 
P. alcaligenes, P. chlororaphis, P. flavescens, P. 
fluorescens, P. fulva, P. fuscovagina, P. mendocin, 
P. oleovorans, P. pertuciniogena, P. 
pseudoalcaligenes, P. putida, P. resinovorans, P. 
stutzeri, P. syringae, P. tolaasii, Burkholderia 
cepacia complex, Pandoraea, Ralstonia, 
Achromobacter xylosoxidans, Strenotrophomonas 
maltophilia, Acinetobacter, Serratia marcescens, 
Herbaspirillum frisingense, Klebsiella pneumonia, 
Morganella morganii, Moraxella osloensis and E. 
coli 
 
Looked at 
environmental 
Pseudomonads 
Primers Both 100% 
• Sensitivity 100%. Specificity 94%. 
Amplified P.fragi (Lavenir et al. 
(2007)).  
• Issues with cross reactivity (used 
real-time with no probes) 63/63 
sensitivity and 2/28 specifcity 
(Anuj et al.( 2009)).  
• gryB is a better target (Motoshima 
et al. (2007)) 
Feizabadi et al. 
(2010) 
oprL TaqMan 
based real time 
PCR assay 
  
FASTA analysis.  A. baumannii, 
Stenotrophomonas maltophilia, S. aureus, S. 
epidermidis,  E. faecalis,  K. pneumonia, E. coli 
    2 primers and 1 probe 
98.85% specific 100% 
sensitive   
Applied 
Biosystems Kit   
100 reactions. Need to grow 
cultures. Prepare DNA then run 
PCR.  
  
I already have 
prepared DNA 
extracts and this 
method requires 
re-culturing of 
isolates 
  
$1154 (One kit 
does 100 
reactions) 
  A large amount of specimen is required (Feizabadi et al. (2010)) 
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Lavenir et al. 
(2007) 
ecfX gene 
 528bp product 
size 
Evaluated sensitivity of the most 
frequently used P.aeruginosa 
PCR screenings on clinical and 
environmental strains and tested 
specificity of pseudomonas 
species strains  
 
Conventional PCR 
P. agaraci, P. alcaligenes, P. asplenii, P. balaerica. 
P. chlororaphis,  P. cichorii, P. citronellosis, P. 
fluorescens, P. flavescens, P. fragi, P. 
pseudoalcaligenes, P. putida, P. tolaasii, P.stutzeri, 
P. viridiflava and for ecfX (P. olevorans and P. 
resinovorans) 
 
Successfully 
applied to 241 
clinical samples 
and on direct 
water/soil 
extracts.  
primers 100% sensitive 100% specific   
De Vos et al. 
(1997) Oprl  See below 
112/113 amplified P. 
aeruginosa 
 1/87 non-P. 
aeruginosa (was 
actually A. 
xylosoxidans) 
• 100% sensitive; 80% specificity. 
Amplified P. fragi, P. 
citronellolis and P.viridiflava 
(Lavenir et al. (2007)) 
• 100% sensitive for isolates 
easy identified phenotypically  
• 100% sensitive for isolate that 
"could be identified by basic 
biochemical testing  
• 12/13 isolates requiring more 
extensive biochemical 
evaluation were classed as P. 
aeruginosa.  
• 98.4% sensitive and 98.9% 
specific for isolates belonging 
to the ‘hard’ to  classify 
category Qin et al. (2003) 
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De Vos et al. 
(1997) OprL 
Examined OprI and OprL for P. 
aeruginosa and OprI for other 
fluorescent pseudomonads.  
 
Tested on: Skin biopsy 
specimens from burn wounds 
and expirations from CF patients 
 
Conventional PCR 
P. aeruginosa (150 isolates) P. agarici, P. 
alcaligenes, P. aplenii, P. aureofaciens, P. 
chlororaphis, P. cichorii, P. corrugata, P. 
fluorescens, P. fragi, P. fuscovaginae, P. 
marginalis, P. olevorans, P. pseudoalcaligenes, P. 
putida, P. reptilovora, P. stutzeri, P. syringae, P. 
taloaasii, Burkholderia cepacia, P. diminuta. 
Stenotrophomonas maltophilia, Ralstonia 
solanacearum, Acinetobacter sp, Alcaligenes 
eutrophus, Azotomonas macrocytogenes, 
Comamonas acidovorans, Escherichia coli, 
Klebsiella aerogenes, Proteus sp, Serratia 
marcescenes, Providencia sp, Salmonella sp, 
Staphylococcus aureus 
Not tested on 
environmental 
samples  
  Primers 100% specific  100% sensitive  
• 100% sensitive and 86% specific.  
• Amplified P. balearica and P. 
citronellolis)  
• unspecific amplification of 
Achromobacter, xylosoxidans, 
Ralstonia pickettii, Shewanella spp 
and Pseudomonas fluorescens. 
• Found false-positives for 4 
isolates. 
Anuj et al. (2009)  
Khan and 
Cerniglia 
(1994) 
toxA   
95 environmental P. aeruginosa strains.  
 
Also tested clinical strains.   
  probe primers 100% specific  96% sensitive 
• 95% sensitive and 100% specific 
Lavenir et al.( 2007).  
• 62/63 sensitivity and amplified 
0/28 non-P. aeruginosa (used real-
time PCR format without probes) 
Anuj et al.( 2009) 
 
Tyler et al. 
(1995) 
16S-23S rDNA 
ITS   
Comamonas testeroni, P. cepacia, Pseudomonas 
alcaligenes, P. allicola,  P. caryophylli,  P. 
diminuta,  P. fluorescens,  P. gladoli,  P. mallei,  P. 
mendocina,  P. picketti,  P. pseudoalcaligens,  P. 
pseudomallei, P. putida,  P. solancearum,  P. 
stutzerie-vesicularis 
        
• 100% sensitive and 
100% specific.  
Suggested that it can’t 
be used with confidence 
on water/soil extracts 
Lavenir et al.( 2007) 
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Song et al. 
(2000) Exotoxin A gene Conventional PCR  
Ocular P. aeruginosa isolate and 2x ATCC 
cultures.  
 
Tested against non-pseudomonads  
 
Not against other pseudomonads  
Non- specific 
product 
formation  
 
Did not test 
environmental 
P. aeruginosa 
strains 
      
• 98% sensitive in isolates that 
are easily identified 
phenotypically;  
• 96% sensitive on isolates 
identified with basic 
biochemical testing;  
• 96% sensitive on isolates 
requiring more extensive 
biochemical testing;  
• 93% sensitive and 100% specific 
for isolates that are classified as 
‘hard’ to identify Qin et al. 
(2003) 
 
da silva filho 
et al. (1999) algD gene Conventional PCR  
Tested 182 isolates. Staphylcoccus aureas, 
Streptococcus pneumonia, Haemophilus influenza, 
Escherichia coli, Klebsiella pneumonia, 
Acinetobacter calcoaceticus, Enterobacter 
aerogenes, P.stutzeri, Stentrophomonas 
maltophilia, Burkholderia cepacia 
Not tested on 
environmental 
strains.  
Looked at CF 
strains 
    100% sensitive  100% specific 
• 90% sensitive for isolates easily 
identified phenotipically  
• 92% sensitive for isolates 
identified by basic biochemical 
testing  
• 10/13 sensitive for isolates 
requiring more extensive 
biochemical evaluation 
• 88.9% sensitive and 100% 
specific for isolates considered 
‘hard’ to classify.  
Qin et al. (2003) Adapted as a 
real-time PCR method 
Jaffe et al. 
(2001) 
oprL gene 
(primers from de 
Vos et al. (1997) 
Compared conventional and 
Real- time PCR. Found 
concordant results.  
P. putida,  P. stutzeri,  Bulkholderia cepacia,  
Bulkholderia cocovenenan,  Xanthomonas, 
Ochrobactrum anthropi, Ralstonia picketti, 
Salmonella enteritidis, Klebsiella pneumonia, 
Proteus vulgaris,  Escherichia coli, Neisseria 
gonorrhoea, Staphylococus aureus.   
Tested with 
clinical isolates  
 
 
Real-time PCR 
without probes   
Amplified all P 
.aeruginosa did not 
amplify other non-P. 
aeruginosa test strains.  
N/A 
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Motoshima et 
al.( 2007) gyrB  
Real-time PCR with Melt curve 
analysis.  
 
Used the same primers as Qin et 
al. 2003 
Gram negative bacteria: B. cepacia, R. pickettii,  
P. fluorescens, P. putida, P. stutzeri, C. 
testosteroni, S. paucimobilis, Acinobacter 
baumannii, Stenotrophomonas maltophilia, 
Achromobacter xylosoxidans, Chryseobacterium 
indologenes, Klebsiella spp, Citrobacter, E .coli, 
Morganella morganii, Proteus mirabilis, 
Enterobacter genus, Serratia marcenes.  
Used melt curve 
analysis. 
Difficult 
interpretation.  
 
Primers no 
probes 
Review article  
Deschaght et al. 
(2011) : P. aeruginosa 
104/104.  
Non-P. aeruginosa 
0/120  
N/A 
Schwartz et al. 
(2006) 23s rRNA 
Specificity was determined from 
sequence alignments; BLAST. 
Based on waste-water isolates 
P. aeruginosa, P. putida, P. alcaligenes, P. 
fluorescens, P. peudoalcaligenes, P. stutziri, P. 
syringae  
a weak cross-
reaction with P. 
putida 
  2 primers and 1 probe 
no 
specificity/sensitivity 
scores given 
  
Qin et al. 
(2003) gryB 
Real-time PCR with Sybr green. 
Confirmed gryB results with 
sequencing. Primers based on 
alignment of 88 gyrB sequence 
data from the ICB database.  
 
Does not recommend looking at 
only one target due to false 
negatives 
100 phenotypically characterised strains. 4 
species closely related to P. aeruginosa. 100 
oxidase positive gram-negative isolates that 
could not be easily ruled in or out as P. 
aeruginosa by phenotypic methods. 200 Gram 
Negative isolates from CF patients (sputum, 
oropharyngeal swabs, bronchoalveolar lavage 
specimens) 
Not tested on 
environmental 
stains.  
 
Annealing temp 
is high at 68 ⁰C  
Real-time PCR - 
Sybr green 
Sybr green dye. 
No probes 
required. 
Primers 
• Easily identified 
as P. aeruginosa 
phenotypically: 
100% sensitive.  
 
• Isolates that could 
be identified by 
basic biochemical 
testing: 100% 
sensitive.  
• Isolates requiring 
more extensive 
biochemical 
evaluation: 100% 
sensitive  
 
• "100% sensitive, 100% specific" 
Lavenir et al.( 2007)  
•  Motoshima et al. (2007) used 
these primers and detected 
issues. 
 
183  
Paper Gene Targeted Method details  Specificity (bacteria tested against) Cons Pros Cost Specificity/ Sensitivity Analysis by other literary works 
Lee et al. 
(2011) gyrB  
Based on sequence alignments of 
611 gyrB sequences 
11 P. aeruginosa strains. P. fluorescens, P. putida, 
and P. stutzeri strains 
• Environmental 
strains are 
sourced from 
taps and 
aerosols only.  
• Can’t be used 
as a 
conventional 
PCR method 
as it all will 
amplify 
pseudomonad
s.  
• Looked at CT 
values. 
Positive  for P. 
aeruginosa=  
12-20 cycles 
Negative for P. 
aeruginosa 
around 40 
cycles.  
• Not alot of 
strains tested 
  2 primers and 1 probe 
claims high 
specificity N/A 
Anuj et al. 
(2009)   ecfX and gyrB 
2 targets to reduce false-
negatives. Used gyrB primers 
from motoshima et al. 2007. ecfX 
and gyrB monoplex PCR 
reactions were in agreement 
with each other but the authors 
do not suggest using only one 
target gene. Used Qin et al. 
(2003) primers and designed 
own ecfX primers 
 
Real-time PCR method 
Achromobacter xylosoxidans, Burkholderia cepacia, 
Burkholderia gladioli allicoli, B. gladioli, B. 
multivorans, B. pseudomallei, Ralstonia eutropha, 
Ralstonia solanacearum, Stenotrophomonas 
maltophilia.   
Used 
‘environmental’ 
stains from 
homes of people 
with CF instead 
of soil/water 
strains from 
natural 
environment 
 
 
 
2 probes. 4 
primers. Not Given  N/A  
 
  
APPENDIX C 
DNA sequencing protocol  
See supplementary material
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APPENDIX D 
In silico SNP analysis of environmental and CF STs  
See supplementary material
 
  
APPENDIX E 
In silico analysis of Primer Options 
See supplementary material 
 
  
 
  
 
  
 
  
 
  
 
